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ABSTRACT 
 
Mutations in profilin 1 (PFN1) cause amyotrophic lateral sclerosis (ALS), a 
fatal neurodegenerative disease that targets motor neurons. PFN1 is a 15 kDa 
protein that is best known for its role in actin dynamics. However, little is known 
about the pathological mechanisms of PFN1 in ALS. In this dissertation, it is 
demonstrated that certain familial ALS-linked mutations severely destabilize the 
native conformation of PFN1 in vitro and cause accelerated turnover of the PFN1 
protein in neuronal cells. This mutation-induced destabilization can account for the 
high propensity of ALS-linked variants to aggregate and also provides rationale for 
their reported functional defects in cell-based assays. The source of this 
destabilization is illuminated by the crystal structures of several PFN1 proteins, 
revealing an expanded cavity near the protein core of one ALS variant and 
predicting a non-surface exposed cavity in another. Functional biochemical 
experiments point to abnormalities in actin filament nucleation and elongation 
caused by PFN1 mutants. In HeLa cells, PFN1 is essential for the generation of 
actin-rich filopodia and expression of mutant PFN1 alters filopodia density further 
supporting a pathogenesis mechanism involving actin cytoskeleton. Taken 
together, this dissertation infers that the pathogenesis of ALS due to mutations in 
PFN1 can be mediated at least by two possibly related mechanisms, a 
destabilization of the native PFN1 structure and an impact on the actin assembly 
processes.  
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CHAPTER I – INTRODUCTION 
 
Amyotrophic Lateral Sclerosis 
Clinical presentation 
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a 
progressive and fatal motor neuron disease that occurs during mid-adulthood at 
about 55 years. This disease is characterized by the death of both upper and lower 
motor neurons. The upper or corticospinal motor neurons originate from the motor 
cortex and synapse in the brain stem and spinal cord, from which the lower or 
bulbar, spinal motor neurons project into skeletal muscles. The common initial 
symptoms are weakness of the limbs in the case of limb onset, with hyperreflexia, 
fasciculations and spasticity. As the motor neurons degenerate, the muscles 
atrophy leading to paralysis, and eventually leading to death 3-5 years post-onset 
due to respiratory failure. About one-third of the ALS cases are bulbar in nature 
characterized by difficulty in chewing, swallowing and speech caused by tongue 
atrophy. The incidence of ALS is 1-2 individuals per 100,000 per year in most 
countries and the prevalence is about 5 cases per 100,000 people (1,2). Despite 
all the progress in research, no cure has been found and the drugs approved for 
treatment, riluzole and edaravone, merely extend survival by a few months (1). 
Genetics and pathogenesis 
About 10% of ALS cases are inherited dominantly and referred to as familial 
ALS (FALS). The remaining 90% of cases are sporadic in nature (SALS). Of the 
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familial cases, 20% are due to mutations in superoxide dismutase 1 (SOD1), which 
was also the first gene genetically linked to ALS (3). About 25% of FALS cases 
carry hexanucleotide repeat expansions in the gene c9orf72. Mutations in the 
genes encoding RNA binding proteins fused in sarcoma/translocated in 
liposarcoma (FUS/TLS) and transactive response DNA-binding protein 43 
(TDP43) each account for 5% of FALS cases. Other genes contributing to FALS 
at varying proportions are angiogenin (ANG), vasolin containing protein (VCP), 
dynactin subunit 1 (DCTN1), optineurin (OPTN), ubiquilin 2 (UBQLN2), 
sequestosome 1 (SQSTM1), profilin 1 (PFN1), hnRNPA1, matrin 3, tubulin α-4A 
(TUBA4A), CHCHD10, TBK1 and NEK1. (1,2,4). Less frequently, mutations in 
certain genes such as SOD1, c9orf72, TDP43 and FUS also account for SALS (2). 
About 15-20% of the ALS patients display cognitive defects and behavioral 
changes culminating in dementia. These symptoms correlate with the 
degeneration of frontal and temporal lobes, a condition commonly seen in 
frontotemporal dementia (FTD) (1). ALS and FTD are considered two ends of a 
spectrum of disorders and varying degrees of genetic and symptomatic overlap 
between the two are often observed (4). 
The ALS genes can be classified into three groups based on the primary 
pathophysiological features – (i) disturbances in protein homeostasis caused by 
protein stability, misfolding, aggregation and defective degradation of proteins by 
proteasome and autophagy (SOD1, VCP, OPTN, SQSTM1, UBQLN2), (ii) 
disturbances in RNA metabolism due to defects in RNA splicing, impairment in 
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nucleocytoplasmic and axonal transport of RNA, deposition of RNA in nuclear foci 
and cytoplasmic granules (FUS, TDP43, c9orf72, hnRNPA1, ANG and many other 
ALS-linked genes encoding RNA binding proteins), (iii) cytoskeletal abnormalities 
leading to defects in transport of cargo along axons, growth cone elongation. The 
primary pathways converge on a number of secondary downstream effects such 
as endoplasmic reticulum (ER) stress, autophagy, proteasome and mitochondrial 
dysfunction, alterations in dendritic morphology, neuroinflammation and 
excitotoxicity (1,2,4). While the first two features are well studied in ALS, detailed 
mechanistic studies of actin-related cytoskeletal defects caused by ALS-mutations 
in PFN1 are lacking. This dissertation attempts to decipher disease mechanisms 
caused by ALS mutations in PFN1. 
 
The chemistry and biology of profilins 
Profilins 
Profilins are a class of molecules involved in actin cytoskeletal modeling, 
ranging in size from 12-15 kDa. It is present in all eukaryotic cells and several 
species, including humans, have more than one isoform. Profilins are evolutionarily 
diverse with respect to their sequence (5). Nevertheless, they are well conserved 
among mammals (6,7). The structures of profilins studied from different species 
exhibit high similarity despite low sequence similarity (8). Four profilin isoforms 
have been identified in humans – PFN1 expressed ubiquitously, the two splice 
variants PFN2a (major form, here onwards referred to as PFN2) and PFN2b are 
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expressed in brain and kidney respectively, PFN3 and PFN4 are expressed in 
kidneys and testes (8,9). The structure of human PFN1, like other profilins, 
consists of a 7-stranded anti-parallel β-sheet in the center, the N- and C-terminal 
helices (α1 and α4) on the convex face and two more helices (α2 and α3) and 
possibly a third single-turn 310-helix on the concave face of the β-sheet preceding 
helix α2 (Figure I-1) (10). Oligomerization of PFN1 has been reported previously, 
but the functional significance of this process needs to be elucidated (11-13). Much 
of our understanding of human PFN1 is based on studies of profilins from many 
species and their properties, discussed below and in the following sections, may 
be applicable to human PFN1 as well. 
Profilin was initially isolated as a complex with actin (14) and actin is the 
best-characterized binding partner to date (15). The actin binding residues on 
PFN1 can be inferred from the structure of the bovine profilin-β-actin complex. The 
residues that interact with the barbed face of actin are in helix α3, amino-terminal 
of helix α4, strands β4, β5 and β6 (16,17) (Figure I-1, II-10). The affinity of profilin 
for actin is higher for ATP-G-actin over ADP-G-actin and the affinity is higher for 
G-actin over F-actin (18-20). The dissociation constant (Kd) of human PFN1-G-
actin interaction is about 0.3 μM (21). 
Profilins can interact with proteins containing poly(L-proline) motifs via the 
cleft formed by the N- and C-terminal helices (α1 and α4) and the β-sheet (22-26) 
(Figure I-1, II-10). The poly(L-proline) binding surface is roughly on the opposite 
side of the actin-binding face and hence profilins can bind both actin and poly(L-
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proline) containing proteins simultaneously. Profilin is thought to bind more than 
50 proteins via the interaction with poly(L-proline) (9,15). Most notable among 
those are the cytoskeletal proteins, formins and Ena/VASP. Between 6 and 10 
prolines are required for profilin binding, with maximum affinity observed with 10 
prolines (27). But in actual proteins, prolines are usually interrupted. It appears that 
the motif containing multiple prolines has to form a stable type-II helix for a strong 
interaction with profilin (27). The consensus sequence for this interaction is ZPPX 
(Z is P, G or A; X is any hydrophobic residue) and hence the binding constant is 
likely to be different for different poly(L-proline) containing ligands (15). 
Phosphatidylinositols (PtdIns) comprise the third class of interacting 
partners of profilin. Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) is 
hypothesized to predominantly interact through electrostatic attraction between the 
negatively charged phosphate group and the basic patch of residues K70, R89, 
K91, K126 (actin binding side), R136, R137 (poly(L-proline) binding side) of human 
PFN1 (28-31) (Figure I-1). These residues overlap with both the actin and poly(L-
Figure I-1. Structure of human PFN1. The crystal structure (PDB ID code 
4X1L) and the amino acid sequence of human PFN1 are shown. The secondary 
structural elements are mapped below the amino acid sequence. The residues 
involved in binding to actin and poly(L-proline) are highlighted in blue and yellow 
respectively. The residues that are mutated in ALS mutations are depicted as 
green sticks. The residues missing from the structure are 1, 2, 57-62, 92-96. 
The numbering of the sequence starts from the methionine encoded by the start 
codon. This numbering scheme for PFN1 adopted throughout this dissertation 
is different from the published literature in which the alanine following the start 
methionine is considered the first amino acid in the sequence. 
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proline) binding sites of PFN1, and PtdIns(4,5)P2 has been shown to disrupt 
profilin-actin and proflin-poly(L-proline) interactions (32-34). Several groups have 
reported various binding affinities (between 0.1 μM and 1000 μM) depending on 
whether PtdIns(4,5)P2 was in sub-micellar, micellar concentrations or part of 
unilamellar vesicles (29,31,35-38). But phosphatidylinositol 3,4-bisphosphate 
(PtdIns(3,4)P2) and phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3) 
interact more strongly with human PFN1 than PtdIns(4,5)P2 (37,39). Interestingly, 
tryptophan fluorescence and circular dichroism (CD) spectroscopy measurements 
show that binding to phosphatidylinositols introduces structural changes by 
increasing α-helical content in PFN1 (39,40). Structures of profilin-
phoasphatidylinositols are lacking and are needed to accurately map the binding 
sites. 
Profilins in the test tube 
A wealth of information on the role of profilin in actin dynamics have been 
accumulated mainly through in vitro biochemical, fluorimetric and single molecule 
biophysical methods using fluorescently labeled actin. Actin can spontaneously 
nucleate and give rise to actin filaments. Once nucleated, the filaments can 
proceed to elongate bi-directionally, but actin assembly from pointed end is 
negligible compared to that of barbed end (41) (Figure I-2A). The interaction of 
profilin with actin serves three main purposes. First, it sequesters monomeric G-
actin and prevents its spontaneous nucleation. Increasing concentrations of profilin 
prevents actin polymerization by inhibiting nucleation and possibly promoting 
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Figure I-2. Functional consequences of profilin-actin binding. (A) Actin has 
the tendency to spontaneously nucleate under the right ionic conditions when 
its critical concentration is exceeded. Once a stable actin seed is formed, it can 
polymerize to produce filaments. The assembly from the barbed end or plus end 
determines the rate of elongation, since pointed end or minus end assembly is 
negligible. During the course of the polymerization, the ATP bound to the actin 
subunits gets hydrolyzed to ADP, favoring recognition by factors such as cofilin. 
(B) Profilin is one of the actin sequestering proteins that can inhibit nucleation. 
Once nucleated, polymerization still proceeds, but profilin prohibits pointed end 
assembly. (C) Profilin can accelerate ADP-ATP exchange on actin thereby 
maintaining a pool of polymerization-ready actin. 
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depolymerization from the barbed end (19,42-46) (Figure I-2B). Second, it prohibits 
subunit addition to the pointed end of filamentous (F) actin (Figure I-2B) due to 
steric effects (41,43,45). Third, profilins catalyze the exchange of ADP to ATP on 
monomeric (G) actin, speeding up the process by about 1000 fold thereby 
effectively “recharging” it for polymerization (15,47,48) (Figure I-2C). The ATP-
bound form of actin is polymerization-competent and due to the intrinsic ATPase 
activity of actin, the bound ATP in F-actin gets hydrolyzed to ADP, which favors 
recognition by severing factors such as cofilin for recycling G-actin (8,49,50). The 
presence of PtdIns(4,5)P2 effectively reduces the ability of profilin to inhibit actin 
polymerization (29,39). 
Three main classes of actin assembly machineries exist – (i) the Arp2/3 
complex and its activator WASP nucleate branched actin filaments (51,52), (ii) 
members of formin family nucleate and elongate unbranched actin filaments 
(41,53), (iii) Ena/VASP family members elongate unbranched actin filaments (54-
56). All three machineries present a free barbed end facilitating actin subunit 
addition. The feature that ties these machineries to profilin is poly(L-proline). 
WASP consisting of poly(L-proline) motifs is an interactor of profilin (57). The 
significance of this interaction in nucleation by Arp2/3 is yet to be established. But 
the presence of profilin inhibits nucleation by Arp2/3 in vitro (58-60). Formins, 
which function as a homodimer, are a class of proteins characterized by the 
presence of formin homology (FH1) and formin homology (FH2) domains, in 
addition to other domains such as those involved in cellular localization and 
10 
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signaling (41,53,61). The FH2 is the actin nucleating domain that can nucleate 
actin filaments by binding free actin monomers. Notably, the FH1 domain is rich in 
poly(L-proline) motifs, the number of which varies depending on the formin. The 
FH1 domain recruits several profilin-actin complexes which in turn feeds actin 
subunits to the growing barbed end. The FH2 domain stays attached to the barbed 
end by a “helical stair-stepping” mechanism (41,53,62-64) (Figure I-3). Formins in 
general accelerate filament elongation rates to different extents although 
exceptions do exist (41,53,64,65), and the elongation rate is positively correlated 
with the number of profilin-binding poly(L-proline) sites in the FH1 domain (66). 
The Ena/VASP family members exhibit parallelism to formins in their properties. 
They contain proline-rich motifs between the Ena/VASP homology domains 1 and 
2 (EVH1 and EVH2) and when they operate as functional tetramers, they recruit 
profilin-actin complexes, deliver actin subunits to the barbed end and stay 
associated to the barbed end by stepping along the growing filaments (54-56,67). 
The coordinated activities of several factors in addition to actin, profilin and Arp2/3 
have been studied using bead motility assays by several groups and demonstrate 
Figure I-3. Nucleation and elongation by formins. (A) Most formins in their 
functional homodimeric form can nucleate actin filaments via their FH2 domains 
(depicted as a ring). After nucleation the formin molecule stays attached to the 
barbed end by exhibiting “helical stair-stepping” motions. (B) The FH1 domain 
of formins can recruit profilin-actin complexes and deliver them to the growing 
barbed end. Formins such as mDia1 greatly accelerate filament assembly. The 
ability of formins to accelerate filament assembly depends on the number of 
profilin-actin recruiting poly(L-proline) motifs in the FH1 domain. The elongation 
factor Ena/VASP operates in a similar manner by forming a tetramer. 
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the intricate nature of nucleation, assembly, disassembly and turnover of actin 
filaments (68,69). 
Profilins in cells 
 The cellular concentration of PFN1 is greater than 50 μM, but much lower 
than actin concentration (15). The major actin sequestration role in some animal 
cells is performed by thymosin family proteins. In cells, the role of profilin is mainly 
to maintain a pool of polymerization-ready ATP-actin (9,15). Supporting this view 
is the fact that microinjecting excess profilin in mammalian cells depolymerizes 
actin whereas microinjection of profilin-actin complexes favors actin polymerization 
(70). PFN1 localizes in both the cytoplasm and the nucleus (9,15). PFN1 can also 
possibly localize to the plasma membrane facilitated by interacting with 
phosphatidylinositols. This has been shown for yeast profilin (71). 
Profilin can act as a signal transducer in at least three ways. Profilin 
localized to the membrane via PtdIns(4,5)P2, protects the latter from hydrolysis by 
phospholipase C-γ1 (PLCγ1) (35,36). Receptor tyrosine kinases, on stimulation, 
can phosphorylate PLCγ1 which overcomes inhibition by profilin to hydrolyze 
PtdIns(4,5)P2. Profilin, released from the breakdown of PtdIns(4,5)P2, can interact 
with actin (9,15,35,36). Profilin association with formins can be indirectly linked to 
its signaling. Diaphanous formins, such as mDia1, exist in an autoinhibited 
conformation, in which the N-terminal diaphanous inhibitory domain interacts with 
the C-terminal diaphanous autoregulatory domain (41). On activation by Rho 
family GTPases, mDia1 is relieved from this autoinhibition, which can then 
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nucleate actin and recruit profilin-actin for actin polymerization (41). In addition, 
several phosphorylation sites have been reported on PFN1 (72-75). Notably, 
phosphorylation of residue S138 occurs downstream of Rho signaling. Some of 
these modifications regulate binding to actin or poly(L-proline) (76). 
There are different kinds of F-actin structures generated by formins, Arp2/3 
complex and Ena/VASP. Profilin, by its association with these actin assembly 
machineries, have been implicated in the formation of F-actin structures 
associated with stress fibers, cell polarity, centrosome organization, mitotic and 
meiotic divisions, migration, endocytosis, trafficking and focal adhesions. (9,15). 
There are about 15 mammalian formins some of which are cell-type specific. In 
addition to FH1 and FH2, they possess exclusive domains that might help in 
localization and filament generation in different cellular compartments (41,53,77). 
Interestingly, the presence of profilin favors assembly of F-actin by formins over 
Arp2/3 (59,60). 
Both actin and mammalian profilins, PFN1 and PFN2, are found in the 
nucleus. The small size of profilins should enable them to diffuse through the 
nuclear pores (15). PFN1 has been found in nuclear gems complexed with survival 
of motor neuron (SMN) (78). SMN interacts with mammalian profilins via its poly(L-
proline) motif and is associated with the neurodegenerative disease spinal 
muscular atrophy (SMA). Further, PFN1 is possibly involved in RNA splicing due 
to its co-localization with small nuclear ribonuclear proteins (snRNPs) and Cajal 
bodies (79). Moreover, there is an export factor exportin 6 that transports the 
14 
 
PFN1-actin complex out of the nucleus (80). While the presence of PFN1 in the 
nucleus is clear, a suitable role for PFN1 in nuclear events needs to be 
ascertained. Interestingly, actin is believed to participate in a variety of nuclear 
processes such as chromatin remodeling and transcription (81-83). In addition, 
formin-2 (FMN2) generated actin filaments in the nucleus participate in DNA repair 
after drug-induced DNA damage (84). Therefore, if F-actin, formins and PFN1 exist 
in the nucleus, it is plausible to think of nuclear PFN1 acting to favor polymerization 
(84-86). 
While PFN2 is a brain specific isoform, PFN1 is also found in most neuronal 
tissues. Both isoforms are present in pre- and post-synaptic compartments, but 
more so in the latter (87). Both pre-synaptic and post-synaptic proteins that contain 
poly(L-proline) serve as ligands for profilins in neurons. Examples include (i) 
gephyrin which is responsible for glycine receptor clustering, (ii) drebrin which is 
required for dendritic spine morphology, (iii) aczonin is a pre-synaptic scaffold and 
(iv) delphilin, a formin, is a post-synaptic scaffold that binds glutamate receptor δ2 
subunit, indicating that profilins likely contribute to synaptic vesicle cycling, 
synaptic activity and plasticity (15,88,89). The post-synaptic densities and spines 
are also enriched in actin filaments suggesting a role for these profilin isoforms in 
modulating actin dynamics (87). In addition, neuronal stimulation drives both 
profilin isoforms to dendritic spines (87,90,91). 
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Profilins in animals 
PFN1 is ubiquitously expressed in mammals with the exception of skeletal 
muscles where the levels are very low (92,93). Homozygous PFN1 knockout in 
mice is embryonic lethal. The embryos die very early in gestation, as early as two- 
or four-cell stage, possibly due to failed cleavages (93). This is not surprising in 
light of the number of binding partners and hence a variety or cellular processes 
that PFN1 is involved (9,15). PFN1 heterozygous knockout had reduced chances 
of survival, but the survivors were normal (93). 
PFN1 in general acts in the capacity of a pro-migratory and motility factor 
during development and in adults. Migratory behavior seen during neuronal 
differentiation, neuritogenesis, and outgrowth of astrocytic processes requires 
PFN1 (94-98). Whilst PFN1 deletion is embryonic lethal, studies using PFN1 
conditional knockout models has aided in understanding the role of PFN1 at the 
organism level. For example, PFN1 is required for glial cell adhesion and radial 
migration of cerebellar granule neurons during development. Conditional deletion 
of PFN1 using nestin-Cre led to cerebellar hypoplasia, disorganized cerebellar 
cortex layers, Purkinje cell loss and impaired motor coordination (99-102). Deletion 
of PFN1 in Schwann cells led to impaired lamellipodia formation in vitro and radial 
sorting and myelination in vivo (103).  
Both PFN1 and PFN2 are found in post-synaptic dendritic spines as well as 
in pre-synaptic boutons (91,104,105). In addition to exhibiting neuronal subtype 
specific differential localization with respect to pre- vs. post-synaptic 
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compartments, PFN1 expression levels vary from one brain region to another (91). 
Both PFN1 and PFN2 are necessary for the maintenance of dendritic complexity, 
spine density and morphology (106), the former for spinogenesis and the latter for 
synaptic function and plasticity (104). Moreover, both PFN1 and PFN2 interact with 
endocytic components in mouse brains, pointing to their role in synaptic vesicle 
cycling in the pre-synaptic compartment (92). Surprisingly, conditional knockout of 
PFN1 in adult forebrain did not affect spine density or structure, synaptic 
transmission or physiology, suggesting that PFN1 functions can be partly 
complemented by the PFN2 (107). 
 On the other hand, PFN2 knockout mice are hyperactive and show 
increased novelty seeking behavior (105). They impair actin polymerization at 
synaptosomes under stimulation and increase synaptic vesicle exocytosis. 
However, loss of PFN2 did not affect neurite outgrowth, long-term potentiation 
(LTP), long-term depression (LTD), learning and memory further supporting that 
PFN1 and PFN2 can somewhat complement each other in adult brains (105). 
Profilins in diseases 
This is the first time disease causing mutations have been identified in PFN1 
(7). But PFN1 has been linked to other neurodegenerative conditions such as 
Huntington’s disease (HD) and SMA. Interestingly, huntingtin (HTT) and SMN have 
both been reported as binding partners of PFN1 (78,108). I will focus on these two 
neurodegenerative disorders as they are most relevant to this dissertation. 
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In HTT, the poly(L-proline) motifs occur proximal to the poly-glutamine tract. 
The levels of both PFN1 and PFN2 were found to be decreased in HD patient 
brains, cell culture and Drosophila models of poly-glutamine disease (108). 
Contrary to that, Narayanan et al. reported an increase in both PFN1 mRNA and 
protein levels among other Rho kinase pathway-linked cytoskeletal genes in HD 
patient brains (109). In cell culture models, expression of mutant HTT enhances 
PFN1 degradation by the ubiquitin-proteasome system (UPS) and reduces the F/G 
actin ratio. Exogenous expression of PFN1 restores the F/G actin ratio, mitigates 
mutant HTT aggregation and toxicity in cell culture models and Drosophila (108). 
Inhibition of HTT aggregation by PFN1 requires its binding to both actin and poly(L-
proline) of HTT (75). 
The Rho/Rac/Cdc42 family of small GTPases play prominent roles in actin 
cytoskeletal remodeling (110,111). The diaphanous formins, Arp2/3 and 
Ena/VASP are all direct or indirect effectors of this family of GTPases (112-114). 
Rho-associated coiled-coil-containing protein kinases (ROCKs), another 
downstream effector of RhoA-GTPase, has a number of substrates including 
myosin light chain, LIM kinases (that phosphorylate cofilin) and profilin (115,116). 
ROCKs have been considered as therapeutic target for neurological disorders 
(117,118). 
S138 phosphorylation of PFN1 by ROCK1 diminishes its binding to actin 
and blocks its interaction with HTT (75). ROCK1 inhibition by the drug Y-27632 
minimizes poly-glutamine expanded HTT, androgen receptor (AR), ataxin-3, 
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atrophin-1 aggregation and elevates the activity of UPS and autophagy causing 
degradation of the poly-glutamine expanded proteins (75,119). PFN1 also has 
somewhat similar effects in poly-glutamine expanded AR associated with 
spinobulbar muscular atrophy (SBMA) (75). Another ROCK inhibitor HA-1077 also 
inhibits profilin phosphorylation in vivo and improves retinal defects observed in 
R6/2 HD mouse model (120). The pathogenic mechanism may involve the 
interaction of HTT and AR to F-actin (121). 
SMA is a motor neuron disease characterized by decreased levels of SMN 
or loss-of-function mutations in SMN. SMN is essential for mRNA splicing, snRNP 
transport and neuritogenesis (78,122). Both PFN1 and PFN2 bind to SMN but the 
latter binds more strongly (78). PFN2 colocalizes with SMN in nuclear gems and 
growth cones of differentiated PC12 cells in motor neurons (122). PFN1 was also 
shown to colocalize with gems in HeLa cells (78). Knockdown of both PFN1 and 
PFN2 in PC12 cells, prevents neurite growth and causes aggregation of SMN in 
the cytoplasm. Pathogenic mutations in SMN also inhibit neurite outgrowth (123) 
and diminishes its binding PFN2 (122,123). Knockdown of SMN in PC12 also leads 
to fewer differentiated cells, short neurites, increased levels of RhoA-GTPase and 
accumulation of F-actin at the cell periphery. There was an elevated level of PFN2 
and its increased association with ROCK (124) possibly resulting in its 
phosphorylation at S138 (123). The latter was also observed in a severe SMA 
mouse model (123). In SMA mouse models, there are increased levels of PFN2, 
decreased plastin 3 (an actin-bundling protein responsible for axon growth) levels 
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in the brain stem and spinal cord (125) and higher F/G actin ratio (123). Drugs that 
inhibit RhoA or ROCK including Y-27632, rescued certain neurite outgrowth 
defects caused by SMN knockdown in PC12 cells (123,124). Further, in U87MG 
astroglioma cells, SMN knockdown caused decreased migration, loss of stress 
fibers, reduction in F/G actin ratio, and an increase in PFN1 levels. These cells 
also show signs of increased RhoA activation and treatment with the ROCK 
inhibitor Y-27632 restored migration rates of U87MG (126). Taken together, the 
loss of SMN function point to a dysregulation of PFN2 and to some extent PFN1, 
and the pathogenesis is probably mediated through RhoA signaling and actin 
dynamics. 
In Drosophila the fragile X mental retardation protein (dFMRP) binds and 
negatively regulates profilin mRNA regulating neurodevelopment (127). In another 
Drosophila study, dFMRP was shown to influence profilin mRNA mobility and 
transport (128). In fmr1 knockout mouse, a model of fragile X syndrome, PFN1 
levels, but not PFN2, were significantly reduced. Overexpression of PFN1 in fmr1 
knockout mouse rescues the spine phenotypic defects (104). 
PFN1 is well studied in the context of cancer proliferation and metastasis 
where both pro- and anti-migratory roles have been assigned to it (129-131). It is 
interesting to note that FUS/TLS, another ALS-associated gene, was first 
implicated in cancers as well. In addition, PFN1 is implicated in a variety of 
disorders such as vascular hypertrophy, diabetic retinopathy and adipose tissue 
inflammation, which are beyond the scope of this dissertation and are not 
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discussed (129,132,133). Nevertheless, understanding the role of PFN1 in other 
diseases can help in our efforts to understand PFN1-ALS pathogenesis. 
  
PFN1 in ALS 
ALS-mutations on PFN1 identified till date 
Exome sequencing of FALS and SALS patients have resulted in the 
identification of several mutations in the gene encoding PFN1, namely, C71G, 
M114T, G118V (7), E117G (7,134), T109M (74), R136W (135), A20T, Q139L (6). 
The variant E117D was found in Australian SALS patients (136). All the residues 
that are mutated in ALS are conserved in mammals. The frequency of occurrence 
of PFN1 mutations in ALS is similar to those of the other ALS genes, VCP, OPTN, 
UBQLN2 and SQSTM1 and is estimated to be 1% (2,6). The sites of mutations in 
PFN1 are indicated in the PFN1 structure shown in Figure I-1. 
In addition, several groups reported synonymous mutations when screening 
for ALS-mutations in PFN1 (137). The most commonly occurring ones are L112L 
(134,135,138-140) and Q139Q (140). In addition, three novel synonymous 
mutations, G15G (134), L88L (135), T16T (136) were identified during these 
screens. Most synonymous mutations have been reported in SNP databases but 
the allelic frequency in patients needs to be carefully examined to understand their 
role in ALS. 
The genes c9orf72, TDP43 and FUS are clearly linked to both ALS and 
FTD. The only mutation in PFN1 that seems to be associated with FTD is E117G 
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(74,141,142). It is believed that patients carrying PFN1 mutations represent the 
ALS-end of the ALS-FTD spectrum of disorders (4,74). 
The curious case of E117G 
So far, the mutation E117G has been linked to FALS, SALS and FTD. It 
was also found in controls in several studies (6,7,74,142,143). One study 
suggested that it is a benign polymorphism (142). But later studies suggest that 
this mutation occurs at a slightly higher frequency in disease cases compared to 
controls and is a susceptibility allele (6,74,143). The cellular phenotypes of E117G 
observed by other groups resemble that of WT (7,144,145), suggesting that it is 
less pathogenic compared to the other variants. 
Progress towards understanding pathogenesis 
ALS patients with PFN1 mutations present a predominantly lower motor 
neuron, spinal onset phenotypes (6,74). At the cellular level, mutations in PFN1, 
especially C17G, M114T, G118V, A20T cause the protein to aggregate (6,7), 
although aggregate formation was not observed in Drosophila models (7). The 
mutations cause cytoskeletal abnormalities such as reduced actin binding, defects 
in axonal growth cone in mouse motor neurons, increased dendritic arborisation 
and spine density in mouse hippocampal neurons and a reduction in synaptic 
boutons and F-actin levels at Drosophila neuromuscular junction (NMJ) 
(7,146,147). The mutation T109M does not impair PFN1 binding to actin or affect 
actin cytoskeleton in HEK293 cells (148). 
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The ALS-PFN1 variants were linked to RNA metabolism in recent studies. 
A synthetic lethal screen performed in yeast lacking profilin identified several P-
body and stress granule components besides actin-cytoskeletal proteins (144). 
Under arsenite stress, PFN1 was found in stress granules along with ATXN2, 
another ALS-associated protein, and the mutants show differences in their 
association to the stress granules (144). Immunohistochemistry of patient tissues 
harboring E117G or Q139L mutations show TDP43-positive cytoplasmic 
inclusions (6,142). In addition, Lewy body pathology was found in the brainstem of 
one E117G patient (6). This classic TDP43 pathology was confirmed in neuron-
like SH-SY5Y cells where it was shown that WT PFN1 interacts with TDP43 and 
the ALS-mutations cause nuclear depletion, phosphorylation and cytoplasmic 
aggregation of TDP43 with PFN1 which in turn seeds further TDP43 aggregation 
(145). Overexpression of mutant PFN1 and TDP43 in Drosophila exacerbates 
TDP43-induced retinal degeneration in addition to causing cytoplasmic localization 
of TDP43 in retinal cells (149). 
Transgenic mice expressing C71G and G118V have been generated which 
recapitulate key ALS-phenotypes (150,151). The C71G transgenic mice display 
late onset, progressive ALS-like motor phenotypes and paralysis in a dose-
dependent manner and loss of spinal motor neurons. PFN1 aggregates that stain 
with ubiquitin were observed in end-stage spinal cord sections. In addition, 
elevated levels of p62/SQSTM were observed, indicating signs of proteostatic 
stress. Further, there was reduced expression and disorganized network of 
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neurofilaments (151). The G118V transgenic mice display reduced amplitude of 
compound muscle action potential in the hind limb, progressive muscle 
denervation and loss of ventral horn spinal neurons and NMJs. There was dense 
nuclear and punctate cytoplasmic skein-like staining of TDP43 and elevated levels 
of phospho-TDP43 in the end-stage spinal cord sections. The fully symptomatic 
and end-stage G118V mice showed reduced F/G staining in lumbar spinal cord 
sections suggesting dysregulation of actin polymerization. Moreover, there was 
evidence of astrocytosis, microgliosis indicating non-cell autonomous pathways. 
Other pathological features of the G118V mice include ubiquitinated, insoluble 
PFN1 aggregates from spinal cord homogenates, axonal degeneration, 
mitochondrial defects and a reduction in upper motor neurons in the end-stage 
mice (150). These mouse models will be valuable for researchers in the future to 
study PFN1-ALS pathogenesis mechanisms. 
 
The burden of misfolded proteins in neurodegeneration 
Protein folding 
 The folding of a protein from a relatively simple primary sequence of amino 
acids to a biologically functional three-dimensional form is a remarkable process. 
On the path to acquire a functional native form, a protein encounters less stable 
intermediate states that can be harmful at times (152). Purely from a chemistry 
perspective, each state – unfolded, intermediates and folded – have a Gibbs free 
energy, ΔG°, of formation or folding (also called the thermodynamic or 
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conformational stability) associated with it. The ΔG° is negative in the direction of 
spontaneity, and a structural state that has the most negative ΔG° (or a high 
absolute value of ΔG°) is most stable and vice versa (153). A protein samples 
several states or conformations before it reaches its native state and is often 
associated with a stable ΔG° value. The process of folding is often intuitively and 
conveniently represented as a folding funnel (Figure I-4). The protein is 
“channeled” towards the bottom of the funnel which represents a stable state (154). 
Figure I-4. The protein folding funnel. During the process of folding, the 
nascent protein chain with high Gibbs free energy samples several states of 
progressively low free energy until it reaches a native functional form that 
typically possesses the lowest free energy. But mutations can destabilize or 
increase the free energy of the native folded state causing them to sample 
dysfunctional or even toxic misfolded states that have comparable or even lower 
free energies than the native folded state. 
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In a cell free system, once the protein reaches a stable intermediate state with a 
certain structure, it can preclude the protein from sampling less stable states. In 
cells, in addition to this element of spontaneous folding, there are chaperones that 
assist folding towards the functional state avoiding pitfalls and at the same time 
reducing the folding time of the protein (154-156). If the free energy gap narrows 
between a folded protein and a toxic intermediate perhaps due to a destabilizing 
mutation, then lessons from thermodynamics says that the chances of populating 
the misfolded intermediate states are higher. Then at equilibrium, a larger fraction 
of misfolded protein will be present that can become the substrate for an off 
pathway reaction such as aggregation. 
Protein misfolding, aggregation and toxicity 
The presence of aggregates of PFN1 mutants in motor neurons puts the 
topic of protein misfolding in the spotlight. Historically, there has been a heavy 
emphasis on protein misfolding and aggregation as key mediators of 
neurodegeneration, most notably the amyloid hypothesis proposed for Alzheimer’s 
disease (AD) (157,158). However, in recent times, new mechanisms underlying 
neurodegeneration, such as dysregulation of both coding and non-coding RNAs 
(159-161), started to emerge. Nevertheless, protein misfolding and failure of 
protein quality control (PQC) mechanisms are actively being studied. 
The structure of a protein is crucial for its proper function. Proteins, being 
dynamic molecules, sample a variety of conformations. When a protein misfolds 
or adopts a biologically-irrelevant conformation, it can lose its function, aggregate, 
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or in severe cases it can gain aberrant functions that can be toxic to cells (162,163). 
There are numerous examples of protein misfolding and aggregation in 
neurodegeneration – amyloid plaques consisting of amyloid-β (Aβ) fibrils in AD, 
neurofibrillary tangles consisting of tau in AD and related tauopathies, α-synuclein 
forming Lewy bodies in Parkinson’s disease (PD), poly-glutamine expanded HTT 
aggregates in HD, prion protein in prion diseases, SOD1 aggregation, cytoplasmic 
inclusions of TDP43 and FUS, and c9orf72 dipeptides in ALS (162,164-167). 
Aggregates can be amorphous or structured as in amyloid fibrils (162). A new type 
of aggregation or inclusion body formation is seen with RNA-binding proteins 
containing low complexity domains. The aggregation of the disordered low 
complexity domains of such proteins result in liquid-liquid phase separation whose 
persistence cause them to become solid-like. Through their RNA recognition motifs 
these proteins can drag RNAs to the inclusions (168,169). 
What causes the toxicity associated with protein misfolding and 
aggregation? The longstanding question in protein aggregation-mediated 
neurodegeneration is whether the aggregates are neurotoxic or neuroprotective. It 
is understood that the toxicity arises from the oligomeric species that are generated 
during the process of aggregation (162). Oligomers act as seeds for aggregation. 
These oligomers or the misfolded proteins present hydrophobic groups on their 
surfaces that can mediate aberrant interactions with cell membranes, receptors, 
components of endoplasmic reticulum (ER), Golgi and mitochondria, and soluble 
proteins leading to the drainage of key cellular factors (162). More oligomers can 
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be generated from fragmentation of aggregates amplifying the toxic effects. 
Further, these oligomers are capable of prion-like transmission from cell to cell 
causing aggravation (162). In the case of cytoplasmic inclusions of RNA binding 
proteins, depletion of RNA and RNA-binding proteins can affect global RNA 
regulation (170). Understanding the nature of misfolding and aggregate formation 
is therefore necessary for therapeutic interventions. The advent of new tools such 
as conformation specific antibodies and structural techniques such as solid-state 
nuclear magnetic resonance (NMR), cryo-electron microscopy (cryo-EM) is 
enabling researchers to study protein misfolding and the aberrant nature of 
aggregates in great detail (171). 
Protein quality controls mechanisms 
Many proteins have an intrinsic tendency to misfold or aggregate. Naturally, 
eukaryotic cells have evolved a dedicated and intricate set of machineries to deal 
with the dissolution of these non-relevant protein species. These protein quality 
control mechanisms carefully monitor the folding status at every stage during the 
lifetime of a protein and begin to operate under circumstances of proteostatic 
stress. At the level of translation, ribosome quality control surveys and degrades 
nascent chains produced by stalled ribosomes. There are chaperones that help 
the protein fold in the ER and cytoplasm. Accumulation of misfolded and or 
aggregated proteins still happen from time to time, but there are mechanisms that 
recognize misfolded proteins in membranes, cytosol and nucleus and spatially 
sequester them into different spatial compartments where they can be refolded by 
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chaperones or degraded by UPS or autophagy. Under conditions of cellular stress 
such as ER stress, the unfolded protein response (UPR) is initiated, a three-
pronged signaling cascade aimed at inhibiting translation, elevating chaperones, 
evaluating cell health for expression of pro-survival or pro-apoptotic genes. Post-
mortem brains of patients with AD, tauopathies, PD, ALS often show signs of 
oxidative stress, ER stress and UPR (172). 
The key issue with the quality control mechanisms is their downgrading with 
age (162). Research shows age-related (i) increase of oxidative stress, (ii) 
disturbance in mitochondrial activity, (iii) reduction of chaperone levels, (iv) decline 
of UPS activity and (v) decreased efficiency of autophagy (162,173-175). With 
disease causing mutations and other determinants that increase the propensity for 
misfolding – which happens to be both a cause and an effect of PQC decline – 
these PQC are over-burdened to the point of a cellular catastrophe (162). Here, I 
emphasize again the post-mitotic nature of neurons, as there is no chance of 
recuperation when these quality control mechanisms are compromised. A 
significant effort, therefore, towards treatment of neurodegenerative diseases has 
been intervention at the level of protein quality control to minimize build-up of 
misfolded proteins and is an active area of research (172,176,177). 
On account of the presence of PFN1 aggregates in overexpression models 
(6,7) and the above mentioned implications due to the presence of misfolded 
proteins and aggregates, it assumes significance to deduce the structural 
29 
 
determinants that leads to its aggregation and potential toxicity. This aspect is 
explored in detail in Chapter II. 
 
Cytoskeletal defects in neurodegeneration 
The neuronal cytoskeleton 
Neurons are highly specialized, polarized and asymmetric cells 
compartmentalized into axons, cell body and dendrites (178). In human motor 
neurons, axons extend as far as 1 m from the cell body (179), possess complex 
dendritic branches and synaptic contacts (178). Neurons during development have 
to constantly seek out cues to form the right synaptic contacts (180). Once post-
mitotic, they have to stably maintain axonal structures especially during 
mechanical stress and at the same time should allow for spatiotemporal changes 
in synaptic contacts in response to neuronal activity, and repair during injury. This 
is not possible without the coordinated activity of actin and microtubule 
cytoskeleton. In short, the neuronal cytoskeleton is significant for proper neuronal 
function (178,180,181). 
The stability and the dynamic nature of microtubules is predominantly 
determined by post-translational modifications of the tubulin subunits and the 
hydrolysis-state of bound GTP (178). The axons are composed of stable parallel 
bundles of microtubules with their plus ends directed away from the cell body 
towards the axon terminals. Such an orientation aids in bidirectional transport of 
cargo such as vesicles, RNPs and nutrients by the anterograde kinesin and 
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retrograde dynein motors (178,181). The axon initial segment close to the cell body 
consists of a meshwork of actin filaments, probably acting as a filter and sorting 
cargo for transport along the axons to the distal pre-synaptic terminals (182). Two 
breakthrough studies described a two-tier organization of actin filaments in axons. 
The first study, employing high resolution stochastic optical reconstruction 
microscopy (STORM), identified the presence of periodic adducin-capped F-actin 
rings connected by spectrins along the axons of hippocampal neurons (183). The 
presence of these structures was subsequently confirmed in other neuronal cell 
types (184). These rings appear to be very stable and potentially offer mechanical 
support to the axons. The second study, using live cell imaging, described dynamic 
actin trails defined by spurts of rapid formin mediated actin assembly and 
disassembly along axons that originate from stationary endosomes situated along 
the axons. They are thought to deliver actin to distal regions of the axons such as 
the pre-synaptic terminals (185). F-actin is enriched in the form of patches at pre-
synaptic boutons and several studies point to a role of these patches in synaptic 
vesicle clustering, fusion and endocytosis (88,186). 
During development, the axonal growth cone regions are rich in both actin 
and microtubule filaments. The central or C-domain is where the microtubules 
terminate. Bundles of actin filaments radiate from this region into the peripheral P-
domain primarily consisting of F-actin lamellipodia and protruding filopodia that 
seek out cues from the environment. Between the C- and P-domain is the transition 
T-domain where contractile actin arcs lie perpendicular to the F-actin bundles. Both 
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F-actin and microtubules are dynamic in this region allowing for growth cone 
extension or retraction (178,181). 
The dendrites are also comprised of actin and microtubules. The 
microtubules adopt mixed polarity in the dendrites. The dendritic spines are rich in 
F-actin and even microtubules have been found to invade these structures. These 
cytoskeletal assemblies in the spines are modulated and remodeled in response 
to synaptic activity (187-190). Actin and microtubule dynamics are tightly coupled 
in both the pre-synaptic and dendritic compartments and there are several factors 
that mediate the cross-talk and co-ordination between these two (178,181). 
Neurofilaments (NF), a type of intermediate filament (IF) found in neurons, 
are assembled from four proteins NF-H, NF-M, NF-L and α-internexin (adult central 
nervous system) or peripherin (adult peripheral nervous system). In addition 
neurons express the Ifs, nestin, vimentin and synemin during development in 
neurons, but they disappear after maturation. The formation and function of NFs 
are highly regulated by phosphorylation and glycosylation. Overall NFs act as 
scaffolds for docking, organizing and regulating synaptic vesicles, endosomes, 
lysosomes, ER and mitochondria. NFs are present mainly in axons in close co-
ordination with microtubules, but are also present in post-synaptic regions. It is 
required for radial axon growth and stability, modulation of ion channels for proper 
conduction of electrical impulses along axons. In post-synapses it is involved in 
dopamine-D1 receptor recycling and synaptic plasticity (LTP in hippocampal 
neurons). NFs communicate with both microtubule and actin cytoskeleton (191). 
32 
 
A multitude of cytoskeletal proteins have been implicated both directly and 
indirectly in neurodegeneration. In the rest of this section, I will discuss only key 
aberrant cytoskeletal features that profoundly dictate disease course. 
Microtubule defects 
The major cytoskeletal dysfunction associated with neurodegeneration is 
due to alterations in the stability and dynamics of microtubules which has direct 
consequences on axonal transport (178). In AD, besides the extracellular amyloid 
plaques composed of Aβ, aggregates of hyperphosphorylated tau are found in the 
soma and dendrites where they are referred to as neurofibrillary tangles and 
neuropil threads respectively (178,192). This pathology is observed in a number 
of related neurodegenerative conditions collectively termed tauopathies. Certain 
inherited forms of FTD are due to mutations in tau (192). Tau is a microtubule 
binding protein and its hyperphosphorylation in diseased states reduces its affinity 
for microtubules, thereby failing to stabilize microtubules rendering them hyper-
dynamic (179,192). However, it has been argued that the effect of tau on 
microtubules can be limited and that there are also tau-independent mechanisms 
of microtubule disruption at play (178,179). An example of tau-independent but 
direct disruption of microtubule function is caused by aberrant regulation of post-
translational modifications of tubulin subunits such as acetylation, tyrosination and 
polyglutamylation and has been observed in several neurodegenerative conditions 
including AD, PD and HD (178,179,192-195). 
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The major consequence of alterations of microtubule dynamics such as 
microtubule destabilization, hyper-dynamicity etc. is the disruption of cargo 
transport along axons. The Wallerian degeneration or the axon dying back pattern 
observed in neurodegenerative conditions is characterized by the occurrence of 
microtubule fragmentation in early stages (179,193). Almost all disease causing 
mutations in LRRK2, α-synuclein, parkin (PD), SOD1, FUS, TDP43, DCTN1 (ALS), 
HTT (HD), SMN (SMA) show some form of microtubule abnormalities and axonal 
transport defects (178,192,196-199). In ALS, disease-causing mutations in SOD1 
and FUS cause both anterograde and retrograde transport defects in squid 
axoplasm assays (200,201). The recently described ALS-causing mutations in 
TUBA4A alters microtubule dynamics through a dominant-negative mechanism 
(202). Although axonal microtubule cytoskeleton has been extensively studied, 
there is evidence for loss of dendritic spines leading to dendritic simplification and 
decreased synaptic activity (178,179). Significant research efforts have been 
directed towards developing therapeutics that modulate microtubule cytoskeleton 
(178). 
Actin cytoskeletal defects 
Rho-GTPase has been implicated in a number of neurodegenerative 
diseases (178). The involvement of actin cytoskeleton and Rho/ROCK signaling in 
HD, SBMA and SMA was discussed earlier in the section “Profilins in diseases”. 
Actin associated neurite outgrowth defects are frequently reported phenotypes in 
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neurodegenerative disease models. In ALS, this is observed in SOD1 and TDP43 
models (203,204). 
Pathological actin structures saturated with cofilin are found in brains of AD 
patients (205,206). These structures differ from regular F-actin in that they are 
composed of ADP-actin subunits, cannot be stained with phalloidin and are 
believed to form in response to energy deficit. The understanding of cofilin-actin 
rod formation comes from studies in animal and cell culture models of AD and 
tauopathies where they can be induced by a variety of stimuli such as ATP 
depletion, oxygen radicals, pro-inflammatory cytokines, Aβ oligomers, cellular 
prion protein etc. (207-210). An age dependent increase in rods is reported in rat 
hippocampal neurons (211). A precise pathological mechanism for these 
structures is not known, but both neuroprotective and neurotoxic roles have been 
attributed to it. Actin polymerization being an energy-expensive process, cofilin-
actin rod formation is thought to freeze actin dynamics during energy stress 
reallocating ATP for processes that promote survival. On the other hand, these 
structures are responsible for blocking intracellular transport, loss of synapses and 
decreased synaptic transmission (205,207,211). Closely related to cofilin-actin 
rods are actin-rich Hirano bodies found in AD patients and models of AD and 
tauopathies (212-214). Cofilin-actin rods that contain HTT also form in the nucleus 
in response to heat shock, and mutant HTT causes persistence of rods (215). 
Cofilin-actin rods are unreported in ALS. For further information, readers are 
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encouraged to consult an excellent review article published by Bamburg and 
Bernstein in the journal Cytoskeleton (207). 
The non-neurological muscle disorder relevant to this discussion, 
intranuclear rod myopathy, are caused by mutations in the skeletal muscle α1-
actin (ACTA1). This disease is characterized by intranuclear rod-aggregates of 
actin and actin-binding proteins. In cell culture models these rods can be mostly 
stained with phalloidin (unlike cofilin-actin rods). Pathogenic mechanisms include 
nuclear rod induced changes to RNA polymerase II localization and chromatin 
organization patterns in addition to disrupted sarcomeric structure (216-219). 
Neurofilament defects 
Mutations in NF-L cause Charcot-Marie-Tooth disease (CMTD) type 2E and 
1F. The mutations affect assembly and transport of NF proteins along axons, 
reduce axon calibers and impair nerve conduction. Mutations in NF-H and 
peripherin cause ALS. Mutations in NF-M domain are linked to familial PD and AD. 
A type of frontotemporal dementia (FTD) called neurofilament inclusion body 
disease is characterized by the presence of α-internexin in NF protein aggregates. 
Typically, the pathological feature associated with mutations in NF genes is NF 
aggregation and failure of NF protein transport along axons leading to axonal 
dysfunction and degeneration. The NF pathology can also be caused by mutations 
in other genes such as HSPB1 in CMTD2F, gigaxonin in giant axonal neuropathy, 
SOD1 in ALS (191). 
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Summary 
ALS is a debilitating disease leading to paralysis and death. Like most 
neurodegenerative diseases, ALS is a complicated disease for which no cure has 
been found despite extensive research following the discovery of the first gene 
three decades ago. A multitude of interconnected pathways are ascribed to the 
disease pathogenesis driven by various genes. PFN1 mutations bring forward the 
case of actin cytoskeletal alterations in ALS. In this dissertation, I look at the two 
aspects meriting attention and that were also alluded to in this chapter – structural 
and functional defects of the ALS causing mutations on PFN1. In Chapter II, I try 
to establish the reasons behind its aggregation in cells. In Chapter III, I attempt to 
decipher the biochemical implications of mutant PFN1 in actin cytoskeletal 
assembly. Since structure and function of a protein are interdependent, the 
functional alterations observed in PFN1 could result directly from the structural 
defects, and therefore correcting the structure should help correct abnormalities in 
function. 
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PREFACE TO CHAPTER II 
 
Dr. Kristin Boggio analyzed the mass spectrograms of purified PFN1 
proteins. Noah Cohen provided assistance in fitting the chemical denaturation 
data. Maeve Tischbein performed the PFN1 turnover experiments in SKNAS cells. 
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PFN1. Tania Silvas, Dr. Shivender Shandilya and Dr. Celia Schiffer solved PFN1 
crystal structures. Dr. Silvia Jansen and Dr. Bruce Goode performed pyrene-actin 
polymerization assays. Most of Chapter II, except for Figure II-7, appeared in the 
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Boopathy S, Silvas TV, Tischbein M, Jansen S, Shandilya SM, Zitzewitz JA, 
Landers JE, Goode BL, Schiffer CA, Bosco DA. Structural basis for mutation-
induced destabilization of profilin 1 in ALS. Proc Natl Acad Sci U S A. 2015 Jun 
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CHAPTER II – STRUCTURAL BASIS FOR MUTATION-INDUCED 
DESTABILIZATION OF PFN1 IN ALS 
 
Introduction 
The observation that most ALS-linked PFN1 variants are highly prone to 
aggregation in mammalian cultured cells suggests that disease-causing mutations 
induce an altered, or misfolded, conformation within PFN1 (7). Protein misfolding 
is a hallmark feature of most neurodegenerative diseases, including ALS (220), 
and can contribute to disease through both gain-of-toxic-function and loss-of-
normal-function mechanisms (221). 
While ALS-linked mutations were shown to induce PFN1 aggregation, the 
effect of these mutations on protein stability and structure has not been studied. 
Because the impact of disease-causing mutations on protein stability varies from 
protein to protein (222-224), these parameters must be determined empirically. 
Here, we demonstrate that certain familial ALS-linked mutations severely 
destabilize PFN1 in vitro and cause faster turnover of the protein in neuronal cells. 
To gain insight into the source of this mutation-induced instability, the three-
dimensional crystal structures for three PFN1 proteins, including the WT protein, 
were solved by X-ray crystallography. We discovered that the M114T mutation 
created a cleft that extended into the interior of PFN1. Further, we predict that the 
most severely destabilizing C71G mutation also creates a cavity near the core of 
the PFN1 protein, proximal to the cleft formed by M114T. Experimental mutations 
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that create enlarged pockets or cavities are known to exert a destabilizing effect 
on the native conformation of the protein (225), and there are several examples of 
mutation-induced cavity formation occurring in nature and disease (226,227). 
Interestingly, the variant predicted to be the least pathogenic according to recent 
genetics studies, E117G, was relatively stable and closely resembled the WT 
protein in every assessment performed herein (7,143). These data implicate a 
Figure II-1. ALS-linked mutations destabilize PFN1. Chemical and thermal 
denaturation studies reveal that ALS-linked variants C71G, M114T, and G118V, 
but not E117G, are severely destabilized relative to PFN1 WT. (A) Equilibrium 
unfolding curves for PFN1 WT and ALS-linked variants generated by measuring 
the intrinsic tryptophan fluorescence of the indicated protein equilibrated in 
increasing concentrations of urea. Data were processed to obtain the center of 
mass (COM) of the emission spectrum and then fit to a two-state model for 
protein folding. The resulting fits are displayed as solid lines. The corresponding 
thermodynamic parameters obtained from the fitted data are shown in Table II-
1. (B) Thermal denaturation profiles of PFN1 proteins measured by SYPRO 
Orange fluorescence as a function of increasing temperature were used to 
determine the apparent Tm, which is the temperature corresponding to 0.50 
fluorescence signal as denoted by the intersection of the dashed lines for each 
curve. 
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destabilized form of PFN1 in ALS pathogenesis and call for therapeutic strategies 
that can stabilize mutant PFN1. 
 
Results 
ALS-linked mutations destabilize PFN1 in vitro 
To investigate the effect of ALS-linked mutations on the stability of PFN1, 
PFN1 proteins were expressed and purified from Escherichia coli (E. coli) and 
subjected to chemical and thermal denaturation analyses. A novel purification 
protocol that includes sequential cation-exchange and gel filtration 
chromatography steps was developed here and applied to all PFN1 variants (see 
Appendix I). PFN1 C71G was found to be highly prone to aggregation in E. coli, 
consistent with observations that this variant exhibited particularly low solubility in 
mammalian cells (7), and therefore was isolated from inclusion bodies (see 
Appendix I). The biochemical properties of PFN1 C71G purified from inclusion 
bodies are indistinguishable from PFN1 C71G purified from the soluble lysate of 
E. coli as determined by several assays (Figure AI-4), providing confidence that 
PFN1 proteins purified by these two methods can be directly compared. 
  To examine the stability of PFN1 proteins, fluorescence from tryptophans 
(W4 and W32) in PFN1 WT and ALS-linked variants was measured as a function 
of increasing urea concentration (Figure II-1A). To ensure reversibility, the 
reciprocal analysis was also performed, where denatured PFN1 proteins in urea 
were refolded upon dilution with buffer (Figure II-2A-E). Only one transition was 
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observed between the folded or native (N) and unfolded (U) states for all PFN1 
proteins, indicative of a two-state (NU) unfolding mechanism. This two-state 
unfolding model was further substantiated with an unfolding study of two PFN1 
proteins (WT and M114T) using circular dichroism (CD) spectroscopy (Figure II-
2F). The following thermodynamic parameters were determined by fitting the 
fluorescence data to a two-state folding model: apparent ΔG°, the free energy of 
folding; m, the denaturant dependence of ΔG°; and Cm, the midpoint of the 
unfolding transition (Table II-1). Both ΔG° and Cm were reduced for ALS-linked 
variants relative to PFN1 WT, particularly for the PFN1 variants C71G, M114T and 
G118V, indicating these variants are severely destabilized compared to PFN1 WT 
(Figure II-1A and Table II-1). Differential scanning fluorimetry (DSF) with SYPRO 
Orange, a fluorescent indicator of hydrophobic regions exposed upon protein 
Figure II-2. All PFN1 variants unfold by a two-state process. (A–E) PFN1 
variants denatured in urea were refolded by diluting the urea. The final 
concentration of PFN1 in each sample was 10 μM and tryptophan fluorescence 
was used to monitor folding. The equilibrium transition regions overlay closely 
for the unfolding and refolding curves, indicating that the unfolding reaction is 
reversible. Filled and open circles represent unfolding and refolding, 
respectively. (F) The two-state unfolding of PFN1 observed by intrinsic 
fluorescence (data from Figure II-1A; Fluor) was verified by CD measurements 
for PFN1 WT and M114T. The concentration of protein used was 2 μM and 10 
μM for tryptophan fluorescence and CD measurements, respectively. The y axis 
on the left is the mean residue ellipticity at 220 nm (MRE220) obtained from CD 
experiments, whereas the y axis on the right reflects the change in the COM (as 
shown in Figure II-1A). The thermodynamic parameters obtained by fitting the 
CD data agree well with those obtained from the fluorescence data (Table II-1) 
and are as follows: for WT ΔG° = 7.16 ± 0.11 kcal⋅mol−1, m = 2.36 ± 0.04 
kcal⋅mol−1⋅M−1, Cm = 3.03 ± 0.07 M; for M114T ΔG° = 4.35 ± 0.10 kcal⋅mol−1, m 
= 2.95 ± 0.06 kcal⋅mol−1⋅M−1, Cm = 1.47 ± 0.05 M. 
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unfolding, was employed next to determine the apparent melting temperature, Tm, 
for all PFN1 proteins used in this study (228). Consistent with the chemical 
denaturation results, all ALS-linked variants except E117G exhibited a Tm that was 
at least 10 °C lower than WT (Figure II-1B, Table II-1). Based on the denaturation 
studies, C71G emerges as the most destabilizing mutation in the context of PFN1, 
whereas the E117G mutation has a relatively modest impact on PFN1 stability. 
ALS-linked PFN1 exhibits faster turnover in a neuronal cell line 
The turnover rate for proteins with destabilizing mutations is often faster 
relative to their wild-type counterparts, generally because destabilized proteins are 
misfolded and targeted for degradation by the cellular quality control machinery 
(229). To determine whether the results of our in vitro denaturation studies extend 
to a cellular environment, V5-tagged PFN1 variants were transiently transfected 
into human neuronal SKNAS cells, and PFN1 turnover was assessed by tracking 
Table II-1. Summary of experimental stability and binding measurements for 
PFN1 variants. 
Variant 
Equilibrium unfolding (NU)a Melting temperature, Tm (°C)b 
Binding 
to poly-L-
prolineb, 
Kd (μM)c 
ΔG° (kcal 
mol–1) 
m (kcal 
mol–1 M–1) Cm (M) 
Protein 
alone 
+ 4 mM 
proline 
WT 7.04 ± 0.49 2.25 ± 0.16 3.13 ± 0.31 54.68 ± 0.04 57.25 ± 0.03 463 ± 26 
C71G 1.89 ± 0.70 1.95 ± 0.40 0.97 ± 0.41 34.60 ± 0.03 39.96 ± 0.03 687 ± 77 
M114T 3.51 ± 0.40 2.51 ± 0.24 1.40 ± 0.21 42.62 ± 0.03 46.52 ± 0.02 572 ± 23 
E117G 6.90 ± 0.74 2.49 ± 0.26 2.77 ± 0.42 51.05 ± 0.04 53.78 ± 0.03 407 ± 27 
G118V 3.70 ± 0.44 2.20 ± 0.23 1.68 ± 0.26 42.84 ± 0.04 46.92 ± 0.04 397 ± 40 
 
aErrors are shown as SD. 
bErrors are shown as SEM. 
cKd values are reported in terms of proline residues. 
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Figure II-3. ALS-linked PFN1 variants exhibit faster turnover in a neuronal 
cell line. SKNAS cells transiently transfected with V5-PFN1 constructs were 
treated with cycloheximide (CHX) for up to 12.5 h, during which time lysates 
were collected and probed by Western analysis with a V5-specific antibody to 
assess the rate of PFN1 turnover in cells. (A and B) A representative Western 
blot analysis of soluble and insoluble fractions from cell lysates demonstrates a 
decrease in V5-PFN1 protein with time. GAPDH serves a loading control for the 
soluble fraction. (C) Densitometry analysis of (A) reveals that the turnover of 
PFN1 C71G and M114T is significantly faster than that of PFN1 WT. Statistical 
significance was determined using a two-way ANOVA followed by a Tukey’s 
post hoc analysis (*P < 0.05, **P < 0.01, #P < 0.0001). Error bars represent 
SEM. WT and E117G, n = 3; G118V, M114T and C71G, n = 4 independent 
experiments. 
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V5-PFN1 protein expression over a 12.5 h time course in the presence of 
cycloheximide. At the start of the experiment (t = 0 of the cycloheximide time 
course), all V5-tagged PFN1 variants were expressed at similar levels except that 
V5-PFN1 C71G, M114T and G118V partitioned into the insoluble fraction (Figure 
Figure II-4. The turnover of insoluble PFN1 in SKNAS cells. The experiment 
was carried out as described in Figure II-3, and a representative Western blot 
analysis of the insoluble fraction is shown in Figure II-3B. The data above reflect 
the densitometry results from an average of n = 2 (M114T) or n = 3 (C71G and 
G118V) independent experiments and error bars represent SEM. Each sample 
was normalized to the PFN1 C71G band corresponding to “time 0.” The turnover 
of C71G within the insoluble fraction was slower relative to C71G within the 
soluble fraction (compare this graph to that in Figure II-3C). There was relatively 
less M114T and G118V in the insoluble fraction compared with C71G, and the 
small fraction of insoluble G118V persisted throughout the experimental time 
course. 
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II-3A and B) as reported previously (7). The turnover of both PFN1 C71G and 
M114T occurred significantly faster than PFN1 WT. As early as 2.5 h, the majority 
of PFN1 C71G and M114T within the soluble fraction had already degraded 
(Figure II-3A and C). This decrease in soluble PFN1 content was not simply due 
to further PFN1 aggregation, which could confound our analysis, as evidenced by 
the concomitant clearance of PFN1 from the insoluble fraction at the early time 
points of cycloheximide exposure (Figure II-3B). The faster turnover of PFN1 C71G 
and M114T in cells closely correlates with their reduced stabilities in vitro, 
confirming the destabilizing effect of the C71G and M114T mutations. We note that 
the turnover of PFN1 C71G was faster in the soluble fraction compared to the 
insoluble fraction (Figure II-4), likely because clearance of insoluble cellular 
aggregates by the quality control machinery is less efficient compared to the 
turnover of smaller, soluble species (230). Although PFN1 G118V was destabilized 
to a similar degree as M114T in vitro, the turnover of this variant within the soluble 
fraction appeared slower in cells (Figure II-3C), which may reflect a stabilizing 
effect of other proteins and/or factors that interact with PFN1 in the cellular milieu 
(15), or that this variant is not properly handled by the quality control machinery in 
the cell. In fact, we detected a low level of insoluble PFN1 G118V that persisted 
throughout the 12.5 h time course (Figure II-3B and Figure II-4). 
ALS-linked mutations induce a misfolded conformation within PFN1 
We reasoned that ALS-linked variants must undergo some degree of 
structural or conformational change to account for their destabilization. However, 
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ALS-causing mutations did not perturb the secondary structural elements of PFN1 
as determined by circular dichroism (CD) spectroscopy (Figure II-5) and the fact 
that similar m values were determined for all PFN1 variants by the urea 
denaturation analysis suggested these proteins adopt similar tertiary structures as 
well (Table II-1) (231). To probe further for potential structural differences between 
PFN1 WT and ALS-linked variants, these proteins were subjected to native gel 
electrophoresis, a biochemical technique capable of detecting conformational 
differences between misfolded variants and their wild-type counterparts (232). 
PFN1 WT and E117G migrated predominately as single, distinct bands with similar 
mobility, whereas multiple bands of slower mobility were observed for PFN1 
 
Figure II-5. ALS-linked PFN1 variants retain the same secondary structure 
as PFN1 WT. (A–D) Far UV CD spectra for the indicated PFN1 variant (10 μM) 
overlaid with CD spectrum for PFN1 WT (10 μM). 
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variants C71G, M114T and G118V (Figure II-6A). The slower mobility bands likely 
reflect the larger hydrodynamic volume due to partial unfolding of these variants. 
Figure II-6. Analysis of PFN1 proteins by native page and analytical size-
exclusion chromatography. (A) PFN1 proteins (10 μg) were subjected to 
native (top) or denaturing (bottom) gel electrophoresis and detected with 
Coomassie Brilliant Blue stain. The mobility of native PFN1 WT is indicated. 
PFN1 E117G migrates with a slightly faster mobility than PFN1 WT owing to the 
addition of a negatively charged amino acid. Misfolded ALS-linked PFN1 
variants migrate with slower mobility and form aggregated species that are 
retained in the stacking gel. This gel is representative of n = 2 experiments using 
proteins from different purification preparations. (B–F) The indicated PFN1 
protein (40 μg) was subjected to analytical size-exclusion chromatography 
using a Superdex 75 column. A single peak corresponding to the expected 
elution volume (∼15 ml) for monomeric PFN1 was detected for all PFN1 
proteins. The experiments were carried out in duplicate for each variant, 
indicated by solid (n = 1 experiment) and dashed (n = 2 experiment) lines. The 
average relative peak area ± the SD is indicated to the right of each curve. 
Despite equal sample loading, the peak area of PFN1 C71G and M114T is lower 
than that of WT (within error), consistent with a reduced level of soluble protein 
for these ALS-linked variants. (G) An overlay of B–F for the n = 1 experiment 
demonstrates a similar elution profile for all PFN1 proteins. 
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In addition, PFN1 C71G, M114T and G118V produced relatively large molecular-
weight species that were retained in the stacking gel and unable to electrophorese 
through the separating native gel, but were resolublized under conditions 
employed for the denaturing gel (Figure II-6A). Analytical size exclusion 
chromatography revealed that all PFN1 proteins eluted as expected for soluble, 
monomeric PFN1 (Figure II-6B-G). However, despite equal loading of PFN1 
proteins onto the analytical size exclusion column, the peak area corresponding to 
soluble monomer PFN1 is reduced for ALS-linked variants, particularly for the most 
aggregation prone variant C71G. These data are consistent with a loss of soluble 
monomer PFN1 in the form of insoluble species that cannot pass through the 
analytical size exclusion column filter. In addition, measurements of tryptophan 
Figure II-7. The PFN1 mutants exhibit relatively slower tryptophan 
fluorescence decay. PFN1 proteins (4 μM) were excited with vertically 
polarized light at 295 nm and the horizontal and vertical emission at 350 nm 
were measured over time. Figures show the total fluorescence decay plots of 
(A) WT, M114T, E117G and G118V and (B) WT, C71G, M114T and G118V. 
The decay profiles of WT and E117G were similar, but the mutants C71G, 
M114T and G118V decayed relatively slowly compared to WT and E117G. This 
figure was not part of the original publication. 
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Table II-2. Crystallographic and refinement statistics of human PFN1 
structures. 
 WT E117G M114T 
Resolution  (Å) 2.160 2.170 2.230 
Space group C121 C121 P6 
a (Å) 74.26 73.65 81.69 
b (Å) 31.84 31.71 81.69 
c (Å) 61.02 60.54 65.35 
Α 90° 90° 90° 
Β 122.66° 122.03° 90° 
Γ 90° 90° 120° 
Z 1 1 2 
Rmerge (%) linear 0.075 0.036 0.147 
I/sigma 13.3 12.2 12.4 
Completeness (%) 99.28 99.49 99.58 
Total no. of 
reflections 20783 16453 76801 
No. of unique 
reflections 6416 6422 12156 
Rfactor (%) 0.2159 0.1965 0.1952 
Rfree (%) 0.2469 0.2139 0.2383 
RMSD in: Bond 
lengths (Å) 0.002 0.003 0.003 
RMS Angle (°) 0.62 0.67 0.61 
Temperature (°C) -80 -80 -80 
Residues Missing: 
Chain A 
 
Chain B 
 
1, 2, 57-62, 92-96 
 
--- 
1, 2, 59-62, 81,82, 
93-95, 140 
--- 
1, 93-97 
 
1, 13, 91-97 
PDB ID 4X1L 4X1M 4X25 
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fluorescence decay revealed that the variants C71G, M114T and G118V exhibited 
a slower decay relative to WT and E117G whose decay profiles were similar, 
further pointing to the existence of a misfolded conformation among the ALS-PFN1 
variants (Figure II-7). 
A source of mutation-induced destabilization revealed by X-ray 
crystallography of PFN1 
Crystal structures of PFN1 proteins were determined in order to identify 
regions within mutant PFN1 that are conformationally distinct from PFN1 WT at 
atomic resolution. PFN1 WT, E117G and M114T produced crystals that diffracted 
at relatively high resolution (~2.2 Å; Table II-2). The three-dimensional structure of 
human PFN1 WT agrees well with previously determined structures (25,67,233). 
PFN1 WT and E117G crystallized in the same space group, C121, whereas 
M114T crystallized in the P6 space group, with two molecules (designated as 
chains A and B) in the asymmetric unit (Table II-2). 
Residues 22–36, 46–52, 101–105, 112–120 and 125–128 within PFN1 
were used for Cα superimposition of the four molecules (PFN1 WT, M114T chains 
A and B, and E117G). In agreement with the biochemical analyses described 
above (Table II-1 and Figure II-5), the secondary and tertiary structures of all three 
PFN1 proteins, including chains A and B of M114T, are highly similar (Figure II-8). 
Although the space groups for PFN1 WT and M114T crystals were different, we 
calculated the double difference plots between these and the other PFN1 
structures to get a sense for structural perturbations potentially induced by the 
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ALS-linked mutations. Double difference plots were constructed by calculating the 
distances between all of the Cα atoms in PFN1 WT and an ALS-linked variant 
separately, and then plotting the difference of the difference between PFN1 
structures as described previously (234). Virtually no structural deviations were 
observed between PFN1 WT and E117G, whereas moderate differences were 
detected between WT and M114T (Figure II-9). 
Figure II-8. Superimposition of the crystal structures for PFN1 WT, E117G, 
and M114T. (A and B) The secondary and tertiary structures for PFN1 WT 
(green), E117G (mustard), M114T chain A (pink), and B (red) are highly 
superimposable. For each structure, sticks and spheres denote the side chains 
and van der Waals radii, respectively, for residues at position 114 and 117. 
Residue 117 is located within a solvent-exposed flexible loop that has no 
discernible secondary structure, whereas Met114 is located within a β-sheet 
toward the interior of the protein. (B) A zoomed cartoon representation showing 
residues within 4 Å of residue 114. The side chains of these residues are 
indicated as sticks with nitrogen, oxygen, and sulfur atoms indicated in blue, 
red, and yellow, respectively. The van der Waals radii of the atoms comprising 
residue 114 are reduced upon mutation of methionine (green and mustard 
structures) to threonine (red and pink structures). 
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Next we sought to determine whether these moderate structural changes 
between PFN1 WT and M114T mapped to regions involved in PFN1 function, 
namely to residues that make contact with actin (17,31,47,57,235-238) or poly(L-
proline) (22,25,67,235,239). The ternary complex comprised of PFN1 WT, actin 
and the poly(L-proline) peptide derived from vasodilator-stimulated 
phosphoprotein (VASP) (67) (PDB ID: 2PAV) is shown in Figure II-10. Residues 
with the highest (0.3 Å or greater) average of absolute double difference (Avg-Abs-
DD) values between PFN1 WT and M114T chain B (Figure II-9C) were mapped 
onto PFN1 WT (Figure II-11). PFN1 M114T chain B was used for this and all 
subsequent structural comparisons because chain B had lower B-factors 
compared to chain A (Figure II-12). Indeed, several PFN1 residues that reportedly 
make contacts with actin (V119, H120, G122, K126) and poly(L-proline) (W4, Y7, 
H134, S138) also have relatively high Avg-Abs-DD values (Figure II-11). 
To assess whether these mutation-induced structural changes are sufficient 
to alter the normal binding interactions of PFN1, we first monitored changes in the 
intrinsic tryptophan fluorescence of PFN1 as a function of poly(L-proline) peptide 
Figure II-9. Structural changes induced by the M114T mutation revealed in 
double difference plots. Double difference plots (left) of WT vs. E117G (A), 
WT vs. M114T chain A (B), WT vs. M114T chain B (C), and M114T chains A 
vs. B (D). The Avg-Abs-DD values are plotted as a function of residue number 
for each structural comparison (middle); these plots provide an indication for 
residues that undergo a structural change between the proteins that are being 
compared. Residues with Avg-Abs-DD values of 0.3 Å or greater are plotted 
onto the structure (right) of PFN1 WT (A–C) and PFN1 M114T chain A (D) in 
green. Residues not used in this analysis are colored black. 
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Figure II-10. Structure of actin–PFN1–VASP peptide ternary complex with 
the actin and poly(L-proline) binding residues mapped on PFN1. The X-ray 
structure of the PFN1 WT (gray)–actin (blue)–poly(L-proline) peptide (gold) 
complex (PDB ID code 2PAV) is shown. Residues reportedly involved in actin 
binding (V61, K70, S72, V73, I74, R75, E83, R89, K91, P97, T98, N100, V119, 
H120, G122, N125, K126, Y129, and E130) and poly(L-proline) binding (W4, 
Y7, N10, A13, S28, S30, W32, H134, S138, and Y140) are highlighted in blue 
and gold, respectively. The sites of ALS-linked mutations investigated in this 
study are highlighted and labeled in black with side chains displayed as black 
sticks. Residues involved in actin or poly(L-proline) binding that also exhibit 
Avg-Abs-DD values of 0.3 Å or greater between PFN1 WT and M114T chain B 
(W4, K126, and S138) are labeled in black (the remaining residues that fulfill 
this criteria are shown in Figure II-11). 
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Figure II-11. Actin and poly(L-proline) binding residues exhibit relatively 
high double difference values. Residues that have Avg-Abs-DD values of 0.3 
Å or greater that are also engaged in actin binding (V119, H120, G122, and 
K126) or poly-Pro binding (W4, Y7, H134, and S138) are mapped onto the 
structure of PFN1 WT in magenta. All other residues with Avg-Abs-DD values 
of 0.3 Å or greater are highlighted in green. Residues with Avg-Abs-DD values 
between chain A and chain B of M114T 0.3 Å or greater (Figure II-9D) were 
excluded from this analysis. Residues not used in this analysis are colored 
black. 
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Figure II-12. The calculated α-carbon B factors for all PFN1 structures. 
Cartoon representations of WT (A), E117G (B), and M114T chains A (C) and B 
(D). Residues are colored according to the α-carbon B factors using the scale 
shown at the bottom. The average α-carbon B factor for WT, E117G, and 
M114T chains A and B structures are 30.52, 22.94, 29.47, and 27.33, 
respectively. Because the average B factor is higher for M114T chain A, M114T 
chain B was used for structural analyses unless otherwise noted. 
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concentration (Figure II-13A). Our results revealed that the effect of ALS-linked 
mutations on the PFN1-poly(L-proline) interaction was modest, as the apparent 
dissociation constants (Kd) were within 2-fold for all PFN1 proteins in this study  
(Table II-1). In fact, excess concentrations of poly(L-proline) effectively stabilized 
all PFN1 proteins as determined by DSF, with the largest increase in Tm observed 
upon poly(L-proline) peptide binding to C71G (Figure II-13B and Table II-1). Next, 
we measured the binding capacity of our PFN1 proteins for G-actin by comparing 
their concentration-dependent abilities to suppress spontaneous polymerization of 
pyrenyliodoacetamide‐labeled actin monomers (240). This assay is based on the 
Figure II-13. ALS-linked PFN1 variants retain the ability to bind poly(L-
proline). (A) Binding of PFN1 to the poly(L-proline) peptide was monitored by 
measuring the intrinsic tryptophan fluorescence of the indicated PFN1 protein 
as a function of increasing peptide concentration. The data points were fit using 
a one-site total binding model in GraphPad Prism and the apparent dissociation 
constants (Kd) obtained from the fit are shown in Table II-1. Note that the 
concentration of the peptide is reported in terms of [proline] because the peptide 
stock is supplied as a mixture of poly(L-proline) species (see Materials and 
Methods). (B) DSF was performed as described in Figure II-1B in the presence 
(dashed lines) and absence (solid lines) of 4 mM proline. The presence of 
proline increases the Tm for all PFN1 proteins used in this study (Table II-1), as 
illustrated here for WT, C71G, and M114T. 
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fact that PFN1 binds G-actin and inhibits actin nucleation in the absence of formins 
(Figure I-2B) (240). As expected, increasing concentrations of recombinant PFN1 
WT reduced the rate of actin polymerization, whereas the H120E variant that 
exhibits impaired binding to actin failed to suppress actin polymerization to the 
Figure II-14. The binding of PFN1 proteins to G-actin. Polymerization of 
monomeric rabbit muscle actin (3 μM, 5% pyrene-labeled) was monitored in the 
presence of increasing concentrations of WT or ALS-linked PFN1 variants and 
used to derive relative rates of polymerization (n = 3). The variant H120E, which 
is impaired in binding to actin, fails to suppress spontaneous actin 
polymerization as effectively as WT PFN1. Although G118V is relatively weak 
in suppressing actin polymerization, the data did not reach statistical 
significance. Statistical significance was determined using a two-way ANOVA 
followed by a Tukey’s post hoc analysis. **P ≤ 0.01 for WT vs. H120E at 7 μM 
concentration. No other significant comparisons with WT were obtained. Other 
significant comparisons included C71G vs. H120E and E117G vs. H120E (P ≤ 
0.05) at 7 μM concentration. Error bars represent SD. 
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same extent (Figure II-14). Of the four ALS-linked variants, only G118V was 
defective in suppressing actin polymerization, which was most apparent at the 
highest concentration of PFN1 used in this assay, although this effect did not reach 
statistical significance (Figure II-14). These data argue against a general 
Figure II-15. The M114T mutation causes a surface-exposed pocket to 
expand into the core of the PFN1 protein. (A) Residues are depicted as 
described in Figure II-8. The van der Waals radii of residues 90, 114, and 18 
are in contact in the PFN1 WT structure (Top). These contacts are reduced by 
the M114T mutation (Bottom) owing to the smaller size of threonine, leading to 
an enlargement of the surface-exposed pocket. (B) PFN1 WT is shown with a 
transparent surface and the secondary structure is shown in cartoon 
representation. The surface pocket volume for PFN1 WT (green) and the cleft 
volume for PFN1 M114T chain B (red-brown) are depicted as opaque surfaces 
and were generated using SiteMap. The predicted cavity (blue) for PFN1 C71G 
(generated using PyMOL) overlays with the M114T void, and unlike the WT and 
M114T volumes, is not surface-exposed. The insets (Right) show the 
aforementioned voids for WT (Top), M114T chain B (Middle), and C71G 
(Bottom). 
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mechanism for PFN1-mediated ALS pathogenesis that involves impaired direct-
binding between PFN1 and either poly(L-proline) or actin. 
Importantly, the X-ray crystal structures reveal a possible mechanism by 
which ALS-linked mutations destabilize PFN1. Residues Thr90, Met114 and Gln18 
contribute to the formation of a surface exposed pocket that was detected using 
SiteMap (Figure II-15). Mutation of methionine to threonine at position 114 
increased the size of this pocket, thereby forming a cleft, because the residues 
nearby failed to rearrange and compensate for the loss of van der Waals contacts 
(Figure II-15B). This cleft is expected to exert a destabilizing effect on the native 
conformation of PFN1 due to this loss of van der Waals contacts and the reduced 
Figure II-16. Electrostatic surface potential (ESP) of PFN1 WT and PFN1 
M114T. A comparison of the ESP for PFN1 WT (A) and M114T (B) around the 
surface pocket (for WT) and cleft (for M114T) shown in Figure II-15. 
Comparison of the ESP was calculated using Maestro (Schrödinger, LLC). The 
Red_White_Blue color scheme was used to depict the ESP of both surfaces, 
where red denotes negative, blue denotes positive, and white denotes neutral 
ESP. The minimum and maximum values are −0.12 and 0.12, respectively. The 
cleft (boxed region in B) formed by M114T exposes a deeper pocket comprised 
of hydrophobic residues that would otherwise be buried beneath the surface-
exposed pocket (boxed region in A) in PFN1 WT. 
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hydrophobicity of the threonine side chain relative to that of methionine (225). 
Moreover, hydrophobic residues that are otherwise buried in the PFN1 WT 
structure were exposed by the cleft in the PFN1 M114T structure (Figure II-15 and 
Figure II-16). In order to investigate the potential impact of the C71G mutation on 
PFN1 structure, the cysteine side-chain of residue 71 was removed to mimic a 
glycine amino acid in the PFN1 WT structure using PyMOL. Interestingly, this 
mutation is predicted to form a void in the core of the protein that partially overlaps 
with the cleft observed in the PFN1 M114T crystal structure (Figure II-15B). 
Analysis using PyMOL and SiteMap suggest that, unlike the solvent accessible 
WT and the M114T pocket, the proposed C71G void is buried within the core of 
the protein. Solvent inaccessible voids have a more destabilizing effect than 
solvent exposed cavities (225,241), providing an explanation for why the C71G 
mutation is more destabilizing than M114T (Figure II-1). 
 
Discussion 
Here we show that ALS-linked mutations severely destabilize (Figure II-1) 
and alter the native protein conformation (Figure II-8) of PFN1. Changes in protein 
stability due to disease-causing mutations, whether these mutations stabilize or 
destabilize the protein, are thought to play a pivotal role in various disease 
mechanisms (227). In the context of ALS, disease-linked mutations destabilize 
Cu,Zn-superoxide dismutase (SOD1) (223), but instead hyper-stabilize TAR DNA-
binding protein 43 (TDP-43) (222,224,242). These findings underscore the 
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importance of defining the toxic properties of disease-linked proteins, thereby 
directing the rational design of therapeutic strategies against those offending 
proteins (220). 
Our X-ray crystal structures of PFN1 proteins illuminate a probable source 
of mutation-induced destabilization. An enlarged surface pocket, or void, forms as 
a result of the M114T mutation (Figure II-15). The destabilizing effect of similar 
voids has been demonstrated using a systematic site-directed mutagenesis 
approach with lysozyme, and is thought to arise from a loss of hydrophobic 
interactions (225,241). Examples of mutation-induced cavity formation and 
destabilization have also been observed in nature (227). Interestingly, modeling 
the removal of the cysteine side-chain at position 71 creates an internal cavity that 
is predicted to partially overlap the cleft formed by M114T, raising the intriguing 
possibility that both mutations destabilize PFN1 through a common mechanism 
that involves the loss of hydrophobic and van der Waals contacts within the same 
region of PFN1 (Figure II-15). Because G118V is located within a solvent exposed 
flexible loop, it is difficult to predict whether this mutation propagates structural 
changes to the same region affected by M114T. We note that the phi and psi 
angles for Gly118 are in a region of the Ramachandran plot that are generally 
disallowed for a valine residue, and therefore we speculate that the G118V 
mutation also induces a conformational change within PFN1 that allows valine to 
adapt dihedral angles that are energetically more favorable. 
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Our study also provides insight into the relative pathogenicity of ALS-linked 
PFN1 variants. The pathogenicity of the E117G variant was called into question 
after it had been detected in the control population (7,141-143). Moreover, this 
variant exhibited mild phenotypes compared to other ALS-linked PFN1 variants in 
cell-based functional experiments (7,144). Here, the E117G mutation had only a 
modest effect on the stability and structure of PFN1 (Table II-1 and Figure II-9), 
supporting the view that E117G is a risk factor for disease rather than overtly 
pathogenic (6,143). Further, the E117G mutation was detected in sporadic ALS 
and frontotemporal lobar degeneration cases (134,136,141-143), consistent with 
the idea that environmental factors and/or genetic modifiers contribute to PFN1 
E117G toxicity. In fact, proteasome inhibition triggered the aggregation of PFN1 
E117G (7), suggesting that cellular stress may exacerbate PFN1 misfolding and 
dysfunction in vivo. 
Although the mechanism of PFN1 in ALS has yet to be fully elucidated, the 
destabilized mutant-PFN1 species identified here can serve as an upstream trigger 
for either loss-of-function or gain-of-toxic-function mechanisms. Several 
investigations from cell-based experiments support a loss-of-function mechanism 
for ALS-linked PFN1 variants with respect to actin binding (7), actin dynamics (7) 
and stress granule assembly (144). For example, PFN1 variants 
immunoprecipitated less actin from mammalian cells compared to PFN1 WT (7). 
Our in vitro results suggest this is unlikely due to a general defect in the inherent 
ability of mutant PFN1 to directly bind actin (Figure II-14), but may be the 
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consequence of mutant PFN1 being sequestered away from actin and/or engaged 
in other aberrant interactions within the cell. Moreover, ALS-linked mutations do 
not simply abrogate the direct-binding interaction between PFN1 and the poly(L-
proline) motif (Figure II-13A) that is present in many biological PFN1 ligands. 
These data, however, do not rule out the possibility that mutation-induced 
misfolding and destabilization culminate in defective actin homeostasis in vivo. 
PFN1 plays a complex role in actin homeostasis, requiring coordinated interactions 
between PFN1 and many other cellular factors that ultimately dictate the fate of 
different actin networks within the cell (59). 
The misfolding of PFN1 variants may also induce gain-of-toxic-functions 
and interactions, the latter via aberrant protein-protein interactions through 
exposed hydrophobic patches, such as those detected for PFN1 M114T (Figure II-
16). Further, the aggregation of PFN1 variants can potentially sequester other vital 
proteins, including those with poly(L-proline) binding motifs (15), culminating in 
compromised actin and/or cellular homeostasis (221). 
Although the downstream effect of ALS-linked PFN1 on actin dynamics and 
other cellular processes have not been elucidated, our data identify misfolded and 
destabilized PFN1 as a potential upstream trigger of the adverse events that 
culminate in ALS, opening new avenues for therapeutic advancement in ALS. One 
potential direction is the development of pharmacological chaperones (229). For 
example, small molecules that fill the void formed by the M114T mutation are 
expected to stabilize the protein (241). Our data with poly(L-proline) (Figure II-13B) 
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suggest that small-molecules binding to other regions of PFN1 could also stabilize 
the protein. We posit that stabilizing mutant PFN1 will restore the normal structure 
and function of the protein, thereby preventing the pathogenic cascade leading to 
ALS. 
 
Materials and Methods 
Recombinant PFN1 cloning, expression and purification 
A pET vector containing human PFN1 flanked by NdeI and EcoRI restriction 
sites was kindly provided by Dr. Bruce Goode (Brandeis University). The mutant 
PFN1 DNA (7) was amplified using primers 5’- GGACCATATGGCCGGGTGGAAC 
-3’ and 5’- GCCTGAATTCTCAGTACTGGGAACGC -3’ and ligated into the pET 
vector using NdeI and EcoRI restriction sites. Please see Appendix I for 
information on PFN1 expression and purification. 
Equilibrium unfolding experiments 
For equilibrium unfolding experiments using tryptophan fluorescence, 
solutions of increasing urea concentration were prepared from a concentrated 
stock-solution of 10.546 M urea in phosphate buffered saline (PBS) using a 
Hamilton Microlab 500 titrator. PFN1 was mixed into the urea solutions to a final 
concentration of 2 µM with 1 mM tris(2-carboxyethyl)phosphine (TCEP) and the 
samples were equilibrated for 15–30 min. The intrinsic tryptophan fluorescence of 
PFN1 was measured at 25 °C with a T-format Horiba Fluorolog fluorimeter using 
an excitation wavelength of 295 nm. Three emission spectra (310 nm to 450 nm) 
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were collected for each sample and averaged. The concentration of the urea in 
each sample was measured using an Abbe refractometer after data acquisition. 
Data were processed to obtain the center-of-mass (COM) of the emission 
spectrum. The COM was fit to a two-state transition model as previously described 
and the thermodynamic parameters, apparent ΔG° (the free energy of folding), m 
(the denaturant dependence of ΔG°) and Cm (the midpoint of the unfolding 
transition) were determined with the program Savuka (243,244). Because the 
quantum yield of the native and unfolded states were within a factor of 2, the use 
of COM analysis is justified. We explicitly checked this by a rigorous global analysis 
using singular value decomposition and showed that the fit of the urea dependence 
basis vector gave thermodynamic parameters that were within the error of the 
COM and circular dichroism (CD) spectroscopy analyses, and no indications of 
non-two-state behavior. For equilibrium unfolding experiments using CD 
spectroscopy, PFN1 (10 μM) was equilibrated in various concentrations of urea as 
described above and CD spectra were acquired from 215 nm to 260 nm using a 
Jasco J-810 spectropolarimeter. Three spectra were averaged and the mean 
residual ellipticity (MRE) at 220 nm was plotted as a function of urea concentration 
and fit to a two-state equilibrium unfolding model. 
For protein refolding experiments, a concentrated stock of PFN1 (100-250 
μM) denatured in urea (4-8.5 M) was diluted in urea/PBS to obtain a series of 
samples with decreasing concentrations of urea, 10 μM PFN1 and 1 mM TCEP. 
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Samples were equilibrated for 30 min prior to acquisition of fluorescence emission 
spectra as described above. 
Differential scanning fluorimetry 
Samples containing WT or mutant PFN1 (20 μM) in PBS with 20x SYPRO 
Orange (Invitrogen, S6651) were pipetted in quadruplicate into a 384 well plate 
(BioRAD, HSR4805) and subjected to heat denaturation using a Bio-RadCFX384 
Touch™ Real-Time PCR Detection System. The temperature was increased from 
25 °C to 100 °C in 0.3 °C increments and at each increment fluorescent intensities 
were acquired using HEX detector (excitation 515–535 nm, emission 560–580 
nm). PFN1 proteins were analyzed alone and in the presence of the poly(L-proline) 
peptide (MW 1,000–10,000, Sigma, P2254). Because this peptide was supplied 
from the manufacturer as a mixture of poly(L-proline) species, the concentration is 
reported here in units of proline (MW 115.13 g mol–1). For experiments with the 
poly(L-proline) peptide, PFN1 was prepared with 4 mM proline. The fluorescence 
intensities for the four replicates were averaged, normalized to the maximum 
fluorescence intensity and plotted as a function of temperature to obtain melting 
curves, which were fit with a sigmoidal function in GraphPad Prism to determine 
the midpoint of transition or the apparent melting temperature (Tm). 
Measuring PFN1 turnover in cells 
Human SKNAS cells were cultured in Dulbecco’s minimal essential medium 
(Gibco, 11965) containing 10% (vol/vol) fetal bovine serum (Sigma-Aldrich, F4135) 
and 1% (wt/vol) penicillin and streptomycin (Gibco, 10378) under standard culture 
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conditions (37 °C, 5% CO2/95% air). SKNAS cells were transiently transfected 
with 0.5 µg of V5-PFN1 plasmids (7) in 24-well plates using 1.75 µl NeuroMag (OZ 
Biosciences, NM50500) diluted in Opti-MEM (Invitrogen, 38915). After 12 h of V5-
PFN1 expression, translation was inhibited with 30 µg ml–1 cycloheximide (Sigma 
Aldrich, C7698). Cells were lysed at specific time points during a 12.5 h time course 
following cycloheximide addition using RIPA buffer (Boston BioProducts, BP-115-
500) supplemented with protease inhibitors (Roche, 11836170001), and 
centrifuged at 13,500 rpm (19,357 x g) for 15 min, after which the supernatant 
(containing soluble PFN1) was collected. The remaining pellet (containing 
insoluble PFN1) was washed once with RIPA lysis buffer, centrifuged again, and 
resolubilized with 8 M urea in volumes equal to their soluble counterparts. The 
protein concentration of soluble fractions was determined using a bicinchoninic 
acid assay (Thermo Scientific Pierce, 23227). Samples were processed and 
subjected to western blot and densitometry analyses essentially as described 
(232). Western blots were probed using V5-specific (1:1,000 Invitrogen, R96025) 
and GAPDH-specific (1:20,000 Sigma, G9545) antibodies. Bands corresponding 
to soluble V5-PFN1 were normalized to the loading control, GAPDH, and then to 
the band corresponding to cycloheximide treatment for ‘0 h’ for each protein. For 
each biological replicate, visible bands corresponding to insoluble V5-PFN1 were 
normalized to their respective ‘0 h’ PFN1 C71G band. Statistical significance was 
determined using a two-way ANOVA followed by Tukey’s post-hoc analysis. 
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Circular dichroism spectroscopy 
Circular dichroism (CD) spectra of WT PFN1 or mutants (10 μM in PBS) 
were acquired from 190 nm to 260 nm at a scan speed of 2 seconds per 
wavelength with a 1 mm cuvette at 25 °C using a AVIV Biomedical circular 
dichroism spectrometer model 400. Data reflect an average of five scans that were 
blank subtracted. The resulting ellipticity curves were transformed to mean residue 
ellipticity as described (152). 
Acidic native PAGE 
The method for acidic native PAGE analysis of basic proteins described by 
the Mario Lebendiker laboratory (http://wolfson.huji.ac.il/purification/) was used. 
Briefly, 29:1 acrylamide-bisacrylamide (Fisher Scientific BP1408-1) native gels 
were cast with 7.5% (wt/vol) polyacrylamide in the resolving gel, pH 4.3, and 3% 
(wt/vol) polyacrylamide in the stacking gel, pH 6.8. The gel sample containing WT 
or mutant PFN1 (0.8 μg μl–1) was prepared under native conditions using ice-cold 
acetate-KOH pH 6.8, 10% (vol/vol) glycerol with 0.025% (wt/vol) of methylene blue. 
PFN1 proteins (10 μg) were loaded onto the gel and subjected to reversed polarity 
electrophoresis under ice-cold conditions for 2 h at 100 V. The protein bands were 
visualized with Coomassie Brilliant Blue as described above for denaturing gels. 
Analytical size exclusion chromatography 
WT or mutant PFN1 (50 μl of PFN1 at 0.8 μg μl–1) were subjected to 
analytical size exclusion chromatography at 4 °C using a Superdex 75 column (GE 
Healthcare, 17-5174-01) equilibrated with PBS and a flow rate of 0.5 ml min-1. For 
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each trial (n = 2), elution profiles were acquired using absorbance at 280 nm and 
normalized to the peak value of WT PFN1. The area under peak was calculated 
using GraphPad Prism. 
Fluorescence decay measurements 
The time resolved data were collected using a Becker and Hickl based 
custom time-correlated single photon counting (TCSPC) equipment (245,246). G-
factor was measured using 5 μM N-Acetyl-L-tryptophanamide. The total intensity 
was calculated using the formula, 𝐼𝑉𝑉 + 2𝐺𝐼𝑉𝐻 where 𝐼𝑉𝑉 is the vertical emission 
and 𝐼𝑉𝐻 is the horizontal emission. A python class for reading the TCSPC 
generated .sdt files can be found in Appendix II. 
Protein crystallization and X-ray structural determination 
PFN1 crystals were grown by hanging drop vapor diffusion after mixing the 
PFN1 protein with a 1:1 ratio of reservoir solution at 25 °C for WT and E117G and 
at 18 °C for M114T. Reservoir solution for WT contained 50 mM KH2PO4, 36% 
(wt/vol) PEG 8,000 and 100 mM MES pH 6.0. Reservoir solution for E117G 
contained 50 mM KH2PO4, 41% (wt/vol) PEG 8,000 and 100 mM MES pH 6.0. 
Reservoir solution for M114T contained 750 mM sodium citrate, 200 mM NaCl and 
100 mM tris pH 7.5. 
E117G crystals where soaked in cryo-protectant composed of 25% (vol/vol) 
ethylene glycol, 75% (vol/vol) reservoir solution and M114T crystals were passed 
through mineral oil before mounting for data collection. Diffraction data were 
collected using a Rigaku 007 MicroMax HF rotating anode X ray generator, under 
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a nitrogen cryostream at 100 K (Oxford Cryosystems), on a Saturn944+ CCD 
detector. 
The data were reduced using Xia2 (247) (running XDS (248)) for WT and 
M114T and HKL2000 (HKL Research) for E117G. All three structures were solved 
via molecular replacement with Phaser (249) using the profilin structure PDB ID: 
1FIK (233) as the starting model followed by multiple rounds of manual model 
building performed with Coot (250). WT was refined with PHENIX (251) and 
E117G with REFMAC5 (252) using standard refinement protocols. M114T was 
refined with PHENIX using twin refinement with the twin law {h,-h-k,l} applied 
through refinement, because the data was highly twinned with a twin fraction 
estimated to be 0.48. 
Structural analysis 
SiteMap (Schrödinger, LLC) was used to identify and evaluate the mutation-
site cavity volumes. Figures were generated using PyMOL (Schrödinger, LLC). 
Poly(L-proline) peptide binding experiments 
The intrinsic tryptophan fluorescence of WT or ALS-PFN1 (2 μM) as a 
function of increasing concentrations of the poly(L-proline) peptide described 
above at 25 °C was used to measure binding of PFN1 to poly(L-proline) as 
previously described (21). The samples were excited at 295 nm and three emission 
spectra between 310 nm and 450 nm were collected for each sample and 
averaged. The fluorescence emission intensity at 323 nm was base-line corrected, 
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normalized, plotted as a function of poly(L-proline), and fit to a one-site total 
binding model in GraphPad Prism to yield apparent Kd values. 
Inhibition of spontaneous actin assembly  
Gel-filtered monomeric rabbit muscle actin (3 μM, 5% pyrene labeled) was 
converted to Mg-ATP-actin immediately before use in each reaction and mixed 
with 7 μl of different concentrations of PFN1 WT, PFN1 mutants or control buffer 
and 3 μl of 20x initiation mix (40 mM MgCl2, 10 mM ATP, 1 M KCl) in 60 μl 
reactions. Actin polymerization was monitored over time at 365 nm excitation and 
407 nm emission in a PTI fluorometer at 25 °C. Average relative rates of actin 
polymerization (n = 3) were determined based on the slopes of the assembly 
curves during the first 500 seconds of each reaction and plotted against increasing 
concentrations of PFN1 (mutants). Statistical significance was determined using a 
two-way ANOVA followed by Tukey’s post-hoc analysis. 
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PREFACE TO CHAPTER III 
 
The single molecule experiments were performed in the laboratory of Dr. 
Bruce Goode (Brandeis University) in part by Dr. Jessica Henty-Ridilla and myself. 
Unlabeled and labeled actin, and mDia1 used in single molecule experiments were 
purified by personnel in the laboratory of Dr. Bruce Goode (Brandeis University). 
The stable HeLa lines described in the experiments were generated by Dr. Jeanne 
McKeon. Western blotting experiments were performed with assistance from Dr. 
Jeanne McKeon and Katherine Gall. The artificial 3’-UTR PFN1-miRNAs were 
designed by Dr. Miguel Sena-Esteves and cloned by Sneha Suresh. Lentiviral 
vectors were prepared and titered by Katherine Gall. The construct EGFP*-mDia1-
FH1-mDia2-FH2-C was cloned by Sneha Suresh. Live cell imaging experiments 
were performed with assistance from Dr. Claudia Fallini. Statistical analyses on 
datasets were performed with assistance from Dr. Jeanne McKeon. 
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CHAPTER III – INVESTIGATING DEFECTS IN ACTIN ASSEMBLY DUE TO 
ALS-MUTATIONS IN PFN1 
 
Introduction 
Abnormal binding of ALS-variants of PFN1 to either actin or poly(L-proline) 
containing proteins such as formins, Ena/VASP (9,15) can have a disastrous 
effects on actin dynamics. The ALS-PFN1 mutations C71G, M114T, E117G and 
G118V are close to the actin-binding interface whereas the mutations T109M, 
R136W and Q139L occur near the poly(L-proline) binding surface of PFN1 
(Figures I-1 and II-10). Moreover, the cavity introduced by the mutation M114T and 
possibly C71G (Figures II-15 and II-16) is proximal to the actin-binding interface. 
Although published results point to defects in neuronal actin cytoskeleton 
(7,146,147), the in vitro experiments described in Chapter II did not point to major 
differences in binding to poly(L-proline) or actin (Figures II-13A and II-14). More 
importantly, our experiments showed that the binding of PFN1 to actin is not 
completely impaired as suggested previously (7). There is a need for reconciliation 
of these contrasting results. The pyrene-actin polymerization assays and poly(L-
proline) binding experiments are inadequate and have certain shortcomings. For 
example, the former is not a direct actin-binding experiment that provides 
dissociation constants, and the latter involved poly(L-proline) peptides rather than 
an intact full-length protein. In addition, the actin polymerization assays are bulk 
fluorimetric assays that do not provide any information on the individual filaments. 
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Furthermore, in vivo, there are a number of actin cytoskeletal factors involved in 
nucleation, elongation, capping, severing and depolymerization that act in a 
concerted manner (253). So truly, the functional assays described in Chapter II fall 
short of simulating a situation where multiple interactions of PFN1 occur 
simultaneously and in different contexts as in a cellular environment. 
To address the above shortcomings, we considered certain processes 
discussed in Chapter I where PFN1 could be a key player, (i) the process of actin 
assembly, involving actin nucleation and elongation, (ii) actin disassembly from the 
barbed end, (iii) the exchange reaction of ADP- to ATP-actin catalyzed by profilins, 
(iv) the interaction of profilins with phosphatidylinositols and its connection to 
cellular signaling, and (v) the putative post-translational modifications of PFN1. We 
decided to exclusively study the effect of ALS-PFN1 on actin nucleation and 
elongation events, for which we focused entirely on the “minimal” system 
consisting of actin, PFN1 (WT or ALS-variants) and the constitutively active 
formins mDia1-FH1-FH2-C or mDia2-FH1-FH2-C (254,255) (Figure III-1). A 
combination of single molecule techniques and cell biology experiments were used 
in this study to observe individual filaments and the formin-nucleated filopodial 
actin structures (256,257), respectively. By this way we were able to (i) study the 
behavior of individual or a bundle of actin filaments (254,258) which possesses 
advantages over the bulk pyrene-actin polymerization assays and (ii) at the same 
time partly address the complex nature of actin assembly processes by observing 
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reactions that involve a simultaneous interplay of PFN1-actin, PFN1-formin and 
actin-formin, and formin-PFN1-actin complexes in vitro and in cells. 
Here, we demonstrate that the ALS-variants of PFN1 affect both nucleation 
and elongation rates in vitro. In HeLa cells, PFN1 is necessary for filopodia 
generation by mDia2-FH1-FH2-C and the variant M114T increases filopodia 
density. Our studies show that mutant PFN1 causes defects in actin assembly 
which may be difficult to deduce from simple binding experiments alone. 
 
 
 
Figure III-1. Constitutively active formin constructs used in experiments. 
(A) mDia1-FH1-FH2-C (553-1255). (B) mDia2-FH1-FH2-C (521-1171). (C) 
mDia1-FH1-mDia2-FH2-C (553-747 of mDia1 and 615-1171 of mDia2). For the 
fixed and live cell imaging experiments, mDia2-FH1-FH2-C and mDia1-FH1-
mDia2-FH2-C fused to EGFP* was used (see Materials and Methods). 
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Results 
Abnormalities in actin nucleation and elongation with ALS-PFN1 
Using in vitro single molecule techniques, the effects of WT or ALS-PFN1 
on actin nucleation and elongation in the presence or absence of the formin mDia1 
were investigated. This approach provides information at the individual filament 
resolution and by tracking the filament growth over time the elongation rates can 
be computed (Figure III-2). We chose mDia1 for these experiments as it is well 
characterized in vitro, contains several poly(L-proline) motifs in its FH1 domain and 
is capable of vastly accelerating actin filament elongation in its functional dimeric 
form (41,255,259). To avoid confounding factors that might arise due to 
autoinhibition observed in full-length mDia1 (41), we utilized the constitutively 
active form of mDia1, hereby referred to as mDia1-FH1-FH2-C, consisting of the 
nucleating FH2 and the proline rich FH1 domain (Figure III-1A). 
First, we studied the effect of WT and ALS-PFN1 on actin nucleation in the 
absence of mDia1-FH1-FH2-C using total internal reflection fluorescence (TIRF) 
microscopy (schematics in Figure I-2A and B). The number of filaments 1000 s 
after the start of the reaction were counted as a measure of nucleation. The control 
reaction containing 1 μM actin alone contained about 156 ± 5 filaments per 100 
μm2. In the presence of 1 μM WT PFN1, there were 86 ± 3 filaments per 100 μm2, 
and this decreases with increasing concentration of WT PFN1 as expected. 
Interestingly, at 1 μM concentration, we observed a significant decrease in the 
number of filaments with M114T (37 ± 2 per 100 μm2) and significant increase with 
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G118V (175 ± 7 per 100 μm2). Increasing the concentrations of both M114T and 
G118V reduced the number of filaments, but with M114T the number of filaments 
were lower than WT at all the concentrations tested (Figure III-3A). 
Next the effect of WT and ALS-PFN1 on actin nucleation was evaluated in 
the presence of 100 pM mDia1-FH1-FH2-C (schematics in Figure I-3). After 250 
s, no difference was observed in the number of filaments between the control 
reaction lacking PFN1 (45 ± 2 per 100 μm2) and the reaction containing 5 μM WT 
PFN1. However, the filament count was much higher when 5 μM M114T was 
present in the reaction (196 ± 8 per 100 μm2 with M114T vs. 51 ± 2 per 100 μm2 
with WT). This was in contrast to the behavior of M114T compared to WT in the 
Figure III-2. Actin filaments observed using total internal reflection 
fluorescence (TIRF) microscopy. (A) 0.5 μM actin (10% Oregon Green 
labeled, 0.2% biotin-labeled). (B) 0.5 μM actin and 50 pM mDia1-FH1-FH2-C. 
The increased number of filaments observed is due to the nucleating activity of 
mDia1-FH1-FH2-C. (C) 0.5 μM actin, 50 pM mDia1-FH1-FH2-C and 3 μM WT 
PFN1. The filaments elongated by mDia1-FH1-FH2-C appear faint because 
PFN1 binds unlabeled actin with higher affinity and hence the unlabeled actin 
is favorably added to the growing barbed end by the FH1 domain. For the same 
reason, the spontaneously nucleated filaments are bright as the unbound 
labeled actin can be readily added to these filaments. 
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Figure III-3. Actin nucleation and elongation in the presence of WT or ALS-
PFN1. (A) Number of spontaneously nucleated filaments (absence of mDia1-
FH1-FH2-C) after 1000 s from the start of the reaction. Reactions contained 1 
μM actin (10% Oregon Green labeled) alone or along with varying 
concentrations of PFN1 variants. (B) Number of filaments generated in the 
presence of mDia1-FH1-FH2-C after 250 s from the start of the reaction. 
Reactions contained 1 μM actin and 100 pM mDia1-FH1-FH2-C alone or with 
5 μM of PFN1 variants. (C) Elongation rates of spontaneously nucleated 
filaments in (A) as a function of PFN1 concentration. (D) Elongation rates of 
mDia1-FH1-FH2-C nucleated filaments in (B). In (A) and (B) filaments were 
counted from 6 reactions and averaged. In (C) and (D) elongation rates of 60 
filaments from 6 reactions were averaged. Statistical significance was 
determined using a one-way ANOVA followed by a Tukey’s post hoc analysis. 
All comparisons are with respect to the corresponding WT PFN1 condition (*P 
< 0.05, **P < 0.01, ****P < 0.0001). Error bars represent SEM. 
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absence of mDia1-FH1-FH2-C. G118V (76 ± 4 per 100 μm2) also had a higher 
filament count compared to WT (Figure III-3B). 
Actin, at 1 μM, exhibited an elongation rate of about 11 subunits s–1 μM–1 
actin (Figure III-3C). This is in agreement with published data from other research 
groups (255,259). Actin displayed similar elongation rates with varying 
concentrations of WT and G118V PFN1. Interestingly, M114T shows significantly 
Figure III-4. mDia1-generated filament elongation rates as a function of 
PFN1 concentration. Reactions contained 0.5 μM actin (10% Oregon Green 
labeled), 50 pM mDia1-FH1-FH2-C and varying concentrations of PFN1 WT or 
G118V. Differences in elongation rates of filaments generated by mDia1-FH1-
FH2-C between WT and G118V were apparent at concentrations of PFN1 
above 3 μM. For each condition, between 8 and 16 mDia1-generated filaments 
were analyzed from 3-4 reactions. Statistical significance was determined using 
a one-way ANOVA followed by a Tukey’s post hoc analysis (***P = 0.0002, 
****P < 0.0001). Error bars represent SEM. 
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higher elongation rates for three out of the four concentrations tested (Figure III-
3C). In the presence of 100 pM mDia1 and at a fixed PFN1 concentration of 5 μM, 
no differences in elongation rates were observed among the variants (Figure III-
3D). With 0.5 μM actin, 50 pM mDia1 and varying concentrations of PFN1, we 
observed the biphasic behavior of the elongation rates as described previously 
(255). But the elongation rates of mDia1-generated actin filaments were higher in 
the presence of G118V for most PFN1 concentrations tested (Figure III-4). 
Collectively, our data suggest that differences in actin nucleation and elongation 
between WT and ALS-PFN1 are dependent on the PFN1 variant in question and 
the relative concentrations of actin, PFN1 and mDia1-FH1-FH2-C. 
Tools for studying actin assembly in cells 
We decided to investigate if the in vitro observations in actin nucleation and 
elongation can be recapitulated in a more complex yet physiological cellular milieu 
with all the other cytoskeletal proteins present. Several factors had to be 
considered while studying the role of WT or ALS-PFN1 on nucleation and 
elongation. First, the filament elongation rates display a biphasic behavior with 
respect to profilin concentration (255). Hence, it is absolutely critical to have similar 
expression levels of exogenous WT or ALS-PFN1. To address this issue, we 
generated several stable HeLa lines that express PFN1 shRNA, WT or ALS-
variants of PFN1 at near endogenous levels under doxycycline induction (Figure 
III-5). Second, since mammalian cells express about 15 different formins (77), it 
would be impossible to make observations on nucleation and elongation in the 
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absence of formins, as this would entail knocking down or downregulating all the 
members. Thus, the only processes that can be reliably studied are nucleation and 
Figure III-5. Characterization of generated HeLa cell lines. (A) Western 
blotting of lysates prepared from HeLa cell lines uninduced or induced with 1 
μg ml-1 doxycyline (dox.) for 96 h to express non-silencing (NS) shRNA, PFN1 
shRNA #1 or PFN1 shRNA #2. (B) Quantification of PFN1 levels relative to 
GAPDH from n = 3 experiments by densitometry. A knockdown efficiency of 
90% or above was observed for the two PFN1 shRNAs. (C) Western blotting of 
lysates prepared from HeLa cell lines uninduced or induced with 1 μg ml-1 to 
express V5, V5-WT or V5-M114T. (D) Quantification of V5-PFN1 levels relative 
to endogenous PFN1 from n = 1 experiment by densitometry. The V5-PFN1 
levels were within two-fold of endogenous PFN1 levels. 
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elongation in the presence of formin. Third, the experiments should allow the 
visualization of near individual filaments. Direct actin markers such as GFP-actin, 
lifeact-GFP and phalloidin-derivatives enable one to observe F-actin, but have 
been shown to interfere with actin dynamics in live cells (260-265). Hence, we 
adopted an indirect approach to track individual filaments specifically nucleated by 
formins by utilizing the fact that each filament has a single functional formin 
homodimer attached to its growing barbed end (41). Previously described EGFP-
mDia1-generated filaments in the cytoplasm of Xenopus laevis oocytes required 
sparse labeling coupled with speckle microscopy to avoid background 
fluorescence (266). We used the constitutively active mDia2 (mDia2-FH1-FH2-C) 
which generates filopodia and that allows us to easily visualize actin filaments 
using conventional wide-field microscopy (254). The FH1 domain of mDia2 contain 
fewer PFN1-binding poly(L-proline) stretches than that of mDia1. To address 
whether the number of PFN1-binding sites in the FH1 domain influences actin 
nucleation and elongation, we generated a chimeric construct containing the FH1 
domain of mDia1 and FH2 domain of mDia2 (mDia1-FH1-mDia2-FH2-C) (see 
Materials and Methods). 
Initially, naïve HeLa cells were transiently transfected with EGFP*-mDia2-
FH1-FH2-C. As expected, mDia2 gave rise to filopodia that can be distinctly 
identified by the presence of mDia2 molecules at its tip (Figure III-6). Surprisingly, 
extremely low levels of the constitutively active mDia2 are sufficient to produce 
filopodia. A fraction of mDia2 (and mDia1) expressing cells produced ring like 
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structures (data not shown), which were concluded as focal adhesions based on 
similar observations by other groups (267-269). Low level expression of mDia2-
FH1-FH2-C is critical for two reasons. One, high expression levels can lead to 
toxicity, likely due to the constitutively active nature of this construct. The cells 
sometimes adopt fusiform morphology with elongated nuclei as reported by others 
for mDia1 (268,269). In extreme cases, the cells adopt abnormal shapes possibly 
Figure III-6. The formin mDia2 in its constitutively active form nucleates 
filopodia. Naïve HeLa cells transiently transfected with EGFP*-mDia2-FH1-
FH2-C, fixed and stained with phalloidin (red), anti-GFP antibody (green) and 
DAPI (blue). The region inside the square is enlarged in the inset. The filpodia 
nucleated by mDia2 can be distinctly seen by the presence of mDia2 molecules 
at its tip. 
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as a result of failed cell division. Two, actin nucleation is directly correlated with 
the amount of formin. Hence, care was taken to have very low but similar mDia2 
expression levels (see Materials and Methods) to obtain meaningful data that can 
be compared across different cell lines and experiments. 
 
Figure III-7. PFN1 is required for filopodia formation. HeLa cell lines were 
induced with doxycyline for 96 h to express non-silencing (NS) shRNA (A), 
PFN1 shRNA #1 (B) or PFN1 shRNA #2 (C), transiently transfected with 
EGFP*-mDia2-FH1-FH2-C after 72 h of knockdown, fixed and stained with anti-
GFP antibody and DAPI. (D) The relative filopodia density from n = 1 
experiment was analyzed (18, 21 and 23 cells for NS, shRNA #1 and shRNA 
#2, respectively) and plotted. The filopodia density was significantly reduced 
upon PFN1 knockdown. Statistical significance was determined using a one-
way ANOVA followed by a Tukey’s post hoc analysis (*P < 0.05, **P < 0.01). 
Error bars represent SEM. 
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Loss of PFN1 leads to a reduction in formin-generated filopodia 
To investigate the effect of loss of PFN1 on filopodia formation, EGFP* 
tagged mDia2-FH1-FH2-C or mDia1-FH1-mDia2-FH2-C was expressed in cells 
with inducible PFN1 knockdown (Figure III-5A and B). Robust filopodia formation 
was observed in the control cell line expressing non-silencing shRNA (Figure III-
7A). In contrast, the lines expressing PFN1 shRNA #1 and shRNA #2 displayed 
significant reductions in filopodia density (Figure III-7B, C and D). As additional 
controls, we measured the filopodia density under uninduced conditions. 
Surprisingly, we saw a reduction in filopodia density in the HeLa shRNA #2 line in 
the absence of induction (Figure III-8C). On assessment by Western blotting, about 
50% reduction in PFN1 levels were observed in this line (Figure III-8A and B). This 
happens only under transfection conditions, as the untransfected and uninduced 
cell lines had similar PFN1 expression levels (Figure III-5A and B). In fact, the 
filopodia density correlated strongly with PFN1 levels (Figure III-8D). We reasoned 
that the process of transfection somehow causes a deregulation of shRNA 
expression that should be under doxycycline control. 
To measure the rates of filopodia growth, the transfected cells were 
subjected to live cell imaging (Figure III-9). Under PFN1 knockdown, it was difficult 
to identify transfected cells that contained filopodia, further confirming our fixed cell 
immunofluorescence experiments described above. On qualitative inspection, the 
fewer filopodia observed under PFN1 knockdown had rates indistinguishable from 
that of the non-silencing control (data not shown). Additional experiments need to 
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Figure III-8. Transfection deregulates doxycycline control in the PFN1 
shRNA #2 HeLa line. (A) Western blotting of lysates prepared from HeLa cell 
lines uninduced or induced with 1 μg ml-1 doxycyline (dox.) for 96 h to express 
non-silencing (NS) shRNA, PFN1 shRNA #1 or PFN1 shRNA #2 and transiently 
transfected with EGFP*-mDia2-FH1-FH2-C after 72 h from the start of the 
experiment. (B) Quantification of PFN1 levels relative to GAPDH from n = 2 
experiments by densitometry. The PFN1 levels were similar in the absence of 
transfection under uninduced conditions (Figure III-5A and B), but transfection 
with EGFP*-mDia2-FH1-FH2-C caused about 50% reduction in PFN1 level in 
the HeLa shRNA #2 line even in the absence of induction. (C) The filopodia 
density in the HeLa shRNA #2 under uninduced condition was reduced as a 
consequence of the low PFN1 level in that condition. (D) A correlation was 
observed between the filopodia density and PFN1 levels (+ and – represent 
induction and non-induction respectively). Errors bar represent SEM. 
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be performed under the knockdown conditions to reliably measure potential 
differences in elongation rates as a function of PFN1 expression. 
M114T PFN1 causes a modest increase in formin-generated filopodia 
Next, we tested the impact of the ALS-PFN1 variant M114T on filopodial 
phenotypes. Expression of V5 tag alone for 48 h did not affect filopodia formation. 
Expression of V5-WT over endogenous WT produced filopodia to the same extent 
as V5 tag alone. We reasoned this to be due to the controlled expression of V5-
PFN1 close to endogenous levels. Expression of V5-M114T for 48 h over the 
Figure III-9. Live imaging of filopodia growth. An example of a time series of 
images showing the elongation of filopodia. In this case, HeLa cells were 
induced for expression of non-silencing shRNA for about 90 h, transfected with 
EGFP*-mDia2-FH1-FH2-C after 72 h of expression. Images were acquired 
every 2 s for 3 minutes. Arrowheads point to growing filopodia. 
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endogenous WT produced a modest increase in filopodia density compared to V5-
WT (Figure III-10A). Expression of V5, V5-WT or V5-M114T did not affect the 
filopodia elongation rates (Figure III-10B). To test if the exogenously expressed 
WT or ALS V5-PFN1 can rescue the filopodia density phenotype observed under 
Figure III-10. M114T PFN1 causes modest increase in fliopodia density but 
does not alter filopodia growth rates. (A) HeLa cell lines were induced with 
doxycyline for 48 h to express V5, V5-WT or V5-M114T, transiently transfected 
with EGFP*-mDia2-FH1-FH2-C after 24 h of expression, fixed and stained with 
anti-GFP antibody for quantification and analysis. The relative filopodia density 
from n = 1 experiment was analyzed (29, 29 and 30 cells for V5, V5-WT and 
V5-M114T respectively) and plotted. The filopodia density was higher for V5-
M114T compared to V5-WT or V5. Statistical significance was determined using 
a one-way ANOVA followed by a Tukey’s post hoc analysis (*P < 0.05, ns – non 
significant). Error bars represent SEM. (B) HeLa cells lines were induced and 
transfected as in (A) and imaged live. The apparent speed (root mean square) 
of filopodia growth was similar across all three conditions. Errors represent SD 
from the Gaussian fit. 
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endogenous PFN1 loss, we cloned four artificial 3’-UTR PFN1-miRNAs under the 
control of U6 promoter into the CSCGW2.tdT lentiviral backbone (see Materials 
and Methods and Appendix V). These 3’-UTR PFN1-miRNAs are expected to 
specifically knockdown endogenous PFN1 while not affecting the exogenous V5-
Figure III-11. Characterization of 3’-UTR PFN1-miRNAs. (A) Western blotting 
of lysates prepared from HEK293T cells transduced for 48 h or 96 h with empty 
CSCGW2.tdT vector or the four 3’-UTR PFN1-miRNAs (see Materials and 
Methods). (B) Quantification of PFN1 levels relative to GAPDH from n = 1 
experiment by densitometry. A robust knockdown was observed with the 3’-
UTR PFN1-miRNA-1207 at 96 h. 
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PFN1. Of the four 3’-UTR PFN1-miRNAs tested, miR-1207 was able to robustly 
knockdown endogenous PFN1 in HEK293T cells (Figure III-11). The next steps 
would entail knocking down the endogenous PFN1, simultaneously expressing V5-
PFN1 and assessing the rescue of filopodia density phenotype. 
 
Discussion 
In the single molecule experiments, a reduction in the number of filaments 
for M114T in the absence of mDia1 (Figure III-3A) suggests that M114T might 
exhibit a tighter binding to actin thereby inhibit actin nucleation. In the presence of 
mDia1, unexpectedly, there is an increase in the number of filaments compared to 
WT (Figure III-3B). While there is no clear explanation of the mechanism, we 
reason that in the presence of mDia1 the FH1 domain can efficiently deliver high 
affinity M114T-actin complexes to FH2 sites for nucleation. The other possibility is 
that binding of M114T to formin affects the interaction of M114T with actin. This 
was demonstrated using PFN2; PFN2, upon binding SMN, partially failed to 
suppress spontaneous actin polymerization (122). The number of filaments in the 
presence of G118V was higher than WT without mDia1 (Figure III-3A) implying a 
weaker affinity for actin which supports our pyrene-actin polymerization assays 
(Figure II-14). However, it is unclear why an increase in filament number is seen 
with G118V in the presence of mDia1. Interestingly, the elongation rates of 
spontaneously generated actin filaments in the presence of M114T is significantly 
higher (Figure III-3C). It must be that the M114T PFN1 has an otherwise 
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undescribed manner of interaction with F-actin. Profilin has transient interactions 
with the filament barbed end (19,42-46). Further studies are needed in order to 
verify if this profilin-F-actin interaction influences the filament elongation rate. The 
second possibility is that M114T has enhanced ability to maintain actin in the ATP-
charged state. Our experiments explain why the polymerization status of M114T 
in the fluorimetric assays was indistinguishable from WT (Figure II-14). Although 
there is a reduction in filament number with M114T, this is compensated by an 
increase in F-actin elongation rates effectively resulting in a polymer mass similar 
to WT. 
The elongation rates of mDia1-generated filaments were elevated for 
G118V at higher PFN1 concentrations (Figure III-4). It is quite possible that the 
relative equilibrium levels of PFN1-actin, PFN1-formin, actin-formin, PFN1-actin-
formin can determine filament nucleation and elongation rates. Therefore, the 
relative concentrations of actin, PFN1 and formin assumes significance and 
necessitates careful study of these processes in future. Taken together, we 
speculate that M114T and G118V, both affect actin polymerization but by different 
mechanisms. 
In this study, we adapted certain published methods (254,266) to study the 
role of WT and ALS-PFN1 in actin nucleation and elongation rates. While mDia1 
exhibits faster elongation rates in vitro than mDia2 (255), it requires high resolution 
microscopy to observe these molecules in cells. On the other hand, mDia2-
generated filopodia are much easier to visualize (254). In addition, the actin 
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nucleating FH2 domains of these two formins share about 76% sequence similarity 
(and 59% sequence identity). Hence, we made a compromise by using mDia2 to 
improve detection but at the cost of elongation speed. 
In our experiments in HeLa cells, loss of PFN1 led to a reduction in filopodia 
density. This could reflect unproductive nucleation or elongation due to (i) lack of 
ATP-charged actin normally produced by profilin, (ii) unloaded poly(L-proline) 
motifs in the FH1 domain of mDia2-FH1-FH2-C, (iii) sequestering of excess free 
actin (normally bound to PFN1) by factors such as thymosins, resulting in 
nucleation inhibition. All these unfavorable polymerization conditions can result in 
a net depolymerization. It is also likely that the effective nucleation by formin 
requires PFN1 – the FH1 may help increase local concentration of profilin-actin 
that can be subsequently captured by the FH2 domain for nucleation. Interestingly, 
recent studies show that the loss of profilin leads to a reallocation of actin from 
formins to Arp2/3 machinery (59,60). Expression of V5-M114T causes a small 
increase in filopodia density (Figure III-10), which agrees with our biochemical 
data, further supporting that M114T enhances formin nucleation. 
Although differences in filopodia density were observed, elongation rates of 
filopodia were similar under M114T PFN1 expression (Figure III-10B). In vitro, 
differences in elongation rates between WT and G118V started to emerge only at 
higher PFN1 concentrations (Figure III-4). The concentration of PFN1 in cells is 
estimated to be greater than 50 μM (15), but the local concentration of PFN1 can 
be different depending on the cellular location. Concentrations of PFN1 (and actin) 
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in the neighborhood of actin polymerization are likely to determine rates. So, it is 
possible that the filament elongation rates generated by the same formin can be 
different depending on the cellular location. The average filopodia elongation rate 
in our experiments was about 0.03 μm s–1 (Figure III-10B), which was very slow 
compared to mDia1 (266). Nevertheless, this is in agreement with recent studies 
of actin velocities in motor neuron growth cones (270) and the similar average 
filopodia length in Drosophila NMJs expressing different PFN1 variants (147). 
There could be a number of reasons for relatively slower elongation rate observed 
with mDia2 – the amount of PFN1 localized in the vicinity of filopodia is much lower, 
fewer poly(L-proline) motifs in the FH1 of mDia2, the membrane provides a 
resistance and has to be remodeled to allow filaments to push and protrude out of 
the membrane. Therefore, it is necessary to carefully examine different formins 
capable of generating filaments in different areas of the cell, possibly at different 
rates, and identify the actin structures that behave abnormally under mutant PFN1. 
It is known that the elongation rates are directly correlated with the number 
of profilin-binding poly(L-proline) motifs in the FH1 domain of formins (66). This 
prompted us to test the hypothesis that increasing the number of poly(L-proline) 
motifs in FH1 might amplify certain cellular phenotypic differences caused by 
mutant PFN1, which would otherwise be undetectable due to inherent noise in 
experimental measurements. Hence, by fusing the FH1 of mDia1 to the FH2 of 
mDia2, we expect to see higher filopodia elongation rates, and any differences 
between WT and mutants will become visible. This chimeric mDia1-FH1-mDia2-
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FH2 also gave rise to filopodia (data not shown). It will be interesting to see if the 
increase in profilin-binding sites in FH1 also influences nucleation and rescues 
filopodia density upon PFN1 reduction. 
To summarize, differences in nucleation and elongation are observed with 
ALS-PFN1 both in vitro and in cells. To explain the mechanism, comprehensive 
kinetic and equilibrium binding studies of both the binary (actin-PFN1, formin-
PFN1) (see Appendix III) and the ternary complexes (actin-PFN1-formin) have to 
be performed. In addition, rescue experiments in cells with endogenous PFN1 
knocked down will help to unambiguously determine if ALS-PFN1 variants act by 
a loss-of-function or gain-of-function mechanisms. Our results already suggest that 
M114T or G118V is unlikely to cause a loss-of-function in PFN1. They can both 
bind actin and likely formins, and both enhance nucleation relative to WT, in the 
presence of the formins and therefore act via a gain-of-function mechanism. We 
did not include the variant C71G in our studies as this variant is aggregation prone 
and could have confounded our results. This variant was highly unstable as 
demonstrated by its unfolding below the body temperature of 37 °C (Figure II-1B). 
But we predict that under near endogenous expression levels and in the absence 
of endogenous WT, C71G should fail to induce filopodia. Therefore, C71G can act 
via a loss-of-function mechanism with respect to actin assembly. Nevertheless, it 
needs to be tested if C71G can contribute to defective actin assembly. While the 
study was focused predominantly on the impact of ALS-PFN1 on actin assembly, 
there are other important aspects of actin dynamics such as actin disassembly, the 
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role of PFN1 in ADP-ATP exchange on actin, binding to phosphatidylinositols and 
Rho GTPase signaling that need to be investigated. The use of super-resolution 
microscopy, such as STORM, is also advocated to study neuronal actin 
cytoskeletal structures in the future. 
 
Materials and Methods 
Plasmids, lentiviruses and cloning 
The pEGFP*-C1-mDia2-FH1-FH2-C plasmid was kindly provided by Dr. 
Henry Higgs (Dartmouth College). The EGFP protein contains the mutation A206K 
that prevents its dimerization (254,271). Hence, the protein product is referred to 
as EGFP*-mDia2-FH1-FH2-C throughout this chapter. To construct the chimeric 
plasmid pEGFP*-C1-mDia1-FH1-mDia2-FH2-C, two PCR reactions were carried 
out to generate the mDia1-FH1 domain (amino acids 553 to 745 of full length 
mDia1) and the other large linear fragment consisting of the backbone pEGFP*-
C1 and mDia2-FH2-C (amino acids 609 to 1171 of full length mDia2). The primers 
5'-GAGCTGTACAAGTCCGGACTCAGATC-3', 5'-
GGTTTCAAACCAAATGGCAGAACTGGGGCCGCAGGAA-3' for the former and 
5'-TTCCTGCGGCCCCAGTTCTGCCATTTGGTTTGAAACC-3', 5'-
GATCTGAGTCCGGACTTGTACAGCTC-3' for the latter were designed to 
introduce appropriate overlaps between the fragments for subsequent cloning 
using NEBuilder® HiFi DNA Assembly Cloning Kit (NEB E5520S). 
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Artificial 3’-UTR PFN1-miRNAs, miR-1169, miR-1198, miR-1207, miR-
1217, targeting the 3’ non-coding region of the human PFN1 gene were designed 
by Dr. Miguel Sena-Esteves. G-blocks were synthesized (IDT) (miR-1171 could 
not be synthesized due to technical difficulties) and cloned into the lentiviral 
CSCGW2.tdT background using the NEBuilder® HiFi DNA Assembly Cloning Kit. 
The CSCGW2.tdT differs from the CSCGW2 vector by the presence of tdTomato 
reporter in place of EGFP. To generate the CSCGW2.tdT plasmid, the EGFP 
sequence in the CSCGW2 vector was replaced with the tdTomato sequence using 
the restriction sites NheI and XhoI. The primers 5'-
GAGAGCTAGCGCTACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGGT-
3', 5'-GAGACTCGAGATCCTACTACTTGTACAGCTCGTCCATGCCGTACAG-3' 
were used in a PCR reaction to generate the tdTomato insert flanked by the 
restriction sites from the plasmid pGW1-tdTomato (provided by Dr. John Landers) 
as the template. This was done so as to use it along with the pEGFP*-mDia2-FH1-
FH2-C plasmid. Lentiviruses were generated in HEK293T cells using VSVG and 
CMVdR8.91 packaging plasmids. 
Protein purification 
PFN1 proteins were purified as described in Appendix I. Rabbit muscle actin 
and mDia1-FH1-FH2-C proteins used in single molecule experiments were purified 
as previously described (259). 
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Single molecule experiments 
The single molecule experiments were done as described previously (272). 
The experiments used rabbit muscle actin, recombinant WT or ALS-PFN1 variants. 
To visualize actin filaments, actin labeled at Cys374 with the fluorophore Oregon 
Green (272) was employed and imaged using a Nikon total internal reflection 
fluorescence microscopy. 
Cell culture 
HeLa and HEK293T cells were cultured in Dulbecco’s minimal essential 
medium (Gibco, 11965) containing 10% (vol/vol) fetal bovine serum (Sigma-
Aldrich, F-6178) and 1% (wt/vol) penicillin and streptomycin (Gibco, 10378) under 
standard culture conditions (37 °C, 5% CO2/95% air). 
Stable HeLa cell lines used in the fixed and live cell imaging experiments 
were generated by Dr. Jeanne McKeon. HeLa cell lines expressing doxycycline 
inducible non-silencing shRNA, PFN1 shRNA #1, PFN1 shRNA #2 (Dharmacon 
RHS4743) were made using lentiviral transduction and subsequent selection and 
maintenance using puromycin. Stable lines with inducible expression of V5, V5-
WT or V5-ALS-PFN1 were generated in HeLa cells stably expressing tetracycline 
repressor (Addgene, 17492) using lentiviral transduction followed by puromycin 
selection. The V5-PFN1 used to generate these lines were cloned into the pLenti-
CMV-TO-Puro backbone. To induce knockdown or expression of exogenous 
PFN1, fresh doxycycline at 1 μg ml–1 final concentration was added to the stable 
lines. PFN1 knockdown was induced for approximately 96 h and formin 
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transfections were carried out at 72 h time point using Lipofectamine 2000 
(Invitrogen, 11668-019). Exogenous PFN1 was induced for 48 h with transfections 
at 24 h time point. 
Viral transductions of CSCGW2.tdT-3’-UTR-PFN1-miRNAs in HEK293T 
cells were carried out on a 6-well plate. 225 μl of low titer virus (~107) were added 
on two consecutive days and the levels of PFN1 were assessed by western blotting 
at 48 h and 96 h from the first round of transduction. 
Western blotting 
Cells were lysed using RIPA buffer (Boston BioProducts, BP-115-500) 
containing protease inhibitors (Roche, 11873580001), clarified by centrifugation in 
a table-top centrifuge at 13,000 rpm for 15 minutes at 4 °C. The protein 
concentration of soluble fractions was determined using a bicinchoninic acid assay 
(Thermo Scientific Pierce, 23227). Western blotting experiments were done as 
previously described (232,273). Endogenous PFN1 and exogenous V5-PFN1 
were detected using anti-PFN1 (1:1,000, Sigma-Aldrich, P7749-200UL) and anti-
V5 antibody (1:1,000, Invitrogen, R96025) respectively. GAPDH, detected using 
anti-GAPDH (1:20,000, Sigma-Aldrich, G9545) was used as a loading control. 
Measurement of filopodia densities 
Stable HeLa cells, plated in 24 well plate, were transiently transfected with 
100-150 ng of pEGFP*-C1-mDia2-FH1-FH2-C for 24 h using Lipofectamine 2000 
(Invitrogen, 11668-019) at 1 μl per 500 ng of plasmid. The cells were fixed in 4% 
paraformaldehyde, blocked with DPBS (CellGro, 21-031-CV) containing 4% 
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normal goat serum (Jackson ImmunoResearch, 005-000-121) and 0.1% Triton™ 
X-100 (Sigma-Aldrich, T9284). The antibodies were diluted in DPBS containing 
2% normal goat serum and 0.1% Triton X-100. The cells were incubated with Alexa 
Fluor 488 conjugated anti-GFP antibody (1:2,000, Invitrogen A-21311) for 1 hour 
at room temperature, followed by incubation with Alexa Fluor™ 647 phalloidin 
(1:40 to 1:25, Thermo Fisher Scientific, A22287) for 30 min and DAPI for 15 min. 
To stain V5-PFN1 in the V5-PFN1 lines, the cells were incubated with anti-V5 
antibody (1 h, 1:2,000, Invitrogen, R960-25) and Cy5-conjugated secondary 
antibody (1 h, 1:2,000, Jackson ImmunoResearch, 715-175-151) prior to 
incubation with anti-GFP antibody. The coverslips were mounted on microscope 
slides (Globe Scientific, 1380-20) using ProLong® Gold Antifade Mountant 
(Invitrogen, P36930). The coverslips were blinded before mounting for an unbiased 
image acquisition and analysis. 
Using a 100x objective, Z-stack images at 0.2 μm spacing were collected 
using Leica DMI600 B microscope. Images were acquired from cells that had 
similar levels of low EGFP*-formin expression. Maximum projection images were 
processed using a Gaussian filter, and thresholded EGFP*-formin particles were 
counted using the automated particle counting feature in FIJI (ImageJ). The 
filopodia density was calculated as the number of EGFP*-formin particles per 100 
μm2 and normalized against the control condition (shRNA NS or V5). A macro for 
carrying out the above process is described in Appendix IV. Graphing and statistics 
were performed using GraphPad Prism. 
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Measurement of filopodia elongation rates 
For live cell imaging, 50,000 cells were plated on 6 cm glass bottomed 
plates pre-coated with poly-D-lysine (MatTek, P35GC-1.5-14-C) and transfected 
with 250 ng of plasmid using Lipofectamine 2000 (2 μl per 1 μg of plasmid) 
(Invitrogen, 11668-019) for about 16 h. Images were acquired every 2 seconds for 
3 minutes (60x objective and an added 1.5x magnifier) using a Nikon Eclipse Ti 
microscope equipped with a temperature and CO2 controlled chamber. The 
filopodia growth trajectories were obtained using the TrackMate plugin in FIJI. The 
Laplacian of Gaussian detector with an estimated blob diameter of 0.5 μm and a 
threshold value of 10 was applied to detect the particles in each frame. For 
tracking, the linear alignment program (LAP) linking was used with 1 μm as the 
maximum frame to frame linking distance. Tracks extending less than 20 seconds 
were discarded. The tracks and the co-ordinates of the mDia2 particles at each 
time point were exported to an .xml file which was subsequently read in MATLAB 
using the function written by Tarantino et al. (274). The filopodia in the live cells 
display a variety of motions, but to obtain meaningful elongation rates, only those 
filopodia growing in straight line had to be analyzed. The tracks generated by 
randomly diffusing, non-filopodia generating mDia2 molecules and the filopodial 
“swinging” due to non-attachment to the substrate (coverslip) had to be excluded. 
Two different approaches were used to identify filopodia tracks that exhibit growth 
in a near straight line, which is essential for obtaining elongation rates. The first 
method, qualitative in nature, involves plotting the bivariate distributions of effective 
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speed (y-axis) vs. the root mean square (RMS) speed (x-axis) as a heat map. The 
data points along the line y = x, represent the velocities of mDia2 particles moving 
in a near straight line. The second method involves autocorrelation of the position 
(or velocity) vectors over time within a track. This is similar to the analysis 
described previously (274,275) but instead of applying the analysis to the 
ensemble tracks, it can be applied to each individual track. If the mDia2 particles 
move in a straight line, the corresponding track exhibits high position or velocity 
autocorrelation in time. This method was used to analyze the data presented in 
Figure III-11. Appendix IV lists the MATAB functions written for this analysis. 
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CHAPTER IV – DISCUSSION 
 
Complexity of ALS 
ALS is one of the several complex neurodegenerative diseases for which a 
cure is still elusive (1). The fact that a majority of the people are afflicted 
sporadically, makes neurodegenerative diseases like ALS extremely difficult to 
study. The knowledge accumulated over the past three decades stems mainly from 
the study of familial mutations, and has nevertheless helped gain tremendous 
knowledge on disease pathogenesis (2,4). Mutations in SOD1 were first linked to 
ALS in 1993 (3). The mutations such as A4V, G93A and G85R caused SOD1 to 
be aggregation prone and therefore, the initial focus was on protein misfolding and 
aggregation as in many other neurodegenerative diseases. However, the 
subsequent identification of several functionally distinct genes implicates a disease 
course that involves multiple pathogenesis mechanisms leading to multiple 
failures, culminating in the death of the motor neurons (2,167,276). Many of these 
pathways are interconnected, and so if one is “hit” there could arise a domino effect 
harming other pathways, but somehow, all pathways eventually converge causing 
neuronal loss. 
It has been puzzling that most ALS-linked genes are expressed 
ubiquitously, yet motor neurons are particularly susceptible. This selective death 
of neuronal subtypes is also observed in other neurodegenerative diseases such 
as AD, PD and HD (277-279). The key is to answer the critical question – what 
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makes specific neuronal subtypes susceptible? What is it about these neuronal 
subtypes that makes them very different from other cell types and why are they 
susceptible compared to other cell populations? One possible answer that we 
already saw in Chapter I, is the extremely complex morphology of neurons with 
axons sometimes extending up to one meter and the extensive dendritic 
branching. The second feature is their post-mitotic nature. The features that make 
them distinct and special also make them susceptible to disease-causing insults, 
therefore neuronal quality control mechanisms have to be at their peak capability 
to protect them from mutations, cellular stresses and toxicity. It has been widely 
believed that with age, the general health keeping measures such as proteasome, 
UPR, autophagy etc. deteriorate in their performances (162,163,172,280). Under 
situations of a “second-hit” such as a mutation in a crucial gene, the recovery of 
these neurons is not guaranteed, because they are post-mitotic and cannot divide 
to create new populations. 
The major factor responsible for developing and preserving the overall 
neuronal morphology, yet allowing for changes during neuronal activity, is the 
cytoskeletal system comprised of microtubules, actin filaments and 
neurofilaments. Compromise of the neuronal cytoskeleton during 
neurodegeneration-mediated death of neurons cannot be ignored. While 
microtubule cytoskeletal defects have been studied extensively (192,195), 
research focusing on actin cytoskeletal defects has gained significance. For 
example, the formation of cofilin-actin rods and Hirano bodies has been reported 
106 
 
in AD patients but little is known about these abnormal structures (207,209). These 
structures have not been reported in ALS nevertheless. There is evidence for actin 
dysregulation in HD, SBMA and SMA which was discussed in Chapter I. The 
discovery of mutations in actual cytoskeletal proteins, such as DCTN1, PFN1 and 
more recently, TUBA4A brings the cytoskeletal picture to the forefront. Even 
though there have been suggestions that pathogenic mechanisms can be 
mediated through PFN1 in HD and SMA (75,78,108,109,122,123), this is the first 
time disease causing mutations in PFN1 have been identified. Studying how PFN1 
mutations cause ALS may provide insights into the role of PFN1 in HD and SMA, 
and actin dysregulation in neurodegeneration in general. 
The foremost question to address, when discussing implications of ALS-
PFN1 mutations is whether the mutations act through a loss-of-function or gain-of-
function mechanisms. PFN1 homozygous knockout mice are embryonic lethal 
suggesting PFN1 is required for development (93). Heterozygous PFN1 knockout 
mice have reduced chances of survival but nevertheless develop normally (93). 
PFN1 conditional knockout in nervous tissues of mice do not present overt 
phenotypes (99-103,107) with respect to actin. ALS caused by mutations in PFN1 
is dominantly inherited (6,7). Hence, broadly it can be said that PFN1 mutations 
act through gain-of-function mechanisms. But do the gain-of-function mechanisms 
act through structural destabilization of PFN1, functional defects or a combination 
of different mechanisms? We can hypothesize that the structural destabilization of 
PFN1 due to mutations can lead to protein misfolding or aggregation that can 
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acquire toxicity due to aberrant interactions with other proteins. At the functional 
level, however, the terms loss-of-function and gain-of-function are somewhat 
difficult to delineate. For example, a loss of PFN1 may not simply imply a loss of 
actin polymerization. As already discussed, PFN1 affects nucleation and 
elongation both of which depend on PFN1 levels. In our experimental paradigm, 
the interactions of PFN1 with actin, formin or both determine how actin 
polymerization proceeds. The ALS-mutations can affect these interactions 
triggering an “aberrant” polymerization which would normally be absent in the 
PFN1 heterozygous knockout mouse. Hence the term, “dominant gain-of-function 
of PFN1” in genetics may translate to an “aberrant actin polymerization” or “actin 
cytoskeletal dysregulation” at the biochemical level that can lead to toxicity. It is 
also possible that the ALS-variants of PFN1 studied in our experiments can gain 
toxic functions by an altogether different mechanism, not involving actin 
cytoskeleton or more than just one mechanism. In the rest of this chapter, I expand 
on the two potential pathogenic mechanisms described in this dissertation – 
structural destabilization and defects in actin cytoskeleton – and suggest future 
directions. 
 
Structural complications and beyond 
The seminal study describing the presence of insoluble aggregates 
colocalizing with ubiquitin in motor neurons (7) prompted us to study the 
biophysical characteristics of PFN1 mutants. The variants that were described in 
108 
 
the original study, C71G, M114T and G118V were all destabilized (Figures II-1 and 
II-3). Our data for the most part were supported by equilibrium and kinetic studies 
by Chiti and colleagues (281). However, there were certain differences – C71G in 
their studies had a conformational stability similar to WT, and the CD spectrums 
revealed structural differences compared to WT. Further, they report a correlation 
between aggregation propensities of PFN1 variants and structural changes 
observed in native state but not conformational stabilities; the lack of correlation 
was mainly due to C71G exhibiting near WT conformational stability in their 
experiments (281). The differences could arise due to the protocol employed to 
purify PFN1. While we developed a novel method for purifying PFN1, Chiti and 
colleagues used the poly(L-proline) affinity chromatography eluting bound PFN1 
with 8 M urea (281,282). It is interesting to note that from these two studies that 
C71G can adopt different conformational states further supporting protein 
misfolding as a causative factor in PFN1-ALS. In addition, Chiti and colleagues 
characterized the ALS variants A20T, T109M and Q139L identified in subsequent 
genetic screens. T109M and Q139L had similar conformational stabilities as WT, 
but A20T had a stability similar to that of G118V. The overall aggregation 
propensities of the PFN1 mutants according to their studies were WT ~ E117G, 
Q139L < A20T, G118V < M114T < C71G, T109M and that they are correlated with 
structural changes in the native state as opposed to conformational stability 
(281,283). Here again, in their studies T109M purified using poly(L-proline) affinity 
chromatography had a high aggregation propensity despite a conformational 
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stability similar to WT. It will be interesting to see if T109M purified using our novel 
purification protocol has a lower conformational stability. In cells, the mutants form 
visible aggregates when overexpressed (7). As ALS-mutations in PFN1 are rare, 
verifying the presence of aggregates in brain and spinal cord autopsy tissues has 
been difficult. Immunohistochemistry of patient derived tissues harboring E117G 
or Q139L mutations did not contain PFN1-positive inclusions, although TDP43-
positive cytoplasmic inclusions were observed (6,142). Under near endogenous 
expression levels in HeLa cells, no visible ALS-PFN1 aggregates were seen (Dr. 
Jeanne McKeon in Bosco lab, unpublished results), although the presence of toxic 
PFN1 oligomers cannot be ruled out. Further, the insoluble PFN1 that forms gets 
cleared eventually (Figure II-3). Importantly, the studies should be conducted in 
aging neurons at physiological expression levels as ALS is an adult-onset disorder 
affecting specific neuronal subtypes. It is interesting to note that all PFN1 variants 
when aggregated cause an increase in thioflavin-T fluorescence suggesting the 
aggregates have cross β-sheet structure (281). Analysis of the time course of WT 
PFN1 aggregation by transmission electron microscopy revealed the formation of 
13 nm curvilinear fibrils after 4 days that increase in length and eventually form 
straight fibrils that associate to form larger bundles (281). The presence of 
structured aggregates and the fact that PFN1 and the neuronal isoform PFN2 have 
highly similar structures, raises the possibility that mutant PFN1, in addition to 
recruiting WT PFN1, can also recruit PFN2 thereby leading to loss of key neuronal 
functions mediated by PFN2. In light of these observations, it will be informative to 
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conduct studies in motor neurons harvested from PFN1 ALS-mouse models 
(150,151) or derived from induced pluripotent stem cell (IPSC) models to see if the 
above predictions are true. It is also important to look for signatures of proteostatic 
stress and if the PQC mechanisms are overburdened. Acquiring all this knowledge 
will assist us in designing therapies that can target misfolded PFN1 and 
aggregates. The DSF method described in Chapter II was performed in a 384-well 
plate. This provides an opportunity to design high-throughput screens to probe for 
chemical or biological ligands that can enhance the stability of mutants as a 
therapeutic intervention (229). 
X-ray crystallography is a valuable tool to study protein structures. In the X-
ray crystallographic studies, M114T crystallized in a different space group than WT 
or E117G (Table II-2). The extended cleft observed in M114T (Figures II-15 and II-
16) is unlikely due to normal thermal motions present in PFN1 for several reasons. 
The residue Met114 resides in the interior of a protein and is mutated to a relatively 
small threonine residue (Figures I-1, II-15). The variant M114T had to be 
crystallized under different conditions (see Chapter II Materials and Methods) 
which already suggested existence of structural perturbations. Further, the 
extended cleft was not present in WT PFN1 upon inspection of the ensemble WT 
PFN1 structures solved by NMR (10,284). While a non-surface exposed cavity is 
predicted for C71G using similar arguments, it would be important to verify its 
presence by actually solving structures. The ALS-mutations A20T, T109M and 
R136M also occur in secondary structural elements in the interior of the protein 
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(Figure I-1) and it is important to investigate if these mutations also introduce clefts 
or cavities in the hydrophobic core of PFN1. Even though X-ray crystallography 
allowed us to capture M114T in an aberrant conformation, it usually reports a static 
protein structure. It is therefore essential to perform experiments that report on the 
dynamics of WT and ALS-PFN1 to thoroughly understand the structural 
perturbations present in the mutants that lead to destabilization and aggregation. 
The variant G118V will be particularly interesting, as the residue G118 is surface 
exposed, but is still destabilized. Since PFN1 is small, it is amenable to be studied 
by NMR. Hydrogen-deuterium exchange coupled to NMR or mass-spectrometry 
will further complement these studies and will aid us in structure-based drug 
design. Understanding the structural and conformational dynamics may also 
enable us to understand some of the complex behaviors exhibited by M114T in 
actin assembly (Figure III-3). 
 
Comprehending the role of actin in ALS 
Experiments of increasing complexity were designed to study the 
fundamental actin processes of nucleation and elongation, i.e. we began with 
experiments that reported on binding of PFN1 to its ligands (Chapter II), proceeded 
to functional biochemical experiments, and then to mammalian cells for 
recapitulation of key phenotypes (Chapter III). In the actin polymerization and 
poly(L-proline) binding experiments, there was no evidence for impaired binding of 
PFN1 to poly(L-proline) or actin (Figures II-13 and II-14). Further in vitro, mutant 
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PFN1 participates in mDia1-mediated actin filament assembly (Figures III-3 and 
III-4). Hence, it is important to emphasize that the mutations simply do not abrogate 
the binding of PFN1 to actin as previously suggested (7,129). But anomalies in 
actin filaments were observed in the presence of mutant PFN1 in neurons 
(7,146,147), in HeLa cells under conditions where the exogenous PFN1 
expression levels were comparable to endogenous PFN1 (Figure III-10), and in 
vitro single molecule experiments (Figures III-3 and III-4). The data presented in 
Chapter III do not provide mechanistic details, and several experiments need 
repetition to ensure data reproducibility. Even though actin is highly conserved, the 
use of non-muscle actin such as β- and γ-actin over the rabbit muscle α-actin is 
encouraged. The other ALS-PFN1 mutants – T109M, R136W, A20T and Q139L – 
also need to be examined using the biochemical and cell culture assays. 
Additionally, it needs to be tested if these mutants behave in a dominant manner 
in the experiments. 
Determining the kinetic and equilibrium parameters of binding of PFN1 to 
G-actin, F-actin and mDia1 will be crucial to explain the differences observed in 
actin nucleation and elongation with mutant PFN1. An approach for measuring 
equilibrium dissociation constants is described in Appendix III. The increase in 
actin elongation rates observed with M114T presents an enigma (Figure III-3C). 
Therefore, equilibrium and kinetic binding studies to both G- and F-actin are 
needed to explain the differences observed with mutant PFN1. Our attempts at 
measuring equilibrium dissociation constants using fluorescence anisotropy were 
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not successful and need further optimization (see Appendix III). An alternative to 
fluorescence spectroscopy is fluorescence correlation spectroscopy or biolayer 
interferometry from which kinetic as well as equilibrium parameters can be 
obtained (285). 
It is important to note that the binding to one ligand can have allosteric 
effects or alter the interaction with another. We presented evidence for altered 
structural features in the vicinity of the two tryptophan residues measured by their 
increased lifetimes, even though these residues were distal to site of mutations 
(Figure II-7). Bovine PFN1 has been co-crystallized with actin in two different 
conformations partly explaining how the nucleotide exchange on actin is facilitated 
(17,236,286,287). Moreover, Sharma et al. showed that SMN binding to PFN2 
through its poly(L-proline) motifs affects the ability of PFN2 to suppress 
spontaneous actin polymerization (122). Thus, the binding of PFN1 to poly(L-
proline) containing ligands such as mDia1 can modulate the affinity of PFN1 
towards actin. Therefore, ternary complexes of actin, PFN1 and poly(L-proline) 
ligands such as mDia1 and their binding kinetics deserve attention. Investigating 
their structure and conformations will be useful to deduce their mode of operation. 
With the recent technological achievements in cryo-EM and the growing optimism 
about solving structures of molecules and complexes below 100 kDa, it should be 
possible to capture the conformational dynamics of PFN1-actin, PFN1-mDia1 and 
mDia1-PFN1-actin. 
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The experiments described in Chapter III focused on only a small aspect of 
actin dynamics – actin nucleation and elongation in the absence or presence of 
the formins mDia1 and mDia2. A lot of questions still remain unanswered. Do the 
mutations affect the ability of PFN1 to catalyze ADP-ATP exchange on actin 
(Figure I-2C)? If so, does mDia1 cause allosteric effects on this catalytic activity? 
Can these be used to explain the altered filament nucleation and elongation rates 
observed with the ALS variants? Is binding to phosphatidylinositols impacted by 
the mutations? Aβ oligomers disrupt PtdIns(4,5)P2 metabolism in primary cortical 
neurons and this is linked to its synaptic dysfunction (288). Can the ALS-PFN1 
variants act in a similar manner? Virtually, there is no information regarding ALS-
linked PFN1 and PtdIns(4,5)P2 metabolism. Do the ALS-PFN1 variants contain 
aberrant post-translational modifications? Does manipulating Rho/Rac/Cdc42 
signaling reverse some of the phenotypes observed in cells and mouse models 
(117,118)? Moreover, there is the other side of actin dynamics, actin disassembly, 
turnover and treadmilling that involves coordination between severing factors such 
as cofilin and PFN1 (49). Once mechanistic details on the actin abnormalities due 
to mutant PFN1 are available, the attention should be placed on higher order 
cellular actin structures. In particular, the emphasis should be on filaments 
generated by neuronal formins (such as delphilin), in addition to the other two key 
actin assembly machineries Arp2/3 and Eva/VASP which were not investigated in 
this thesis. Some of the neuronal actin structures that deserve close examination 
are, (i) the axon initial segment, (ii) the F-actin rings along axons, (iii) the formin-
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generated dynamic F-actin trails in axons, (iv) the synaptic vesicle cycle, (v) the 
dendritic spine plasticity and (vi) the actin-microtubule-neurofilament cross-talk 
and co-ordination. Non-cell autonomous effects partly drive ALS pathogenesis. 
Hence, the role of PFN1 in glial cells such as myelination (103) also merits 
attention. Super-resolution microscopy, such as STORM, can prove valuable for 
studying both neuronal and non-neuronal cellular cytoskeletal structures. 
A noteworthy point is that the ubiquitously expressed PFN1 is mutated in 
ALS whereas the neuronal isoform PFN2 is not. Both isoforms are structurally and 
functionally similar albeit differences in affinities towards actin (43) as well as 
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different poly(L-proline) containing protein interaction partners (15,92). It will be 
important to see how the combination of PFN1 and PFN2 can contribute to actin 
dynamics. It is not difficult to envision actin polymerization by a formin that can 
recruit both PFN1-actin and PFN2-actin complexes. I alluded to the possibility of 
co-aggregation of PFN1 and PFN2 earlier. In a similar manner, does mutant PFN1 
mimic and acquire the properties or polarize the activity of PFN2 thereby interfering 
with PFN2? The HeLa cells used in Chapter III do not express PFN2, so neuronal 
cells should be used to test the above hypothesis. 
A pathogenesis mechanism closely associated with DNA/RNA metabolism 
is possible. Disturbances in RNA metabolism and nucleocytoplasmic transport are 
emerging themes in neurodegeneration. Aggregation of TDP43 and mutant HTT 
Figure IV-1. A proposed mechanistic model for PFN1 in ALS 
pathogenesis. (A) ALS-mutations destabilize PFN1 structure which can cause 
the protein to misfold and aggregate, depleting functional PFN1 and at the same 
time burdening the protein quality control mechanisms leading to proteostatic 
stress. Further, the aggregates could recruit key cellular proteins thereby 
acquiring toxic properties. (B) Data presented in this dissertation point to an 
anomaly in actin nucleation and elongation caused by PFN1 mutants. Examples 
of other actin-related processes where mutant PFN1 could interfere are actin 
disassembly and recycling, actin assembly by Ena/VASP and Arp2/3, aberrant 
Rho/Rac/Cdc42 cytoskeletal signaling that could be mediated through PFN1-
PtdIns interactions or PFN1 post-translational modifications. (C) ALS-PFN1 can 
disturb RNA metabolism by altering stress granule dynamics and by causing 
TDP43 mislocalization and aggregation. The presence of PFN1 aggregates can 
also interfere with nucleocytoplasmic transport of RNA and proteins. (D) ALS-
mutations in PFN1 can impact actin nuclear transport, alter nuclear functions of 
actin such as chromatin remodeling, transcription and DNA repair. It can also 
associate with nuclear PFN1 ligands such as SMN and disrupt its function. The 
proposed features for which evidence currently exists are depicted in striped 
boxes. 
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in the cytoplasm interferes with the nucleocytoplasmic transport of RNA and 
proteins (289). The repeat expanded c9orf72 RNA also disrupts nucleocytoplasmic 
transport by direct binding to RanGAP1 causing its mislocalization and disrupting 
RAN gradient (290). ALS-PFN1 alters stress granule dynamics (144) and causes 
mislocalization and aggregation of TDP43 (145,149). More studies are necessary 
to determine if TDP43 mislocalization is caused by aggregates or oligomers of 
PFN1 in the cytoplasm and whether these aggregates disrupt nucleocytoplasmic 
transport of RNA and proteins in general. Moreover, actin has under-appreciated 
roles in the nucleus. Actin is involved in transcription, chromatin remodeling and 
DNA repair in the nucleus (81-84). It is not uncommon for poly(L-proline) 
containing proteins to exist in the nucleus. However, it is not known whether PFN1 
binds these proteins with functional implications and effects nuclear actin 
functions. Genetic screens and proteomics approaches will enable us to identify 
hitherto unknown binding partners that can offer insights into DNA and RNA 
processing roles of PFN1 as well as connections to other biochemical pathways in 
general. 
Finally, on a less relevant yet peculiar note, plant profilins are major 
allergens for humans (291,292). It is not known if human PFN1 can trigger 
inflammation. Intriguingly, extracellular F-actin can trigger inflammatory response 
and autoimmunity (293). Hence, there is a remote possibility that the mutations on 
PFN1 somehow trigger autoimmune reaction towards the motor neurons. This 
theory is purely speculative at this juncture and has to be tested. 
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Concluding remarks 
A mechanistic model is proposed comprising of (but not limited to) four 
features for PFN1-ALS pathogenesis, based on what is known from our studies 
and other research groups as well as the conjectures drawn in this dissertation 
(Figure IV-1). I discussed two possible ways through which PFN1 pathogenesis 
can be mediated. First, ALS-mutations destabilize PFN1 structurally. This could 
lead to misfolding and aggregation of PFN1 causing a functional loss. Further the 
misfolded PFN1 and the fibrillar aggregates can also recruit important cellular 
factors such as PFN2 gaining aberrant and toxic functions (Figure IV-1A). Second, 
evidence was presented for certain irregularities in actin nucleation and elongation 
which need to be thoroughly examined. In addition, PFN1 involvement in actin-
cytoskeletal processes discussed earlier such as actin disassembly, nucleation by 
Arp2/3, elongation by Ena/VASP, Rho signaling, cross-talk with microtubules also 
need to be investigated (Figure IV-1B). At the time of writing this dissertation, the 
role of PFN1 in RNA metabolism with respect to ALS was shown by other groups. 
Notably PFN1 associates with stress granules and the ALS-mutations affect stress 
granule dynamics. In addition, the mutations induce classic TDP43 pathology 
(Figure IV-1C). We also speculate about a few other mechanisms including the 
roles of PFN1 in the nucleus that can be impacted by the mutations such as nuclear 
transport of actin and its role in chromatin remodeling, transcription and DNA repair 
(Figure IV-1D). Not all ALS-PFN1 variants are expected to follow the same 
pathogenesis pathways, and a combination of multiple mechanisms is also 
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possible. Future work in vitro, in neuronal models including IPSC-derived motor 
neurons and ALS mouse models will be instrumental in confirming existing 
observations and testing several new hypotheses proposed in this dissertation. 
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APPENDIX I – A NOVEL METHOD FOR PURIFICATION OF PFN1 
 
Introduction 
Existing methods for purification of profilins utilize the affinity of profilin to 
poly(L-proline). The procedure entails binding of profilin to poly(L-proline) 
Sepharose columns, washing with 3 M urea to remove non-specifically bound 
impurities, eluting the bound PFN1 by denaturation using 8 M urea or DMSO and 
finally refolding in a suitable buffer (294-296). WT PFN1, purified by this procedure, 
is functionally active in pyrene-actin polymerization assays or single molecule TIRF 
microscopy, suggesting that PFN1 refolds successfully (43,255). But the ALS-
variants of PFN1 cannot be guaranteed to refold to fully functional forms. Here, we 
describe a novel method for purifying untagged human WT and ALS-PFN1 
variants from the soluble lysates of E. coli. The soluble levels of ALS-PFN1 
variants varied depending on the mutation in question, but were very low compared 
to WT or E117G PFN1. They were predominantly present in the inclusion bodies. 
In particular, the soluble levels of C71G were extremely low and had to be purified 
from the inclusion bodies. In addition to purifying C71G from soluble lysates, we 
also purified C71G from inclusion bodies and show that this variant refolds and 
functions in the same way as its soluble counterpart. 
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Figure AI-1. Human WT PFN1 purification. (A) Hydrophobic cation exchange 
chromatography. In this particular case, the lysate was salted out by addition of 
ammonium sulfate to a final concentration of 1 M and dialyzed in Buffer A. This 
is not entirely necessary and future PFN1 preparations did not involve this step. 
PFN1 elutes at 100% Buffer B. (B) Anion exchange chromatography of PFN1 
elution fractions from (A) dialyzed in Buffer A. PFN1 does not bind the column 
and elutes in the flow-through. (C) Size exclusion chromatography of 
concentrated flow through fractions in (B). In all three panels, PFN1 elution 
volume is marked blue in the chromatograms and blue bars above the gel. PC 
–pre-column, FT – flow-through. 
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Results 
Expression conditions 
A series of experiments were conducted – (i) expression in three different 
E. coli strains BL21(DE3)pLysS, Rosetta™ 2(DE3), ArcticExpress, (ii) testing 
different isopropyl β-D-thiogalactopyranoside (IPTG) concentrations, (iii) testing 
induction temperature and duration – to identify optimum conditions that give the 
best expression for WT and ALS-PFN1. BL21(DE3)pLysS cells transformed with 
PFN1 constructs were cultured in Luria Broth (LB) containing 100 μg ml–1 ampicillin 
and 34 μg ml–1 chloramphenicol at 37 °C until an OD600 of 0.7, at which point PFN1 
expression was induced by addition of 1 mM IPTG for either 3 h at 37 °C (for WT 
and E117G) or 24 h at 18 °C (for C71G, M114T and G118V). Cells were harvested 
by centrifugation and stored at –80 °C until purification. 
Purification of PFN1 from soluble lysate 
The purification procedure was developed for WT PFN1 and subsequently 
applied to the ALS-PFN1 variants. Since human WT PFN1 is basic with an 
isoelectric point of 8.44, we attempted cation-exchange (S-resin) chromatography. 
Surprisingly, the human WT PFN1 exhibited poor binding to the column. Next we 
used a chromatographic technique which employs a mixed-mode resin with both 
hydrophobic and cation-exchange properties. The harvested cells were lysed by 
sonication in 10 mM citrate and 10 mM NaCl, pH 5.0 (Buffer A) containing protease 
inhibitor. The lysate was cleared by centrifugation and applied to the hydrophobic 
cation exchange column pre-equilibrated with Buffer A. Bound impurities were 
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eluted with 200 ml linear gradient of 10 mM citrate and 1 M NaCl, pH 5.0 (Buffer 
B). PFN1 eluted at 100% Buffer B (Figure AI-1A). For large preparations, PFN1 
elutes on complete saturation of the column with Buffer B. The PFN1-containing 
fractions were pooled and dialyzed into Buffer A with 6000-8000 MWCO dialysis 
tubing prior to being applied to an anion-exchange (Q-resin) column. On account 
of its high isoelectric point and the low pH of Buffer A, PFN1 is not expected to 
bind the Q-column. PFN1 eluted in the flow-through (Figure AI-1B) and was 
concentrated to 1–2 ml using stirred ultrafiltration cells (equipped with 5000 MWCO 
discs) and then applied to a Sephacryl S-100 HR size exclusion column pre-
equilibrated with phosphate buffered saline (PBS). PFN1 proteins eluted at 
approximately 200 ml and were >95% pure as assessed by SDS PAGE analysis 
with Coomassie Brilliant Blue stain (Figure AI-1C). The concentration of PFN1 was 
determined spectrophotometrically at a wavelength of 280 nm using a molar 
extinction coefficient of 18450 M–1 cm–1. Aliquots of PFN1 proteins were stored at 
–80 °C, typically at concentrations between 60-600 μM. 
Figure AI-2. Screening additives for C71G PFN1 refolding. The C71G 
PFN1-containing inclusion bodies was extracted in Buffer D and refolded in a 
variety of buffer-additive combinations. The salts used as additives (top row in 
each heat map) consisted of 10 mM each of zinc chloride, calcium chloride and 
magnesium chloride. The solubility was monitored by measuring OD355 over a 
period of 3 h. Buffers that contained 0.5 M L-arginine invariably maintained the 
solubility of C71G on dilution of guanidinium hydrochloride, indicated by 
relatively small values of OD355. The colorbar represents OD355. 
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Purification of C71G PFN1 from inclusion bodies 
The C71G-containing inclusion bodies were extracted as previously 
described (297). The cells were lysed by sonication in 100 mM Tris-HCl pH 7.0, 5 
mM ethylenediaminetetraacetic acid (EDTA), 5 mM dithiothreitol (DTT) (Buffer C) 
containing 200 μg ml–1 lysozyme and protease inhibitor followed by centrifugation. 
The resulting pellet was washed (4-8 ml per gram of dry weight of cells) three times 
with Buffer C containing 2 M urea and 2% Triton X-100 and once with Buffer C. 
The resulting inclusion body pellet was stored at –80 °C until needed. 
At this juncture, a chemical screen was performed to identify the best 
conditions that promoted C71G refolding. C71G present in the inclusion bodies did 
not refold as previously described (295) in either Buffer A or PBS. On the other 
Figure AI-3. PFN1 proteins purified from E. coli are > 95% pure. Indicated 
PFN1 proteins (10 μg) purified using the novel method were subjected to SDS 
PAGE on a 15% polyacrylamide gel to assess purity. All the PFN1 proteins 
show greater than 95% purity. 
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hand, pure C71G refolded in equilibrium refolding experiments (Figure II-2B). This 
suggests that certain impurities present in the inclusion bodies precluded C71G 
from refolding. Inclusion bodies were solubilized (0.5-1 ml per gram dry weight of 
cells) in 50 mM Tris-HCl pH 7.0 containing 5 mM EDTA, 5 mM DTT and 3 M 
guanidinium hydrochloride (Buffer D) at ambient temperature. The solubilized 
Figure AI-4. A comparison of PFN1 C71G purified from the soluble lysate 
of E. coli vs. from inclusion bodies. (A) Equilibrium unfolding and (B) thermal 
denaturation curves (described in Figure II-1) for PFN1 C71G purified from the 
soluble lysate and inclusion bodies. The apparent melting temperature of PFN1 
C71G purified from inclusion bodies (34.62 ± 0.05 °C) is the same as that 
purified from soluble lysate (34.60 ± 0.03 °C). (C) PFN1 C71G has similar 
affinities to poly(L-proline) as determined by the binding assay described in 
Figure II-13 irrespective of whether this variant was purified from the soluble 
lysate or inclusion bodies. 
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inclusion bodies were diluted in Buffer D to a PFN1 C71G concentration of 
approximately 5 mg ml–1. A 96-well plate was loaded with an array of buffer-
additive combinations (190 μl per well) and the inclusion body extract (10 μl) was 
added to each well, thereby diluting the guanidinium hydrochloride. The scattering 
at 355 nm (protein molecules are less likely to absorb at 355 nm) was measured 
periodically. Buffers that contained 0.5 M L-arginine were able to maintain the 
solubility of C71G over an extended period of time (Figure AI-2). In subsequent 
large-scale purifications, C71G was refolded by drop-wise addition of the inclusion 
body extract to rapidly stirring Buffer A containing 0.5 M L-arginine at ambient 
temperature under conditions where the final concentrations of guanidinium 
hydrochloride and C71G were below 0.1 M and 0.2 mg ml–1, respectively. The 
refolded protein was dialyzed in Buffer A at 4 °C and purified using a Sephacryl S-
100 HR column as described for PFN1 WT. 
 
Table AI-1. Approximate yields of PFN1 proteins from E. coli. 
 Soluble lysate (mg l–1) Inclusion bodies (mg l–1) 
WT 7.0 - 
Y7F 5.2 - 
C71G 0.16 4.3 
M114T 0.3 1.6 
E117G 8.0 - 
G118V 0.5 - 
H120E 1.1 - 
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Characterization of purified PFN1 proteins 
All the purified PFN1 proteins were greater than 95% pure by SDS 
polyacrylamide gel electrophoresis (Figure AI-3). Further, the identity and purity of 
the PFN1 proteins were verified by intact mass analysis. The C71G variant purified 
from inclusions bodies exhibited similar thermodynamic stability, melting 
temperature, poly(L-proline) binding as its soluble counterpart (Figure AI-4). 
 
Discussion 
To summarize, we developed new methods for purifying WT and ALS-
PFN1. WT PFN1 purified by the above method had thermodynamic stability 
comparable to published values (see Table II-1) (29,298), functionally active in 
pyrene-actin polymerization assays and in single molecule experiments (Figure II-
14, Figure III-3). Moreover, C71G purified from soluble lysates and inclusion 
bodies are structurally and functionally similar (Figure AI-4). While the assessed 
expression levels of E117G in E. coli were close to WT, the mutants had low 
expression with C71G being the lowest. In fact, their soluble expression levels and 
yields (Table AI-1) correlate with their thermodynamic stabilities (Figure II-1 and 
Table II-1) as well as published data on aggregation propensities (7). 
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Materials and Methods 
Materials 
The following materials were used for PFN1 protein expression and 
purification – Rosetta™ 2(DE3) (EMD Millipore, 71400-4), ArcticExpress (DE3) 
(Agilent Technologies, 230192), BL21(DE3)pLysS (Agilent Technologies, 200132) 
competent cells, isopropyl β-D-thiogalactopyranoside (IPTG; Amresco, 0487), 
protease inhibitor (Roche, 11873580001), HiTrap™ SP FF cation-exchange 
column (GE Healthcare Life Sciences, 17-5157-01), Nuvia cPrime hydrophobic 
cation exchange column (packed approximately 35 ml of the resin in the column) 
(BioRAD, 156-3402), anion (Q-resin) exchange column (GE Healthcare, 17-0510-
01), Sephacryl S-100 HR (GE Healthcare Life Sciences, 17-1194-01), 
ÄKTAPurifier FPLC system (GE Healthcare Life Sciences), 6000-8000 MWCO 
dialysis tubing (Membrane Filtration Products, Inc., 8015-40), stirred ultrafiltration 
cells (Millipore, 5123 and 5121), 96-well microplates (VWR, 82050-760). 
Absorbance measurements 
Absorbance at 355 nm was measured using a PerkinElmer 2030 Multilabel 
Reader. 
Mass spectrometry 
Mass spectrometry was performed at the UMMS Proteomics and Mass 
Spectrometry Facility. 
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Equilibrium unfolding experiment 
The equilibrium unfolding experiment was performed as described in 
Chapter II Materials and Methods section. 
Poly(L-proline) binding experiment 
The poly(L-proline) binding experiment was performed as described in 
Chapter II Materials and Methods section.  
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APPENDIX II – PYTHON CLASS FOR READING THE TCSPC .SDT FILES 
 
Python code 
This file uses the numpy module. The class is named “ReadSDT”. 
# Class to read Becker and Hickl GmbH TCSPC .sdt files 
# Note the code is not exception handled 
# Feel free to use, simplify or modify code, but remember my name 
import struct 
import numpy 
 
__file__ = 'readsdt.py' 
__author__ = 'siva.kuttiya' 
 
# 32 bit architecture 
# byte size 
CHAR32 = 1 
SHORT32 = 2 
INT32 = 2 
LONG32 = 4 
FLOAT32 = 4 
DOUBLE32 = 8 
UNSIGNED_SHORT32 = 2 
UNSIGNED_LONG32 = 4 
 
TIME_AXIS = 0 
 
# byte order 
# @ - native 
# = - native 
# < - little-endian 
# > - big-endian 
 
 
class ReadSDT: 
    # Class initialization 
    def __init__(self): 
        self.source = "" 
        self.destination = "" 
 
        # Initialize "File Header" parameters 
        self.revision = 0  # SHORT32, "h" 
        self.info_offset = 0  # LONG32, "l" 
        self.info_length = 0  # SHORT32, "h" 
        self.setup_offs = 0  # LONG32, "l" 
        self.setup_length = 0  # SHORT32, "h" 
        self.data_block_offset = 0  # LONG32, "l" 
        self.no_of_data_blocks = 0  # SHORT32, "h" 
        self.data_block_length = 0  # LONG32, "l" 
        self.meas_desc_block_offset = 0  # LONG32, "l" 
        self.no_of_meas_desc_blocks = 0  # LONG32, "h" 
        self.meas_desc_block_length = 0  # LONG32, "h" 
        self.header_valid = 0  # UNSIGNED SHORT32, "H" 
        self.reserved1 = 0  # UNSIGNED LONG32, "L" 
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        self.reserved2 = 0  # UNSIGNED SHORT32, "H" 
        self.chksum = 0  # UNSIGNED SHORT32, "H" 
 
        # # Initialize "File Info" parameter 
        self.file_info = ""  # CHAR[], "s" 
        # 
        # # Initialize "Setup" parameter 
        self.setup = ""  # CHAR[], "s" 
 
        # Initialize "Measurement Description Blocks" parameters 
        self.time = ""  # CHAR32 * 9, "s" 
        self.date = ""  # CHAR32 * 11, "s" 
        self.mod_ser_no = ""  # CHAR32 * 16, "s" 
        self.meas_mode = 0  # SHORT32, "h" 
        self.cfd_ll = 0.0  # FLOAT32, "f" 
        self.cfd_lh = 0.0  # FLOAT32, "f" 
        self.cfd_zc = 0.0  # FLOAT32, "f" 
        self.cfd_hf = 0.0  # FLOAT32, "f" 
        self.syn_zc = 0.0  # FLOAT32, "f" 
        self.syn_fd = 0  # SHORT32, "h" 
        self.syn_hf = 0.0  # FLOAT32, "f" 
        self.tac_r = 0.0  # FLOAT32, "f" 
        self.tac_g = 0  # SHORT32, "h" 
        self.tac_of = 0.0  # FLOAT32, "f" 
        self.tac_ll = 0.0  # FLOAT32, "f" 
        self.tac_lh = 0.0  # FLOAT32, "f" 
        self.adc_re = 0  # SHORT32, "h" 
        self.eal_de = 0  # SHORT32, "h" 
        self.ncx = 0  # SHORT32, "h" 
        self.ncy = 0  # SHORT32, "h" 
        self.page = 0  # UNSIGNED SHORT32, "H" 
        self.col_t = 0.0  # FLOAT32, "f" 
        self.rep_t = 0.0  # FLOAT32, "f" 
        self.stopt = 0  # SHORT32, "h" 
        self.overfl = ""  # CHAR32, "s" 
        self.use_motor = 0  # SHORT32, "h" 
        self.steps = 0  # SHORT32, "h" 
        self.offset = 0.0  # FLOAT32, "f" 
        self.dither = 0  # SHORT32, "h" 
        self.incr = 0  # SHORT32, "h" 
        self.mem_bank = 0  # SHORT32, "h" 
        self.mod_type = ""  # CHAR32 * 16, "s" 
        self.syn_th = 0.0  # FLOAT32, "f" 
        self.dead_time_comp = 0  # SHORT32, "h" 
        self.polarity_l = 0  # SHORT32, "h" 
        self.polarity_f = 0  # SHORT32, "h" 
        self.polarity_p = 0  # SHORT32, "h" 
        self.linediv = 0  # SHORT32, "h" 
        self.accumulate = 0  # SHORT32, "h" 
        self.flbck_y = 0  # INT32, "h" 
        self.flbck_x = 0  # INT32, "h" 
        self.bord_u = 0  # INT32, "h" 
        self.bord_l = 0  # INT32, "h" 
        self.pix_time = 0.0  # FLOAT32, "f" 
        self.pix_clk = 0  # SHORT32, "h" 
        self.trigger = 0  # SHORT32, "h" 
        self.scan_x = 0  # INT32, "h" 
        self.scan_y = 0  # INT32, "h" 
        self.scan_rx = 0  # INT32, "h" 
        self.scan_ry = 0  # INT32, "h" 
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        self.fifo_typ = 0  # SHORT32, "h" 
        self.epx_div = 0  # INT32, "h" 
        self.mod_type_code = 0  # INT32, "h" 
 
        # Initialize "Data Blocks" parameters 
        self.block_no = [0] 
        self.data_offs = [0] 
        self.next_block_off = [0] 
        self.block_type = [0] 
        self.meas_desc_block_no = [0] 
        self.lblock_no = [0] 
        self.block_length = [0] 
 
        # Initialize "Data Points" 
        self.data_points = numpy.zeros(0) 
 
    # A function to read the file 
    def read_sdt_file(self, filename): 
        """ 
        :param filename: The .sdt file 
        :return: The data points are in the form of a numpy array 
        """ 
 
        self.source = filename 
        read_sdt = open(filename, "rb") 
 
        # The return value of "struct.unpack" is always one element tuples 
        # struct.unpack is not being used for "s". It doesn't work and haven't 
figured out why 
 
        # File Header 
        self.revision = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.info_offset = struct.unpack("l", read_sdt.read(LONG32))[0] 
        self.info_length = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.setup_offs = struct.unpack("l", read_sdt.read(LONG32))[0] 
        self.setup_length = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.data_block_offset = struct.unpack("l", read_sdt.read(LONG32))[0] 
        self.no_of_data_blocks = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.data_block_length = struct.unpack("l", read_sdt.read(LONG32))[0] 
        self.meas_desc_block_offset = struct.unpack("l", 
read_sdt.read(LONG32))[0] 
        self.no_of_meas_desc_blocks = struct.unpack("h", 
read_sdt.read(SHORT32))[0] 
        self.meas_desc_block_length = struct.unpack("h", 
read_sdt.read(SHORT32))[0] 
        self.header_valid = struct.unpack("H", 
read_sdt.read(UNSIGNED_SHORT32))[0] 
        self.reserved1 = struct.unpack("L", read_sdt.read(UNSIGNED_LONG32))[0] 
        self.reserved2 = struct.unpack("H", read_sdt.read(UNSIGNED_SHORT32))[0] 
        self.chksum = struct.unpack("H", read_sdt.read(UNSIGNED_SHORT32))[0] 
 
        # File Info 
        read_sdt.seek(self.info_offset, 0) 
        self.file_info = read_sdt.read(self.info_length).decode("ascii", 
"ignore") 
 
        # Setup 
        read_sdt.seek(self.setup_offs, 0) 
        self.setup = read_sdt.read(self.setup_length).decode("ascii", "ignore") 
        # This section ends with the sub-section BIN_PARA_BEGIN: binary values 
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*END 
 
        # Measurement Description Blocks 
        read_sdt.seek(self.meas_desc_block_offset, 0) 
        self.time = read_sdt.read(CHAR32 * 9).decode("ascii", "ignore") 
        self.date = read_sdt.read(CHAR32 * 11).decode("ascii", "ignore") 
        self.mod_ser_no = read_sdt.read(CHAR32 * 16).decode("ascii", "ignore") 
        self.meas_mode = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.cfd_ll = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.cfd_lh = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.cfd_zc = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.cfd_hf = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.syn_zc = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.syn_fd = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.syn_hf = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.tac_r = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.tac_g = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.tac_of = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.tac_ll = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.tac_lh = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.adc_re = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.eal_de = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.ncx = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.ncy = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.page = struct.unpack("H", read_sdt.read(UNSIGNED_SHORT32))[0] 
        self.col_t = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.rep_t = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.stopt = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.overfl = read_sdt.read(CHAR32).decode("ascii", "ignore") 
        self.use_motor = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.steps = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.offset = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.dither = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.incr = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.mem_bank = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.mod_type = read_sdt.read(CHAR32 * 16).decode("ascii", "ignore") 
        self.syn_th = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.dead_time_comp = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.polarity_l = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.polarity_f = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.polarity_p = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.linediv = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.accumulate = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.flbck_y = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.flbck_x = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.bord_u = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.bord_l = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.pix_time = struct.unpack("f", read_sdt.read(FLOAT32))[0] 
        self.pix_clk = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.trigger = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.scan_x = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.scan_y = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.scan_rx = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.scan_ry = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.fifo_typ = struct.unpack("h", read_sdt.read(SHORT32))[0] 
        self.epx_div = struct.unpack("h", read_sdt.read(INT32))[0] 
        self.mod_type_code = struct.unpack("h", read_sdt.read(INT32))[0] 
 
        # Data Blocks 
        read_sdt.seek(self.data_block_offset, 0) 
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        # Initialize "Data Blocks" parameters 
        self.block_no = [0] * self.no_of_data_blocks  # SHORT32, "h" 
        self.data_offs = [0] * self.no_of_data_blocks  # LONG32, "l" 
        self.next_block_off = [0] * self.no_of_data_blocks  # LONG32, "l" 
        self.block_type = [0] * self.no_of_data_blocks  # UNSIGNED SHORT32, "H" 
        self.meas_desc_block_no = [0] * self.no_of_data_blocks  # SHORT32, "h" 
        self.lblock_no = [0] * self.no_of_data_blocks  # UNSIGNED LONG32, "L" 
        self.block_length = [0] * self.no_of_data_blocks  # UNSIGNED LONG32, 
"L" 
 
        # Initialize "Data Points" parameters 
        self.data_points = numpy.zeros((self.adc_re, self.no_of_data_blocks + 
1)) 
 
        for point in range(0, self.adc_re): 
            self.data_points[point, TIME_AXIS] = point * (self.tac_r / 
float(self.tac_g * self.adc_re)) * 10 ** 9 
 
        for blk_no in range(0, self.no_of_data_blocks): 
            # not sure if this should be "no_of_data_blocks" or 
"no_of_meas_desc_blocks" 
            # To generalize there should be multiple for loops 
            self.block_no[blk_no] = struct.unpack("h", 
read_sdt.read(SHORT32))[0] 
            self.data_offs[blk_no] = struct.unpack("l", 
read_sdt.read(LONG32))[0] 
            self.next_block_off[blk_no] = struct.unpack("l", 
read_sdt.read(LONG32))[0] 
            self.block_type[blk_no] = struct.unpack("H", 
read_sdt.read(UNSIGNED_SHORT32))[0] 
            self.meas_desc_block_no[blk_no] = struct.unpack("h", 
read_sdt.read(SHORT32))[0] 
            self.lblock_no[blk_no] = struct.unpack("L", 
read_sdt.read(UNSIGNED_LONG32))[0] 
            # need to break the above further 
            # data block/data set number - bits 0 to 23 
            # module number (0 to 3) - bits 24 to 25 
            self.block_length[blk_no] = struct.unpack("L", 
read_sdt.read(UNSIGNED_LONG32))[0] 
 
            # Data Points 
            read_sdt.seek(self.data_offs[blk_no], 0) 
            for point in range(0, self.adc_re): 
                self.data_points[point, blk_no + 1] = struct.unpack("h", 
read_sdt.read(SHORT32))[0] 
 
            read_sdt.seek(self.next_block_off[blk_no], 0) 
 
        # Close the file 
        read_sdt.close() 
 
Usage 
Python 3.5.2 |Anaconda 4.2.0 (64-bit)| (default, Jul  5 2016, 11:41:13) [MSC 
v.1900 64 bit (AMD64)] on win32 
In[1]: import readsdt 
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In[2]: sdt_object = readsdt.ReadSDT() 
In[3]: 
sdt_object.read_sdt_file("C:\\Users\\siva.kuttiya\\Desktop\\s37c_c006.sdt") 
In[4]: sdt_object.data_points 
Out[4]:  
array([[  0.00000000e+00,   0.00000000e+00,   0.00000000e+00], 
       [  1.46372116e-02,   0.00000000e+00,   0.00000000e+00], 
       [  2.92744232e-02,   0.00000000e+00,   0.00000000e+00], 
       ...,  
       [  5.99101070e+01,   0.00000000e+00,   0.00000000e+00], 
       [  5.99247442e+01,   0.00000000e+00,   0.00000000e+00], 
       [  5.99393814e+01,   0.00000000e+00,   0.00000000e+00]]) 
In[5]: sdt_object.data_points[1000] 
Out[5]:  
array([   14.63721158,  1982.        ,  2179.        ]) 
 
  
137 
 
APPENDIX III – MEASURING AFFINITIES OF PFN1 TO ACTIN AND FORMIN 
 
Introduction 
Conventional methods for measuring binding affinities, such as isothermal 
titration calorimetry, surface plasmon resonance and analytical size exclusion 
chromatography, require large volumes and high concentrations of substrate and 
ligand. Actin, purified from rabbit muscles, is difficult to obtain or maintain at high 
concentrations as it can spontaneously polymerize once the critical concentration 
of 0.1 μM is exceeded (299). Conditions that inhibit actin polymerization, such as 
storage at low concentration in G-buffer supplemented with calcium, does not 
completely prevent polymerization and the purified actin has to be ultracentrifuged 
to remove polymers before experiments. Further, it has a short shelf-life. On the 
other hand, the ALS-PFN1 variants, due to their unstable nature, are aggregation 
prone at high concentrations. Hence, we attempted to use fluorescence anisotropy 
to measure the affinities of PFN1 to actin and formin. Fluorescence anisotropy is 
a sensitive technique that requires very low amounts of substrate and ligand 
(20,300). The approach being adopted is similar to the competition-based binding 
experiments described previously (20,301-303). The first step involves binding and 
semi-saturating Alexa Fluor 488 or tetramethylrhodamine-6-maleimide labelled 
profilin with actin. Profilin, being the smaller molecule of the two, exhibits a much 
smaller fluorescence anisotropy. Profilin, when bound to actin (43 kDa), results in 
an increase in anisotropy. Then, the labeled profilin bound to actin can be 
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competed with unlabeled profilin, such as human WT or ALS-PFN1. This indirect 
competition-based binding experiment will also help avoid labeling the human 
PFN1 variants. 
 
Results 
Experiments using Cy3-, A488-, TMR-labeled Sc-S36C 
Initially, experiments were performed using Cy3-labeled Saccharomyces 
cerevisiae profilin, Cy3-Sc-S36C. Actin-binding experiments using this protein did 
not give a sufficient change in fluorescence anisotropy (Figure AIII-1). Cy3-Sc-
S36C also had a high baseline anisotropy to begin with. This could be because the 
fluorescence lifetime of Cy3 is very small (0.3 ns) 
(http://www.iss.com/resources/reference/data_tables/LifetimeDataFluorophores.h
tml). The fluorescence lifetime of a fluorophore is related to the steady state 
anisotropy by the relation (300), 
𝑟 =
𝑟0
1 +
𝜏
𝜃
 
In this relation, 𝑟 is the steady state anisotropy, 𝑟𝑜 is the limiting anisotropy, 𝜏 is the 
lifetime (property of the fluorophore), and 𝜃 is the correlation time (property of the 
macromolecule). Assuming the fluorescence lifetime of Cy3 is not affected on 
conjugation to S37C, its small fluorescence lifetime of 0.3 ns could contribute to 
the high anisotropy according to the above equation. Since the maximum value of 
the anisotropy is about 0.4 for most fluorophores due to excitation photo-selection 
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and other factors (300), the observable change for Cy3-Sc-S36C will not exceed 
0.12 (i.e. approximately from 0.28 to 0.4). Even this change is possible only when 
the motions of the Cy-Sc-S36C is completely restricted. Hence, two other 
fluorophores were chosen for labeling Sc-S36C, (i) Alexa Fluor 488 (A488), lifetime 
4.1 ns and, (ii) tetramethyl rhodamine-6-maleimide (TMR), lifetime 3.1 ns. 
The steady state anisotropy of 50 nM A488 in 20 mM Tris-HCl, 150 mM KCl, 
pH 7.4 (room temperature) and the limiting anisotropy in 100% glycerol (–20 °C) 
was 0.0257 ± 0.0029 and 0.375 ± 0.0064 respectively. The latter agrees with the 
Figure AIII-1. Binding of Cy3-Sc-S36C to actin measured by fluorescence 
anisotropy. 200 nM Cy3-Sc-S36C was incubated with varying concentrations 
of actin, excited with vertically polarized light at 530 nm (SW 5 nm) and the 
polarized emissions, IVV and IVH, from 580 nm to 610 nm (SW 5 nm, integration 
time 1 s) were measured with 1 nm increments at 25 °C. Emission intensities 
from three scans were summed, the average of fluorescence anisotropy (r) 
values from 580 nm to 610 nm was calculated and plotted as shown. The buffer 
used to prepare the samples was 5 mM Tris-HCl, 0.2 mM CaCl2, 0.2 mM ATP, 
0.5 mM DTT, pH 8.0. Error bars represent SD. SW – slit width. 
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Figure AIII-2. Binding of A488-Sc-S36C and TMR-Sc-S36C to poly(L-
proline) measured by fluorescence anisotropy. (A) 200 nM A488-Sc-S36C 
was titrated with samples of 200 nM A488-Sc-S36C containing poly(L-proline)*, 
excited with vertically polarized light at 488 nm (SW 5 nm) and the polarized 
emissions, IVV and IVH, from 510 nm to 550 nm (SW 5 nm, integration time 1 s) 
were measured with 1 nm increments at 25 °C. Emission intensities from three 
scans were summed, the average fluorescence anisotropy (r) at each 
wavelength was calculated and plotted as shown. (B) 400 nM TMR-Sc-S36C 
was titrated with samples of 400 nM TMR-Sc-S36C containing poly(L-proline)*, 
excited with vertically polarized light at 553 nm (SW 5 nm) and the polarized 
emissions, IVV and IVH, were measured at 580 nm (SW 10 nm, integration time 
0.1 s) every 0.2 s for 60 s. The plot shows the average fluorescence anisotropy 
(r). (C) 200 nM A488-Sc-S36C and 0.5 mM proline* was titrated with samples 
of 200 nM A488-Sc-S36C and 0.5 mM proline* containing unlabeled WT PFN1. 
Intensity measurements and fluorescence anisotropy (r) calculations were 
performed as in (A). In all experiments PBS was used to prepare the samples. 
Error bars represent SD. SW – slit width. *Concentrations were measured in 
terms of proline residues. 
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published value of 0.376 (304). By this way, we ensured the instrument was in 
working condition. Next, binding and competition experiments were performed 
using the poly(L-proline) peptide. The molecular weights of the peptide mixture is 
expected to be between 1,000 and 10,000 Da. This implies the peptide can 
possibly bind at least ten PFN1 molecules as about 6 prolines that form a rigid 
type-II helix are required to bind a single PFN1 molecule (24,25,27). This can lead 
to an increased anisotropy. Binding of A488-Sc-S36C or TMR-Sc-S36C to poly(L-
proline) led to an increase in anisotropy (Figure AIII-2A and B). The very small but 
significant change in anisotropy upon saturation with poly(L-proline) suggests that 
the poly(L-proline) peptides loaded with profilin adopts a globular as opposed to 
Figure AIII-3. Binding of A488-Sc-S36C and TMR-Sc-S36C to actin. (A) 200 
nM A488-Sc-S36C was titrated with samples of 200 nM A488-Sc-S36C 
containing actin. Intensity measurements and fluorescence anisotropy (r) 
calculations were performed as described in Figure AIII-2A. The buffer used 
was 3 mM Tris-HCl, 0.1 mM MgCl2, 0.2 mM ATP, 0.5 mM DTT, 0.01% NaN3, 
pH 8.0. (B) 400 nM TMR-Sc-S36C was titrated with samples of 400 nM TMR-
Sc-S36C containing actin. Polarized emissions at 580 nm were measured as in 
Figure AIII-2B, but every 1.5 s for 60 s with an integration time of 1 s. 
Fluorescence anisotropy (r) calculations were performed as in Figure AIII-2B. 
The buffer used was 2 mM Tris-HCl, 0.1 mM MgCl2, 0.2 mM ATP, 1 mM DTT, 
pH 8.0. Error bars represent SD. 
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an extended conformation. The Förster resonance energy transfer (FRET) effects 
between closely situated A488 molecules in such a conformation can depolarize 
the signal leading to an anisotropy below the value that would be expected for 
A488-Sc-S36C going from 13.6 kDa in the unbound state to about 150 kDa in the 
complexed state. In addition, the poly(L-proline) bound A488-Sc-S36C could be 
competed with human unlabeled WT PFN1 (Figure AIII-2C), although at very high 
concentrations of WT PFN1, there was again an increase in anisotropy which was 
reasoned to be due to co-aggregation of A488-Sc-S36C and WT PFN1. 
The change in anisotropy of labelled profilin, upon saturation with actin, was 
poor (Figure AIII-3). Time resolved studies also yielded very small change in 
anisotropy that were irreproducible and unreliable (the forward and reverse 
titrations did not agree). In contrast, an appreciable change in anisotropy of TMR-
Ac-S38C upon binding actin was reported previously (20). The small anisotropy 
change in our experiments possibly results from the label being located in the 
middle of the loop between β-strand 2 and α-helix 2 in Sc-S36C (Figure I-1) (305). 
If the loop is highly flexible, then it can induce local motions causing the emission 
from the A488 to be depolarized. Hence, the local motions will dominate over the 
overall molecular tumbling, of which the latter is needed to measure binding. On 
examination of the Ac-S38C used in Vinson et al. (20), the label, although present 
in the same loop, resides next to an alpha helix (305,306). This might stabilize and 
limit the movement of the fluorophore. 
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Experiments using TMR-labeled Ac-S38C 
We synthesized, expressed, purified and labeled the Ac-S38C profilin II with 
TMR (TMR-Ac-S38C). The activity of TMR-Ac-S38C was verified in single 
molecule actin assembly experiments using mDia1. The elongation rates of the 
unlabeled (56.5 ±12.3 sub s–1 μm–1 actin) and TMR-Ac-S38C (52.3 ± 9.9 sub s–1 
μm–1 actin) were comparable. Actin alone exhibited an elongation rate of 9.3 ± 1.1 
sub s–1 μm–1 actin (Dr. Richa Jaiswal and Dr. Bruce Goode, Brandeis University). 
Actin-binding experiments performed using TMR-Ac-S38C still yielded little 
change in anisotropy (Figure AIII-4). 
 
Figure AIII-4. Binding of TMR-Ac-S38C to actin. (A) 200 nM TMR-Ac-S38C 
was titrated with samples of 200 nM TMR-Ac-S38C containing actin. Intensity 
measurements and fluorescence anisotropy (r) calculations were performed as 
described in Figure AIII-3B. The buffer used was 2 mM Tris-HCl, 0.1 mM MgCl2, 
0.2 mM ATP, 1 mM DTT, pH 8.0. Error bars represent SD. 
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Discussion 
The binding experiments were largely unsuccessful. There were a few 
suggestions from Dr. Thomas Pollard, Yale University. One, to use actin eluting at 
later volumes in size exclusion chromatography during its purification. There are 
usually trace amounts of certain actin-binding proteins that elute with actin in the 
peak fractions, which could potentially interfere with the PFN1-actin binding 
reactions. Two, in addition to using Mg2+, the use of ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) in the buffer was 
recommended, to chelate the Ca2+ normally bound to the ATP. The same 
fluorescence anisotropy based competition experiments were also proposed to 
measure affinities of PFN1 to formins, but were not performed. The method of 
biolayer interferometry which also requires less substrate and ligand can be 
considered in the future as an alternative to fluorescence anisotropy for measuring 
affinities of PFN1 to actin or formins. 
 
Materials and Methods 
Plasmids 
 The plasmid encoding Saccharomyces cerevisiae S36C profilin (Sc-S36C) 
was kindly provided by Dr. Bruce Goode (Brandeis University). The Acanthamoeba 
castellanii S38C profilin II (Ac-S38C) in pET3a vector with NdeI and BamHI cloning 
sites was synthesized at GenScript. 
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Protein purification 
A modified method based on Dr. Avital Rodal’s (Brandeis University) 
protocol was used for purifying Sc-S36C. BL21(DE3)pLysS cells, expressing Sc-
S36C after induction with 1 mM IPTG for 3 h at 37 °C, were harvested by 
centrifugation and lysed in 20 mM tris-HCl pH 8.0, 1 mM DTT (Buffer A) 
supplemented with protease inhibitor. The lysate was clarified by centrifugation 
and injected into an anionic Q-column pre-equilibrated with Buffer A. Elution was 
achieved using Buffer A containing 1 M NaCl. The fractions containing Sc-S36C 
were combined, concentrated and subjected to size exclusion chromatography 
using a Sephacryl S100 column pre-equilibrated with Buffer A containing 150 mM 
KCl. After combining fractions containing Sc-S36C, NaCl was added to a final 
concentration of 1 M. In the final step, the sample was subjected to hydrophobic 
interaction chromatography with Buffer A containing 1 M NaCl as the 
equilibration/binding buffer and Buffer A as the elution buffer. Pure Sc-S36C in 20 
mM Tris-HCl pH 8.0, 150 mM KCl, 1 mM DTT was aliquoted and stored at –80 °C. 
The method used for purifying Ac-S38C was similar to that of human PFN1 (see 
Appendix I). Actin in G-buffer (3 mM tris-HCl, 0.5 mM DTT, 0.2 mM ATP, 0.1 mM 
CaCl2, 0.01% NaN3) was kindly provided by Dr. Bruce Goode (Brandeis 
University).  
Fluorophore labeling and quantification 
Prior to labeling, the Sc-S36C protein sample was dialyzed in 20 mM Tris-
HCl, 150 mM KCl, pH 7.0. The protein, at 75 μM concentration, was incubated 
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overnight at 4 °C with a 10- or 8-fold molar excess of Alexa Fluor® 488 C5 
maleimide (A488, Thermo Fisher Scientific, A10254) or tetramethylrhodamine-6-
maleimide (TMR, Thermo Fisher Scientific, T6028), respectively. The reactions 
were quenched with approximately 48 mM β-mercaptoethanol, dialyzed 
extensively in 20 mM Tris-HCl, 150 mM, pH 7.4 (A488-Sc-S36C) or 20 mM Tris-
HCl pH 7.0, 20 mM KCl (TMR-Sc-S36C), aliquoted and stored at –80 °C. Labeling 
of Ac-S38C was carried out as above using 80 μM of purified protein and a 10 fold 
molar excess of TMR. The labeled sample was further purified using size exclusion 
chromatography using superdex-75. The Cy3-Sc-S36C was kindly provided by Dr. 
Bruce Goode (Brandeis University). 
The A488-Sc-S36C was quantified using the “Proteins and Labels” feature 
in NanoDrop ND-1000 Spectrophotometer. The concentrations of TMR-Sc-S36C 
and TMR-Ac-S38C were calculated using the relation, 
𝐶 =
𝐴280 − 0.27𝐴553
𝜀𝑙
 
𝐶 is the concentration of the protein, 𝐴280 and 𝐴553 are the absorbance values at 
280 nm and 553 nm respectively, 𝜀 is the molar extinction coefficient of Sc-S36C 
(19940 M–1 cm–1 at 280 nm) and 𝑙 is the path length. Without the right molar 
extinction coefficient for TMR, it was not possible to calculate its concentration and 
hence, the labeling efficiency. The labeled proteins were subjected to native and 
denaturing gel electrophoresis to assess purity, presence of unlabeled protein and 
free dye. The masses of A488-Sc-S36C and TMR-Ac-S38C were verified by mass 
spectrometry and the labeling efficiency was estimated to be over 95%. 
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Native and denaturing gel electrophoresis 
Native and denaturing gel electrophoresis were done as previously 
described (232). Briefly, samples were subjected to electrophoresis on 7.5% 
resolving and 5% stacking polyacrylamide (29:1 acrylamide-bisacrylamide, Fisher 
Scientific, BP1408-1) gels at ice-cold conditions and subsequently stained with 
Coomassie Brilliant Blue stain. 
Fluorescence spectroscopy 
Steady state fluorescence measurements were done using a T-format 
Horiba Fluorolog fluorimeter. Fluorophore-labeled samples were excited with 
vertically polarized light and the vertical (IVV) and horizontal emissions (IVH) were 
measured. The G-factor was measured by exciting the samples with horizontally 
polarized light. The fluorescence anisotropy was calculated using the formula, 
𝑟 = (𝐼𝑉𝑉 − 𝐺𝐼𝑉𝐻)/(𝐼𝑉𝑉 + 2𝐺𝐼𝑉𝐻) 
The time resolved data were collected using a Becker and Hickl based custom 
TCSPC equipment (245,246). 
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APPENDIX IV – RESOURCES FOR THE ANALYSIS OF MICROSCOPY DATA 
 
ImageJ macro for maximum projection of Z-stacks 
/* 
 * Macro to z-project the z-stack and save with the default name 
 */ 
 
input = getDirectory("Input directory"); 
output = input 
 
processFolder(input); 
 
function processFolder(input) { 
list = getFileList(input); 
 for (i = 0; i < list.length; i++) { 
  if(File.isDirectory(input + list[i])) 
   processFolder("" + input + list[i]); 
  if(endsWith(list[i], "_z00_ch00.tif")) // Choose appropriate 
suffix 
   { 
    processFile(input, output, list[i]); 
    i = 10000; // An aribitrary high number, equivalent 
to "break" 
   } 
 } 
} 
 
function processFile(input, output, file) { 
 run("Image Sequence...", "open=[input] starting=2 increment=4 sort"); 
 run("Z Project...", "projection=[Max Intensity]"); 
 save_name = output + getTitle() + ".tif"; 
 run("Save", "save=save_name"); 
 close(); 
 close(); 
} 
 
ImageJ macro for particle counting 
/* 
 * Macro for counting particles and save the overlaid masks and counts roi as 
zip 
 * This assumes there are only three channels and the second channel is the 
EGFP channel 
 * You need to change this if the above condition changes 
 */ 
 
// Enter the right folder 
output_directory = "C:\\Users\\siva.kuttiya\\Desktop\\mDia2_analysis\\"; 
 
// Get the image title name and id 
original_image = getTitle(); 
original_image_id = getImageID(); 
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// Duplicate the image, Gaussian blur the duplicated image 
// Subtract the duplicated blurred image from the original image and create the 
result in a new window 
run("Duplicate...", "title=Duplicate.tif"); 
run("Gaussian Blur...", "sigma=5"); 
imageCalculator("Subtract create", original_image, "Duplicate.tif"); 
  
// Get the title and id of the subtracted image, rename 
subtracted_image = getTitle(); 
subtracted_image_id = getImageID(); 
rename("Subtracted.tif"); 
 
// Threshold. Change the parameters as you see fit 
run("8-bit"); 
setAutoThreshold("Default"); 
run("Threshold..."); 
setThreshold(10, 100); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
 
// Analyze particles. Change the parameters as you see fit 
run("Set Scale...", "distance=1 known=0.0928 pixel=1 unit=um"); 
run("Analyze Particles...", "size=0.02-0.40 circularity=0.75-1.00 show=Outlines 
display clear record add"); 
 
// Get the title of the active window which is the results of the particle 
analysis 
// Modify the image and overlay into the original image 
analyzed_image = getTitle(); 
analyzed_image_id = getImageID(); 
run("Invert LUT"); 
run("Red"); 
run("Invert LUT"); 
run("RGB Color"); 
imageCalculator("Add create", original_image, analyzed_image); 
 
added_image = getTitle(); 
added_image_id = getImageID(); 
rename("Overlaid.tif"); 
 
// Prepare filenames for the anlayzed and overlaid file and the ROI information 
analyzed_file = output_directory + original_image + "(overlaid).tif"; 
roi_counts_file = output_directory + original_image + "(counts).zip"; 
 
// Save files 
run("Save", "save=analyzed_file"); 
if(roiManager("count") > 0) 
 { 
  roiManager("Save", roi_counts_file); 
  selectWindow("Results"); 
  run("Close"); 
 } 
 
//Print the filename and counts in the log window 
print(original_image + ":\t" + roiManager("count")); 
 
// Close windows one by one 
selectWindow("ROI Manager"); 
run("Close"); 
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selectImage(added_image_id); 
close(); 
  
selectImage("Drawing of Subtracted.tif"); 
close(); 
  
selectWindow("Threshold"); 
run("Close"); 
  
selectImage(subtracted_image_id); 
close(); 
 
selectImage("Duplicate.tif"); 
close(); 
 
selectImage(original_image_id); 
close(); 
 
MATLAB code for selecting linear filopodia trajectories 
function tracks_info = analyzetrajectories(tracks_xml_file) 
%analyzetrajectories Plots trajectories and displacement autocorrelation. 
%   This function reads the tracks from the tracks_xml_file and plots the 
%   filopodia trajectory and the displacement autocorrelation as well as 
%   the linear segments within the trajectory. This is useful to see if 
%   there are segments where the motion is in a near straight line. Feel 
%   free to use, modify or simplify this code, but remember my name. 
%    
%   Argument:   tracks xml file generated by TrackMate plugin 
%   Returns:    tracks_info consisting of rms_speed, effective_speed etc. 
  
    % The below function was provided by Jean-Yves Tinevez as part of the 
    % publication... 
    % "Nadine Tarantino, Jean-Yves Tinevez, Elizabeth Faris Crowell,  
    % Bertrand Boisson, Ricardo Henriques, Musa Mhlanga, Fabrice Agou,  
    % Alain Israël, and Emmanuel Laplantine. TNF and IL-1 exhibit distinct  
    % ubiquitin requirements for inducing NEMO-IKK supramolecular  
    % structures. J Cell Biol (2014) vol. 204 (2) pp. 231-45". 
    [tracks, md] = importTrackMateTracks(tracks_xml_file, true, true); 
    no_of_tracks = numel(tracks); 
     
    TIME = 1; 
    X_COORD = 2; 
    Y_COORD = 3; 
    SEGMENT_CORR = 4; 
       
    linear_segments = {}; 
     
    % Initialize the plots. You can comment the below section if you do not  
    % want the plots 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    ax1 = subplot(2, 2, 1); 
    daspect([1 1 1]) 
    xlabel('x (\mum)'); 
    ylabel('y (\mum)'); 
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    ax2 = subplot(2, 2, 2); 
    xlim([0 180]); 
    ylim([-1 1]); 
    xlabel('t (s)'); 
    ylabel('dcorr'); 
     
    ax3 = subplot(2, 2, 3); 
    daspect([1 1 1]) 
    xlabel('x (\mum)'); 
    ylabel('y (\mum)'); 
    title('Linear segments'); 
     
    ax4 = subplot(2, 2, 4); 
    xlim([0 180]); 
    ylim([0.75 1]); 
    xlabel('t (s)'); 
    ylabel('dcorr'); 
    title('Autocorrelation of segments'); 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
     
    % Iterate through the tracks 
    for track_no = 1 : no_of_tracks 
         
        current_track = tracks{track_no}; 
        corr_values = computeautocorrelation(current_track); 
        segments = identifylinearsegments(current_track); 
        segments = discardshortsegments(segments); 
        linear_segments = [linear_segments, segments]; 
         
        % Plot filopodia trajectory and autocorrelation. You can comment 
        % the below section if you do not want the plots 
        %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
        %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
        % Top left plot will be the trajectory 
        subplot(2, 2, 1) 
        cla(ax1) 
        title(strcat('Trajectory of track ', num2str(track_no))); 
        hold on 
        xlim([min(current_track(:, X_COORD)),... 
            max(current_track(:, X_COORD))]); 
        ylim([min(current_track(:, Y_COORD)),... 
            max(current_track(:, Y_COORD))]); 
        plot(current_track(:, X_COORD), current_track(:, Y_COORD), '-x') 
        text(current_track(1, X_COORD), current_track(1, Y_COORD),... 
            '\leftarrow t1') 
        hold off 
  
        % Top right plot will be the autocorrelation of the track 
        subplot(2, 2, 2) 
        cla(ax2) 
        title(strcat('Autocorrelation of track ', num2str(track_no))); 
        hold on 
        plot(current_track(:, TIME), corr_values, '-x') 
        hold off 
         
        % Bottom left plot will display only the linear segments of the 
        % track 
        subplot(2, 2, 3) 
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        cla(ax3) 
        xlim([min(current_track(:, X_COORD)),... 
            max(current_track(:, X_COORD))]); 
        ylim([min(current_track(:, Y_COORD)),... 
            max(current_track(:, Y_COORD))]); 
        hold on 
        if numel(segments) > 0 
            for segment = 1 : numel(segments) 
                plot(segments{segment}(:, X_COORD),... 
                    segments{segment}(:, Y_COORD), '-x') 
            end 
        end 
        hold off 
         
        % Bottom right plot will display the auttocorrelation of segments 
        subplot(2, 2, 4) 
        cla(ax4) 
        hold on 
        if numel(segments) > 0 
            for segment = 1 : numel(segments) 
                plot(segments{segment}(:, TIME),... 
                    segments{segment}(:, SEGMENT_CORR), '-x') 
            end 
        end 
        hold off 
         
        waitforbuttonpress; 
        %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
        %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
         
    end 
     
    % For all the identified linear segments collect the tracks_info which 
    % includes duration, rms_speed, effective_speed etc. 
    no_of_linear_segments = numel(linear_segments); 
    tracks_info = zeros(no_of_linear_segments, 12); 
    for linear_track_no = 1 : no_of_linear_segments 
        % The function processtrack calculates all the quantities and 
        % assigns them in the row of tracks_info 
        tracks_info(linear_track_no, :) = ... 
            processtrack(linear_segments{linear_track_no}); 
    end 
        
end 
 
 
 
function corr_values = computeautocorrelation(track) 
%computeautocorrelation Computes displacment autocorrelation of the track 
%   This function takes the track co-ordinates as input and computes the 
%   displacement autocorrelation as a function of time. Feel free to use, 
%   modify or simplify this code, but remember my name. 
%    
%   t1       t2       t3       t4       t5  - time-points 
%   x1       x2       x3       x4       x5  - x-coordinates 
%   y1       y2       y3       y4       y5  - y-coordinates 
%   --      d21      d31      d41      d51  - unit displacement at time tn 
%    1  d21.d21  d31.d21  d41.d21  d51.d21  - autocorrelation from t1 
%    
%   Argument:   track, an n x 3 matrix [t x_coord y_coord] 
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%   Returns:    corr_values 
  
    % track is a n x 3 matrix, and the columns are time (s), x-coordinate 
    % and y-coordinate 
    X_COORD = 2; 
    Y_COORD = 3; 
     
    t1 = 1; t2 = 2; 
     
    % Calculate the d21 displacement 
    d21 = [track(t2, X_COORD) - track(t1, X_COORD),... 
        track(t2, Y_COORD) - track(t1, Y_COORD)]; 
     
    % Convert to unit vector 
    d21 = d21 / norm(d21); 
     
    % Obtain the number of nodes in the track 
    nodes = length(track); 
     
    % Calculate the correlations 
    corr_values = transpose(zeros(nodes, 1)); 
    corr_values(t1) = 1; 
     
    for tn = 2 : nodes         
        % Calculate the dn1 displacement 
        dn1 = [track(tn, X_COORD) - track(t1, X_COORD),... 
            track(tn, Y_COORD) - track(t1, Y_COORD)]; 
         
        % Convert to unit vector 
        dn1 = dn1 / norm(dn1); 
         
        % Calculate the dot product 
        corr_values(tn) = dot(dn1, d21); 
    end 
     
end 
 
 
 
function segments = identifylinearsegments(track) 
%identifylinearsegments Identifies linear segments of filopodia tracks.   
%   This function is similar to "computeautocorrelation" but does the extra 
%   task of checking whether the autocorrelation values conform to a set of 
%   conditions. It restricts the autocorrelation values (constricts the 
%   "cone" angle) as time increases, thereby picking linear segments. Then 
%   it traverses to the point where there is a break in correlation occurs 
%   and repeats the process and so on. In the end it picks up several 
%   linear segments within the trajectory and returns those segments as a 
%   cell array. Feel free to use, modify or simplify this code, but 
%   remember by name. 
%    
%   t1       t2       t3       t4       t5  - time-points 
%   x1       x2       x3       x4       x5  - x-coordinates 
%   y1       y2       y3       y4       y5  - y-coordinates 
%   --      d21      d31      d41      d51  - unit displacement at time tn 
%    1  d21.d21  d31.d21  d41.d21  d51.d21  - autocorrelation from t1 
%   --        1  d32.d32  d42.d32  d52.d32  - autocorrelation from t2 
%   --       --        1  d43.d43  d53.d43  - autocorrelation from t3   
%    
%   Argument:   track, an n x 3 matrix [t x_coord y_coord] 
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%   Returns:    near linear segments above 20 s duration with corr_values 
     
    % Obtain the number of nodes in the track 
    nodes = length(track); 
  
    % track is a n x 3 matrix, and the columns are time (s), x-coordinate 
    % and y-coordinate 
    X_COORD = 2; 
    Y_COORD = 3; 
     
    segment_no = 1; 
    segments{segment_no} = 0; 
     
    ti = 2; % start from the second time point 
     
    while (ti < nodes) 
         
        tj = ti - 1; 
         
        % Calculate the d21 displacement 
        dij = [track(ti, X_COORD) - track(tj, X_COORD),... 
            track(ti, Y_COORD) - track(tj, Y_COORD)]; 
  
        % Convert to unit vector 
        dij = dij / norm(dij); 
         
        % Calculate the correlations 
        corr_values = zeros(nodes, 1); 
        corr_values(tj) = 1; 
          
        for tn = ti : nodes 
           
            % Calculate the dnj displacement 
            dnj = [track(tn, X_COORD) - track(tj, X_COORD),... 
                track(tn, Y_COORD) - track(tj, Y_COORD)]; 
  
            % Convert to unit vector 
            dnj = dnj / norm(dnj); 
  
            % Calculate the dot product 
            corr_values(tn) = dot(dnj, dij); 
             
            % Increase stringency with time (Here tmax = 90) 
            % Start with 0.98 and then over time increase the stringency 
            % linearly (0.02 comes from 1.00 - 0.98) 
            stringency = 0.98 + (((tn - tj) * 0.02) / 90); 
            if (corr_values(tn) < stringency) || (tn == nodes) 
                segments{segment_no} = [track(tj : tn - 1, :),... 
                    corr_values(tj : tn - 1)]; 
                segment_no = segment_no + 1; 
                ti = tn; 
                break; 
            else 
                continue; 
            end 
             
        end 
             
    end 
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end 
 
 
 
function segments = discardshortsegments(segments) 
%discardshortsegments Discards filopodia track segments below 20 s 
%   This function looks at the segments within a track and discards those 
%   that are below 20 s 
%    
%   Argument:   segments, an n x 4 matrix [t x_coord y_coord corr_values] 
%   Returns:    segments, with short segments discarded 
  
    for segment_no = 1 : numel(segments) 
         
        if length(segments{segment_no}) < 20 
            % empty the cell if less than 20 s 
            segments{segment_no} = []; 
        else 
            continue; 
        end 
         
    end 
    % remove the empty cell 
    segments = segments(~cellfun('isempty', segments)); 
  
end 
 
 
 
function track_info = processtrack(track) 
%processtrack Collects track parameters 
%   This function takes each track or track segment and caluclates 
%   no_of_steps, track_duration, mean_distance, rms_distance, 
%   effective_displacement_xy, effective_distance, mean_speed, rms_speed, 
%   effective_velocity_xy, effective speed. 
% 
%   Argument:   track, an n x 3 matrix [t x_coord y_coord] 
%   Returns:    track_info containing the above parameters 
     
    % The track is n x 3 matrix, and the columns are time (s), x-coordinate 
    % and y-coordinate 
  
    % Obtain the number of nodes in the track 
    nodes = length(track); 
  
    % Initialize the return variables 
    no_of_steps = nodes - 1; 
    track_duration = track(nodes, 1) - track(1, 1); 
    mean_distance = 0; rms_distance = 0; 
    effective_displacement_xy = [track(nodes, 2) - track(1, 2),... 
        track(nodes, 3) - track(1, 3)]; 
    effective_distance = norm(effective_displacement_xy); 
    mean_speed = 0; rms_speed = 0; 
    effective_velocity_xy = effective_displacement_xy / (track(nodes, 1) - 
track(1, 1)); 
    effective_speed = norm(effective_velocity_xy); 
     
    % Iterate through the nodes starting with the second node (second node 
    % because for a track of length n, there will be n-1 displacements and 
    % hence n-1 velocities 
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    for node = 2 : nodes 
        % displacement 
        displacement = [track(node, 2) - track(node - 1, 2),... 
            track(node, 3) - track(node - 1, 3)]; 
        mean_distance = mean_distance + norm(displacement); 
        rms_distance = rms_distance + (norm(displacement))^2; 
         
        % velocity 
        velocity = displacement / (track(node, 1) - track(node - 1, 1)); 
        mean_speed = mean_speed + norm(velocity); 
        rms_speed = rms_speed + (norm(velocity))^2; 
    end 
     
    % calculate mean and rms values 
    mean_distance = mean_distance / (nodes - 1); 
    rms_distance = sqrt(rms_distance / (nodes - 1)); 
     
    mean_speed = mean_speed / (nodes - 1); 
    rms_speed = sqrt(rms_speed / (nodes - 1)); 
     
    track_info = [... 
        no_of_steps,...                 % 1 
        track_duration,...              % 2 
        mean_distance,...               % 3 
        rms_distance,...                % 4 
        effective_displacement_xy,...   % 5, 6 
        effective_distance,...          % 7 
        mean_speed,...                  % 8 
        rms_speed,...                   % 9 
        effective_velocity_xy,...       % 10, 11 
        effective_speed];               % 12         
end 
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Figure AIV-1. Identification of linear segments from the filopodia 
trajectories. (A) An example track whose trajectory (top left), position 
autocorrelation (top right), the linear segment within the trajectory (bottom left) 
and its corresponding autocorrelation values (bottom right) are plotted. The 
algorithm identifies a linear segment in this track. (B) An example of a track 
(plots same as in (A)) that exhibits random motion with no linear segments. 
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APPENDIX V – ARTIFICIAL PFN1 MICRO RNA SEQUENCES 
 
U6 promoter: Green letters 
miR155 flanking sequences: highlighted in blue 
mature miR: underlined 
Passenger strand: blue letters 
 
 
PFN1-1169 
Guide strand: TTGTATGGGGAGGAAAGGGGT 
 
Artificial miR-PFN1-1169 
AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAG
AGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAAT
AATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGA
AAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTGGAGGCTTGCTGAAGGC
TGTATGCTGTTGTATGGGGAGGAAAGGGGTGTTTTGGCCACTGACTGACACCCCTTTTCCCCATACAACAG
GACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCTTTTTT 
 
 
PFN1-1171 
Guide strand: TAATGGTTTGTGTGTGTATGG 
 
Artificial miR-PFN1-1107 
AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAG
AGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAAT
AATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGA
AAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTGGAGGCTTGCTGAAGGC
TGTATGCTGTAATGGTTTGTGTGTGTATGGGTTTTGGCCACTGACTGACCCATACACACAAACCATTACAG
GACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCTTTTTT 
 
 
PFN1-1198 
Guide Strand: TGGTATGGGGTAATGGCCCAA 
 
Artificial miR-PFN1-1169 
AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAG
AGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAAT
AATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGA
AAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTGGAGGCTTGCTGAAGGC
TGTATGCTGTGGTATGGGGTAATGGCCCAAGTTTTGGCCACTGACTGACTTGGGCCAACCCCATACCACAG
GACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCTTTTTT 
 
 
PFN1-1207 
Guide strand: TGCAATAAGGGGTATGGGGTA 
 
Artificial miR-PFN1-1207 
AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAG
AGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAAT
AATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGA
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AAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTGGAGGCTTGCTGAAGGC
TGTATGCTGTGCAATAAGGGGTATGGGGTAGTTTTGGCCACTGACTGACTACCCCATCCCTTATTGCACAG
GACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCTTTTTT 
 
 
PFN1-1217 
Guide strand: TGGTTTTGGCAGCAATAAGGG 
 
Artificial miR-PFN1-1217 
AAGGTCGGGCAGGAAGAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAG
AGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAAT
AATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGA
AAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCTGGAGGCTTGCTGAAGGC
TGTATGCTGTGGTTTTGGCAGCAATAAGGGGTTTTGGCCACTGACTGACCCCTTATTTGCCAAAACCACAG
GACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCTTTTTT  
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